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The barrier surfaces of the lung, intestine and skin are continually exposed to environmental insults,
which can result in infection, inflammation and tissue injury when the barriers become disrupted.
Epithelial barrier repair requires a balance between promoting beneficial remodeling responses that drive
cell proliferation while also acting to limit these responses once homeostasis has been achieved. Failure
to either initiate or resolve these reparative responses has detrimental effects, resulting in either loss of
tissue integrity and function or promotion of chronic inflammation and fibrosis, as observed in multiple
inflammatory diseases of the respiratory and intestinal tracts. While the immune system is integral to
maintaining barrier integrity at these mucosal surfaces, the precise cellular and molecular factors that
orchestrate restoration of homeostasis following tissue injury are poorly understood.
Over the past several years a novel family of immune cells have emerged called innate lymphoid cells
(ILCs) that are crucial regulators of immunity and inflammation at barrier sites. However, whether ILCs
exist in the respiratory tract and how they may influence immunity, inflammation or tissue homeostasis in
the lung was unknown. The data presented in Chapter 2 identify a population of Group 2 ILCs (ILC2s)
constitutively present in the respiratory tract of humans and mice and demonstrate a novel function for
ILC2s in regulating airway epithelial barrier integrity and tissue homeostasis following influenza virusinduced pulmonary damage. Further, studies in Chapter 3 investigate the nature of the crosstalk between
the damaged tissue and ILC2 function, revealing that ILC2s possess a wound healing transcriptional
signature and identifying the amphiregulin (AREG)-epidermal growth factor receptor (EGFR) pathway as
an essential regulator of airway epithelial repair and host recovery from influenza virus infection. Lastly,
Chapter 4 explores the relevance of this pathway in sites outside the lung, uncovering an interleukin
(IL)-33-dependent innate immune mechanism of intestinal tissue repair dependent on AREG-EGFR
interactions. Collectively, the data presented in this thesis identify an evolutionarily conserved feedback
loop in which cytokine cues from damaged epithelia activate innate immune cells to express growth
factors essential for the restoration of epithelial function and maintenance of tissue homeostasis at
multiple barrier surfaces.
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ABSTRACT

REGULATION OF TISSUE HOMEOSTASIS BY INNATE LYMPHOID CELLS

Laurel Anne Monticelli

David Artis, PhD

The barrier surfaces of the lung, intestine and skin are continually exposed to
environmental insults, which can result in infection, inflammation and tissue injury when
the barriers become disrupted. Epithelial barrier repair requires a balance between
promoting beneficial remodeling responses that drive cell proliferation while also acting
to limit these responses once homeostasis has been achieved. Failure to either initiate
or resolve these reparative responses has detrimental effects, resulting in either loss of
tissue integrity and function or promotion of chronic inflammation and fibrosis, as
observed in multiple inflammatory diseases of the respiratory and intestinal tracts. While
the immune system is integral to maintaining barrier integrity at these mucosal surfaces,
the precise cellular and molecular factors that orchestrate restoration of homeostasis
following tissue injury are poorly understood.
Over the past several years a novel family of immune cells have emerged called
innate lymphoid cells (ILCs) that are crucial regulators of immunity and inflammation at
barrier sites. However, whether ILCs exist in the respiratory tract and how they may
influence immunity, inflammation or tissue homeostasis in the lung was unknown. The
data presented in Chapter 2 identify a population of Group 2 ILCs (ILC2s) constitutively
present in the respiratory tract of humans and mice and demonstrate a novel function for
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ILC2s in regulating airway epithelial barrier integrity and tissue homeostasis following
influenza virus-induced pulmonary damage. Further, studies in Chapter 3 investigate the
nature of the crosstalk between the damaged tissue and ILC2 function, revealing that
ILC2s possess a wound healing transcriptional signature and identifying the
amphiregulin (AREG)-epidermal growth factor receptor (EGFR) pathway as an essential
regulator of airway epithelial repair and host recovery from influenza virus infection.
Lastly, Chapter 4 explores the relevance of this pathway in sites outside the lung,
uncovering an interleukin (IL)-33-dependent innate immune mechanism of intestinal
tissue repair dependent on AREG-EGFR interactions. Collectively, the data presented in
this thesis identify an evolutionarily conserved feedback loop in which cytokine cues
from damaged epithelia activate innate immune cells to express growth factors essential
for the restoration of epithelial function and maintenance of tissue homeostasis at
multiple barrier surfaces.
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Chapter 1
Introduction

The mucosal surfaces of the mammalian respiratory and intestinal tracts are continually
exposed to commensal microbes, pathogens and environmental insults, all of which can
result in infection, inflammation and tissue injury if the epithelial barrier is breached.
Restoration of tissue homeostasis and barrier integrity requires a delicate balance
between promoting beneficial remodeling responses that drive cell proliferation while
also acting to limit these responses once homeostasis has been achieved. The failure to
either initiate or resolve these reparative responses can have detrimental effects on the
host, resulting in either loss of tissue integrity and function or promotion of chronic
inflammation and fibrosis, as observed in multiple inflammatory diseases of the
respiratory and intestinal tracts (Barker, 2014; Crosby and Waters, 2010; Gorski et al.,
2012; Peterson and Artis, 2014; Rock et al., 2010).
The aim of this thesis is to interrogate the cellular and molecular factors that
orchestrate restoration of epithelial barrier integrity and tissue homeostasis following
injury in the respiratory and intestinal tracts. Chapter 2 will characterize a novel
population of Group 2 innate lymphoid cells (ILC2s) constitutively present in the
respiratory tract of humans and mice and test whether these cells influence restoration
of airway epithelial barrier integrity and tissue homeostasis following influenza virusinduced pulmonary damage. Further, studies in Chapter 3 will investigate the nature of
the crosstalk between the damaged tissue and ILC2 function, specifically examining how
the amphiregulin (AREG)-epidermal growth factor receptor (EGFR) pathway regulates
airway epithelial repair and host recovery from influenza virus infection. Lastly, Chapter
4 will explore the relevance of this pathway in sites outside the lung, uncovering an
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interleukin (IL)-33-dependent innate immune mechanism of intestinal tissue repair
dependent on AREG-EGFR interactions.
Chapter 1 of this thesis will serve as an introduction into the architecture of the
epithelial barriers in the lung and intestine, the cytokine and growth factor signals that
reciprocally regulate epithelial and innate immune cell function, the family of innate
lymphoid cells and murine models of lung and intestinal tissue injury.

1.1 Barrier function in the lung and intestine
At mucosal surfaces of the mammalian lung and intestine, only a single layer of epithelial
cells separates the host from the dangers of the external environment. As discussed
below, the specialized cellular architecture and production of anti-microbial factors helps
maintain epithelial barrier integrity to preserve tissue homeostasis.

1.1.1 Architecture and defense of the intestinal epithelial barrier
In the intestine, maintenance of intestinal barrier integrity is essential not only to prevent
infection with pathogens, but also to preserve anatomical containment of the trillions of
commensal microbes that inhabit the gut microenvironment (Maloy and Powrie, 2011;
Peterson and Artis, 2014; Rescigno, 2011). While the symbiotic relationship between
commensal bacteria and the mammalian host is essential for normal digestion and
proper nutrition, unrestrained microbial dissemination has severe consequences for the
host, resulting in systemic immune activation that has been associated with progression
of multiple chronic inflammatory diseases, such as HIV, hepatitis infections and cancer
(Brenchley et al., 2006; d'Ettorre et al., 2011; Douek, 2007; Marchetti et al., 2011; Page
et al., 2011; Paiardini et al., 2008; Sandler et al., 2011). Therefore, homeostatic
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maintenance and effective repair of the epithelial barrier is critical for preservation of
human health.
In mammals, the intestinal epithelial barrier is protected by multiple layers of
physical and immuno-regulatory protection. First, a thick layer of mucus secreted by
goblet cells covers surface of the epithelium, thereby thwarting invasion by commensal
microbes, pathogens and environmental agents that attempt to enter from the lumen
(Barker, 2014; Maloy and Powrie, 2011; Peterson and Artis, 2014; Rescigno, 2011). The
single layer of epithelial cells serves as the second line of host defense in the intestine,
with tight junction proteins and adhesion molecules providing an additional mechanism
to prevent microbes or noxious environmental agents from crossing the barrier.
Secretion of anti-microbial peptides such as defensins, cathelicidins, and C-type lectins
produced by specialized paneth cells also provide an effective defense against infection
and injury of the epithelial barrier (Barker, 2014; Peterson and Artis, 2014; Rescigno,
2011).
The small and large intestinal epithelium must undergo rapid renewal to maintain
optimal function of the cells in the crypts and villi. More than 300 million new epithelial
cells are estimated to be generated daily in the small intestine alone as part of normal
homeostatic turnover and an even greater amount during tissue injury (Barker, 2014;
Peterson and Artis, 2014; Rescigno, 2011). Regeneration begins at the crypt base,
where stem cells regularly divide to first generate transit-amplifying (TA) cells and then
differentiate to the absorptive versus secretory cell lineages while migrating upwards.
Cytokines and growth factors expressed by innate and adaptive immune cells can
influence intestinal epithelial cell proliferation and differentiation (Peterson and Artis,
2014; Sato et al., 2011; Sato et al., 2009) (and discussed in greater detail below).
Studies performed in Chapters 3 and 4 of this thesis will specifically explore the ability
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of Group 2 innate lymphoid cells (ILC2s) to produce growth factors that regulate
restoration of epithelial barrier function following acute tissue injury.

1.1.2 Architecture and defense of the lung epithelial barrier
The mammalian lung is a dynamic organ that takes in approximately 10,000 liters of air
every day for efficient gas exchange, providing ample opportunity for circulating
pathogens, allergens or other environmental particulates to invade the airways and
cause disruption of the epithelial barrier leading to tissue damage and inflammation
(Gorski et al., 2012; Hallstrand et al., 2014; Lambrecht and Hammad, 2014; Rock et al.,
2010). The lung barrier consists of a psuedostratified epithelium that contains basal cell
(BCs), ciliated cells, multiple secretory cell lineages (goblet cells, Clara cells and serous
cells) and neuroendocrine cells (Borok et al., 2011; Chen et al., 2009; Morrisey and
Hogan, 2010; Rackley and Stripp, 2012; Rock et al., 2010). At the interface of the lung
epithelium and the circulating air, secretion of mucus by goblet cells and surfactants by
Clara cells form the first line of defense to prevent invasion from noxious environmental
agents and pathogens. Any pathogens or particulate matter caught in the mucus layer
are swept away from the barrier by ciliated cells. Under homeostatic conditions, the
structural integrity of the lung barrier is maintained by tight junction proteins, claudins
and other adhesion molecules while dysregulation of these structural molecules is
associated with development of airway inflammation and tissue damage (Gorski et al.,
2012; Hallstrand et al., 2014; Morrisey and Hogan, 2010; Rackley and Stripp, 2012;
Rock et al., 2010).
Despite intense investigation, it is still controversial whether a single
bronchioalveolar stem cell (BASC) population exists that can give rise to all the different
lineages of the lung or whether there are lineage-restricted facultative precursors that
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only regenerate distinct epithelial subsets (Borok et al., 2011; Crosby and Waters, 2010;
Morrisey and Hogan, 2010; Rawlins et al., 2009; Rock et al., 2010). Further, the majority
of lung epithelial stem cell work has been restricted to studies of prenatal development
and postnatal homeostatic turnover, while the epithelial lineages involved in airway
remodeling and restoration of barrier integrity following pathogen-induced tissue damage
are virtually unexplored.
Similar to the intestinal tract, there is extensive immunoregulation of the lung
epithelia, consisting of cytokines, growth factors and enzymes produced by innate and
adaptive immune cells to maintain integrity of the barrier under steady-state conditions
and coordinate tissue repair if the epithelium is damaged (discussed in further detail
below). Studies undertaken in this thesis investigate how populations of ILCs respond to
cues from the damaged mucosal barrier to orchestrate epithelial repair and promote
restoration of tissue homeostasis in the lung and intestine through production of growth
factors.

1.2 Epithelial cell-derived cytokines regulate the innate immune system
At the epithelial barrier, secretion of the cytokines interleukin(IL)-25, IL-33 and thymic
stromal lymphopoietin (TSLP) are prominent inducers of the type 2 inflammatory
response (Oboki et al., 2011; Saenz et al., 2010a; Smith, 2011) (Fig 1). In particular, IL33 acts an “alarmin” danger signal, releasing rapidly upon epithelial cell damage to
activate resident immune cell populations of the lung and intestine (Le et al., 2013;
Lopetuso et al., 2012; Oboki et al., 2011; Saenz et al., 2010a; Smith, 2011). The ability
of the IL-33-IL-33R signaling pathway to regulate innate cell function and tissue repair
will be investigated in this thesis; therefore the sections below will specifically focus on
the induction, sources and cellular targets of IL-33 in detail.
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1.2.1 Cellular distribution of IL-33 and ST2
IL-33 is a member of the IL-1 cytokine family and is widely expressed in epithelial and
endothelial stromal cell lineages of the central nervous system, lung and intestine under
steady state conditions (Le et al., 2013; Lopetuso et al., 2012; Oboki et al., 2011; Smith,
2011). Upon infection, inflammation or tissue injury, IL-33 can also be upregulated in
dendritic cells, macrophages and fibroblasts. Inside the cell, IL-33 is localized to the
nucleus and can be released in bioactive form from necrotic cells in injured tissue
without any caspase processing (Le et al., 2013; Pastorelli et al., 2011; Smith, 2011). As
such, IL-33 is commonly referred to as an “alarmin” or a damage-associated molecular
pattern (DAMP). The receptor for IL-33 is termed ST2 and can exist in a bioactive
transmembrane form (also called ST2L) or a soluble form (sST2) that acts as a decoy
receptor. Binding of IL-33 to ST2 and recruitment of MyD88 triggers a signaling cascade
involving NF-κB and AP-1 through IRAK, TRAF6 and MAP kinases (Le et al., 2013;
Pastorelli et al., 2011; Smith, 2011).
ST2 can be expressed on virtually every member of the innate and adaptive
immune systems that serve to regulate the balance of immunity, inflammation and tissue
repair at barrier surfaces (Fig 1). The innate cell targets of IL-33 signaling consist
primarily of the classical type 2 immune response: mast cells, basophils, eosinophils,
dendritic cells, macrophages, neutrophils and the newly described Group 2 innate
lymphoid cells (ILC2s) (Le et al., 2013; Lloyd, 2010; Mirchandani et al., 2012; Smith,
2011). Additionally, adaptive immune cells such as CD8 T cells, B cells and Th2 CD4
helper T cells can also express ST2 during ongoing inflammatory or infectious disease
settings. Lastly, ST2 expression is not restricted to hematopoietic lineages, as stromal
cell populations such as fibroblasts, epithelial cells, endothelial cells and osteoclasts
have all been implicated as direct targets of IL-33 signaling (Le et al., 2013; Lloyd,
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2010). The extensive and diverse array of cell types responsive to IL-33-IL-33R
stimulation illustrates the critical importance of this alarmin in regulating immune function
at barrier surfaces.

1.2.2 Role of IL-33 during immune responses in the lung and intestine

In the lung, IL-33 has been shown to be a primary activator of the cell types involved in
initiating airway inflammation and hyper-reactivity (Barlow et al., 2012; Barlow et al.,
2013; Bartemes et al., 2012; Kim et al., 2012; Le et al., 2013; Mirchandani et al., 2012).
Further, GWAS studies in asthma patients have identified IL-33 and ST2 (Ho et al.,
2013), suggesting that therapeutic manipulation of this pathway may result in improved
clinical disease outcomes. Particularly in the case of ILC2s, previous studies have
indicated that IL-33 is a more potent signal than IL-25 or TSLP for eliciting ILC2
proliferation and expression of the type 2 cytokines IL-5 and IL-13 that drive airway
inflammation (Barlow et al., 2013; Saenz et al., 2013). In the context of respiratory viral
infection, IL-33 has been shown to be released by influenza virus-infected epithelial cells
and macrophages (Chang et al., 2011; Le Goffic et al., 2011a), although the functional
role of the IL-33-IL-33R signaling pathway in influencing viral clearance, tissue
inflammation or restoration of epithelial barrier integrity is unknown. Studies in Chapter 2
and 3 will directly test the contribution of the IL-33-IL-33R pathway to immunity and
tissue repair following influenza virus-induced lung damage.
In the intestinal tract, IL-33 along with IL-25 signaling has been shown to be
essential for generating optimal anti-parasitic immune responses to helminth parasites
via activation of IL-13-producing ILC2s (Moro et al., 2010; Neill et al., 2010; Price et al.,
2010). In the context of non-infectious tissue injury such as models of intestinal colitis,
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whether IL-33-IL-33R interactions play a tissue-protective or pathologic role during
disease progression is highly controversial (Duan et al., 2012; Garcia-Miguel et al.,
2013; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso et al., 2012; Pastorelli et al.,
2011; Pushparaj et al., 2013; Sedhom et al., 2013), and the cellular and molecular
mechanisms which act downstream of IL-33 to regulate disease severity are not well
understood. In Chapter 4, we will employ the dextran sodium sulfate model of intestinal
injury to assess whether ILC2s and IL-33 signaling are involved in promoting
inflammation versus tissue repair.

1.3 Role of amphiregulin and the epidermal growth factor receptor at barrier sites
In addition to the cytokine-mediated regulation of innate immunity and barrier function
discussed above, the epithelium is also responsive to growth factor pathways that
promote proliferation, differentiation and survival of distinct stromal cell lineages. In the
lung and intestine, the amphiregulin-epidermal growth factor receptor pathway is a key
regulator of both epithelial and hematopoietic cell function in the steady state and during
tissue injury.

1.3.1 Role of AREG-EGFR signaling in non-hematopoietic stromal cells
The growth factor Amphiregulin (AREG) was originally discovered in a human breast
cancer cell line culture and named “amphi-“ for its dual ability to either promote or to limit
proliferation and differentiation of normal and cancerous epithelial cells (Berasain and
Avila, 2014; Busser et al., 2011b). Amphiregulin is remarkably widespread in its
expression pattern, ranging throughout mammalian tissues to include the reproductive,
urinary, respiratory, and intestinal tracts as well as the circulatory system and bone
structure (Berasain and Avila, 2014; Busser et al., 2011b). As such, AREG is reported to
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regulate diverse physiological processes, most critically mammary gland development,
stromal cell proliferation and differentiation, bone formation and keratinocyte proliferation
(Berasain and Avila, 2014; Busser et al., 2011b).
AREG is a ligand of the epidermal growth factor receptor (EGFR), a
transmembrane tyrosine kinase receptor belonging to the ErbB/human epidermoid
receptor (HER) family (Berasain and Avila, 2014; Busser et al., 2011b). Compared to the
other EGFR ligands (epidermal growth factor (EGF), tumor growth factor-alpha (TGFα),
heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EREG) and betacellulin
(BTC)), AREG binds to EGFR with low affinity yet still exhibits remarkably strong
biological activity at low concentrations (Berasain and Avila, 2014; Busser et al., 2011b;
Kataoka, 2009). Binding of AREG to EGFR leads to receptor dimerization and activation
of multiple downstream signaling pathways including the Ras/MAPK, PI3K/AKT, PLCγ
and STAT pathways. Importantly, EGFR signaling is absolutely required for normal
development of multiple organ systems, as genetically modified mice lacking EGFR
activity die in utero and mice heterozygous for mutations reducing EGFR activity still
exhibit profound defects in sites where EGFR expression is highest, notably
keratinocytes and mammary tissue (Busser et al., 2011b; Du et al., 2004; Kataoka,
2009; Lee and Threadgill, 2009; Luetteke et al., 1999). However, the importance of
EGFR signaling in regulating postnatal tissue function after injury, particularly in the lung,
is not well understood. Chapters 3 and 4 will interrogate the potential role of
endogenous AREG-EGFR interactions in epithelial cell repair and restoration of tissue
homeostasis in response to lung damage or intestinal injury.
Cleavage of the AREG precursor protein (pro-AREG) to generate the mature
active form is accomplished by the tumor-necrosis factor-alpha converting enzyme
(TACE), a member of the disintegrin and metalloproteinase (ADAM) family (also called
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ADAM-17). After cleavage, AREG can act in a paracrine or autocrine fashion on many
stromal cell types that also express EGFR (Burgel and Nadel, 2004, 2008; Busser et al.,
2011b; Kataoka, 2009). Diverse endogenous and exogenous signals induce AREG
production depending on the tissue site; however, the signals that promote AREG in the
stromal cells of the lung and intestinal tracts are virtually unknown except for TGFβ and
cigarette smoke (lung) and prostaglandins (intestine) (Berasain and Avila, 2014;
Kataoka, 2009; Nadel, 2001; Takeyama et al., 2001). Whether cytokine alarmins such as
IL-33 can induce AREG expression and EGFR activity will be examined in Chapter 3 of
this thesis.

1.3.2 Role of AREG-EGFR signaling in hematopoietic cells
EGFR expression was thought to be exclusively restricted to non-hematopoietic
cells, although recent evidence has emerged challenging this dogma and revealing
functional EGFR expression on hematopoietic stem cells (HSCs) (Doan et al., 2013),
regulatory T cells (Tregs) (Zaiss et al., 2013) and macrophages (Lu et al., 2014).
Whether other immune cell populations may express EGFR and respond to AREG
signaling is not yet known.
Until recently, AREG was primarily known for its involvement in human cancers
(most notably lung, intestine, breast and pancreas), where it serves as a prognostic
marker of poor clinical outcome (Berasain and Avila, 2014; Busser et al., 2011b).
However, within the past several years it has become increasingly clear that AREG can
also serve as an important regulator of hematopoietic cell function in context of infection
and tissue injury. Interestingly, the source of AREG in these settings is also
hematopoietic in origin, although it acts in a paracrine, not autocrine, fashion unlike what
has generally been reported for stromal cells (Berasain and Avila, 2014; Burgel and
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Nadel, 2008; Busser et al., 2011b; Kataoka, 2009). First reported as a new component
of the type 2 cytokine franchise produced by Th2 CD4 T cells to expel parasites from the
intestine (Zaiss et al., 2006), AREG is now considered to be an effector molecule of
multiple cells types associated with type 2 immunity, including basophils, eosinophils,
mast cells and Tregs (Burgel et al., 2001; Burzyn et al., 2013; Meulenbroeks et al., 2014;
Qi et al., 2010). Human basophils express AREG in response to IL-3 stimulation while a
functional role for basophil-derived AREG was recently revealed in a murine model of
Ultraviolet-B (UVB) irradiation-induced immunosuppression (Meulenbroeks et al., 2014;
Qi et al., 2010). Human blood eosinophils have been reported to express AREG upon
stimulation with GM-CSF (Burgel et al., 2001; Matsumoto et al., 2009), although the
functional relevance of eosinophil-intrinsic AREG has not been examined. Mast cells
have also been reported to be a critical source of AREG, capable of enhancing
suppressive function of EGFR+ Tregs in culture and in vivo (Zaiss et al., 2013). Lastly,
Tregs themselves have recently been shown to express AREG to promote muscle tissue
repair (Burzyn et al., 2013). Studies in Chapter 3 and 4 will expand upon these findings
to test the signals that induce AREG expression in populations of Group 2 innate
lymphoid cells (ILC2s) and what role ILC2-intrinsic may play in tissue repair responses
of the injured lung and intestine.

1.4 Innate lymphoid cells
Emerging studies over the past several years have revealed the existence of a
previously unrecognized population of immune cells that appear to represent the innate
counterpart to the T cell lineage of the adaptive immune system. Located at multiple
anatomical sites, these heterogeneous populations of innate lymphoid cells (ILCs) serve
as crucial regulators of immunity and inflammation at barrier surfaces such as the skin,
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intestine and respiratory tract (Kim et al., 2013b; Monticelli et al., 2012; Oliphant et al.,
2011; Spits and Cupedo, 2011). The following sections will discuss the phenotypic,
transcription and functional characteristics of the ILC subsets.

1.4.1 The ILC family
ILC populations share morphological, developmental and functional similarities with
CD4+ T helper cells, but lack antigen receptors. Specifically, members of the ILC family
lack expression of cell surface makers associated with granulocytes, dendritic cells (DC),
macrophages and conventional B and T lymphocytes but can be positively identified by
expression of CD90 (Thy1), CD25 (IL-2Rα), CD127 (IL-7Rα) and c-Kit among others
(Kim et al., 2013b; Monticelli et al., 2012; Oliphant et al., 2011; Spits and Cupedo, 2011).
While the cell lineage relationships between heterogeneous ILC populations are still
being elucidated, it has been demonstrated that ILCs develop from the classical
common lymphoid progenitor cell (CLP) and require common gamma chain cytokine
signaling for development (Spits and Cupedo, 2011; Wong et al., 2012; Yang et al.,
2011). All ILCs are thought to develop from a common bone marrow-derived lymphoid
precursor that is dependent on the transcription factor inhibitor of DNA-binding 2 (Id2)
(Monticelli et al., 2011; Moro et al., 2010; Spits and Cupedo, 2011), and recent work has
identified high expression of the transcription repressor promyelocytic leukaemia zinc
finger (PLZF) as a defining feature of an ILC precursor that differentiates into all known
ILC subsets but notably not NK cells (Constantinides et al., 2014) (Fig 2). Heterogeneity
in cell surface marker expression, transcriptional regulation and effector molecule
expression allow mature ILCs to be broadly classified into 3 main population subsets,
referred to as Group 1 ILC (ILC1), Group 2 ILC (ILC2) or Group 3 ILC (ILC3) (Fig. 2 and
(Spits et al., 2013))
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The Group 1 ILC population is the most recently described subset and includes
cells dependent on the Th1 cell-associated transcription factor T-bet that are capable of
responding to IL-12 and IL-15 signaling to produce IFNγ (Bernink et al., 2013; Klose et
al., 2014) (Fig 2). Although the distinctions between ILC1s and classical NK cells are not
fully defined, true ILC1s are thought to be distinguished from NK cells by their absence
of many NK cytotoxicity receptors and by their dependence on the common ILC
precursor transcription factor PLZF (Bernink et al., 2013; Klose et al., 2014).
ILC populations found in Group 2 are composed of cells that express the T
helper type 2-associated cytokines IL-5, IL-9 and IL-13 but do not express much IL-4
(Koyasu et al., 2010; Monticelli et al., 2012; Saenz et al., 2010a). These cell populations,
that were originally termed Natural Helper cells, Nuocytes or Innate Helper Type 2 cells
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010), also express the Th2 cellassociated transcription factor GATA3, as well RORα, TCF-1 and Gfi1 (Furusawa et al.,
2013; Hoyler et al., 2012; Klein Wolterink et al., 2013; Mjosberg et al., 2012; Spooner et
al., 2013; Wong et al., 2012; Yang et al., 2013) (Fig. 2). ILC2s are activated primarily by
the epithelial-derived cytokine IL-33 and to a lesser extent, IL-25. Additional epithelial
cell-derived factors, such as thymic stromal lymphopoetin (TSLP), can augment ILC2
responses (Kim et al., 2013b; Monticelli et al., 2012; Oliphant et al., 2011; Spits and
Cupedo, 2011).
The third ILC subset (ILC3) is comprised of several distinct cell populations that
share a common developmental requirement for RORγt and a cytokine expression
profile reminiscent of CD4+ Th17 cells. A variety of names have been used to describe
IL-17A/IL-22-producing ILCs, including adult lymphoid tissue inducer (LTi)-like cells,
ILC22 and ILC17 (Cella et al., 2009; Sanos et al., 2009; Satoh-Takayama et al., 2008;
Sonnenberg et al., 2011; Spits and Cupedo, 2011; Takatori et al., 2009). Similar to fetal
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LTi cells, these RORγt+ adult LTi-like ILC3s are also capable of producing lymphotoxin
(LT) for lymphoid organ development (Lochner et al., 2011; Marchesi et al., 2009).
Additionally, all ILC3 populations have the ability to produce high amounts of IL-22 or IL17A in response to stimulation with IL-23, IL-1β and dietary AhR ligands (Fig 2).
The focus of this thesis will be to explore the regulation and effector function of
ILC2s in the respiratory and intestinal tracts in response to tissue injury. Therefore, the
following

sections

will

discuss

the

phenotypic,

transcriptional

and

functional

characteristics of ILC2s at barrier sites in more detail.

1.4.2 Identification of murine ILC2s
Expression of the Th2-cell associated cytokines IL-5 and IL-13 is a classic hallmark of
both pathologic allergic inflammation and host-protective anti-parasitic immune
responses at mucosal sites (Allen and Maizels, 2011; Doherty and Broide, 2007;
Oliphant et al., 2011; Saenz et al., 2010a). Group 2 ILCs provide a critical, early innate
source of these cytokines before the onset of adaptive CD4+ Th2 cell-dependent
immune responses. A non-T cell, non-B cell source of type 2 cytokines critical for antihelminth immunity in the intestine was originally reported a decade ago (Fallon et al.,
2006), although it would be several more years until flow cytometric advances allowed
for the characterization and formal identification of this novel innate cell type. These
RORγt-independent, ILCs were first described by Moro and colleagues as Natural Helper
(NH) cells located in fat-associated lymphoid clusters (FALC) surrounding the gut
mesentery that provide aid to B1 cells and promote expulsion of intestinal helminth
parasites (Moro et al., 2010). Subsequent studies by two independent laboratories
further identified populations at multiple tissue sites (termed Nuocytes or Innate Helper
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Type 2 cells (Ih2)) that were critical for optimal protective type 2 immunity against
intestinal helminth parasites (Neill et al., 2010; Price et al., 2010).
Now collectively referred to as Group 2 ILCs (ILC2s), these cells express the
receptors for the epithelial cell-derived cytokines IL-25 (IL-17Rb) and IL-33 (T1/ST2) and
produce IL-5 and IL-13 upon stimulation with IL-25 and/or IL-33 in combination with IL-2
and IL-7 (Koyasu et al., 2010; Neill et al., 2010; Price et al., 2010; Spits et al., 2013). In
parallel with these studies, a separate report identified a population of IL-25-elicited,
multi-potent progenitor type 2 cells (MPPtype2 cells) that also augment anti-helminth
immunity, but are functionally distinct from ILCs by their ability to differentiate into
myeloid cells and their preferential responsiveness to IL-25, but not IL-33, signaling
(Saenz et al., 2010b). Extensive comparison of the phenotypic, functional and
transcriptional profiles of ILC2s and MPPtype2 cells revealed that MPPtype2 cells more
closely resemble common myeloid progenitors than fully differentiated ILC2s (Saenz et
al., 2013).
The discovery of ILC2s at the intestinal barrier surface prompted us to ask
whether ILC populations exist at extra-intestinal barrier sites such as the respiratory
tract. Studies in Chapter 2 will examine the phenotypic, developmental and functional
characteristics of ILC2 populations in the lung and test whether these cells may regulate
immunity, inflammation or tissue repair following infection with Influenza A virus. Notably,
since the completion of these studies in Chapter 2, multiple groups have reported
similar ILC2 populations in murine lung parenchyma (Barlow et al., 2012; Bartemes et
al., 2012; Chang et al., 2011; Halim et al., 2012; Kim et al., 2012; Yang et al., 2011;
Yasuda et al., 2012) that are involved in promoting airway inflammation upon exposure
to environmental allergens or lung pathogens (discussed in detail in section 1.5.1)
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1.4.3 Identification of ILC2s in human tissue
Several studies have identified ILCs in human blood, lymphoid organs, skin and
intestinal tissue that share the phenotypic and cytokine profile reminiscent of murine
ILC1s, ILC2s and ILC3s (Bartemes et al., 2014; Bernink et al., 2013; Cella et al., 2009;
Cella et al., 2010; Crellin et al., 2010a; Crellin et al., 2010b; Cupedo et al., 2009; Hughes
et al., 2010; Kim et al., 2013a; Sonnenberg et al., 2012; Teunissen et al., 2014).
However, the existence and functional characterization of ILCs within the human
respiratory tract was unknown. In Chapter 2, we performed the first interrogation of the
ILC population in healthy human lung tissue and bronchioalveolar lavage (BAL) fluid of
lung transplant patients, discovering an ILC2-like population expressing CD25, CD127
and ST2 (IL-33R) analogous to murine ILC2s. In a parallel study, Mjosberg et al.
identified ILC2 populations at multiple tissue sites, including fetal and adult intestine and
lung that were characterized by expression of CD161 and the chemoattractant receptor
CRTH2 (Mjosberg et al., 2011). CRTH2+ ILC2s expressed high levels of GATA3 and
responded to IL-33 and IL-25 to produce IL-13, similar to their murine counterparts
(Mjosberg et al., 2012; Mjosberg et al., 2011). Notably, CRTH2+ ILCs were also
detectable in human blood and displayed some level of plasticity not observed in tissueresident ILC populations. Blood CRTH2+ ILCs could produce IL-22 and IL-13 (Mjosberg
et al., 2011), suggesting that the blood may contain a progenitor ILC population capable
of differentiating into either IL-22-producing ILCs or IL-13-producing ILCs depending
upon the cytokine signals present in the tissue microenvironment. Since these initial
reports of ILC2s in the respiratory tract, subsequent studies have now identified ILC2
populations in a wide variety of human tissues and disease states, including in BAL from
patients with Idiopathic Pulmonary Fibrosis (IPF) (Hams et al., 2014), polyps from
patients with allergic rhinosinustiis (Mjosberg et al., 2012), skin from patients with atopic
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dermatitis (Kim et al., 2013a), and blood from asthmatic patients (Bartemes et al., 2014).
Collectively these studies indicate that ILC2s populate diverse lymphoid and barrier sites
within the human body, suggesting they may serve crucial roles in balancing immunity,
inflammation and tissue homeostasis during disease.

1.4.4 Transcriptional control of ILC2 development
The molecular cues that direct differentiation of the three ILC lineages are an ongoing
area of investigation. Recent reports have demonstrated striking similarities between the
transcriptional program that instructs ILC and CD4 T cell lineage specification. Mirroring
their Th2 CD4 T cell counterparts, ILC2s express high levels of GATA3 but lack
expression of RORγt and T-bet (Furusawa et al., 2013; Hoyler et al., 2012; Klein
Wolterink et al., 2013; Mjosberg et al., 2012). Interestingly, GATA3 has been shown to
be critical for the early development of both Group 2 and Group 3 ILCs (Serafini et al.,
2014; Yagi et al., 2014). However, temporal deletion of GATA3 only in mature cells
results in a loss of ILC2s while leaving ILC3s unaffected (Hoyler et al., 2012), suggesting
that only ILC2s require continual expression of GATA3 for long-term maintenance.
Additionally, the T cell master regulator TCF-1 (Tcf7), a target of Notch signaling,
instructs

ILC2

development

via

GATA3-dependent

and

GATA3-independent

mechanisms (Yang et al., 2013). Intriguingly, a second report demonstrated TCF-1
regulates ILC3s in addition to ILC2s (Mielke et al., 2013a), suggesting TCF-1 may be
acting on a common ILC2/ILC3 precursor at an early developmental checkpoint.
Whether TCF-1 regulates ILC1s in a similar fashion is currently unclear. ILC2s are
critically dependent on the transcriptional regulator RORα for development although the
developmental stage at which RORα acts remains unknown. (Spits and Cupedo, 2011;
Wong et al., 2012). IL-33R expression is a hallmark of the ILC2 lineage although the
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molecular factors regulating its expression are not well understood. Recent evidence
indicates that the transcription factor Gfi1 controls ILC2 development and activation by
directly regulating IL-33R and GATA3 (Spooner et al., 2013). Collectively these studies
provide insight into the transcriptional network controlling ILC2 development although
further investigation is required to more thoroughly delineate the factors controlling
specification of the ILC1/2/3 lineages.

1.4.5 Cytokine regulation of ILC2 responses
Consistent with their enrichment at epithelial barrier surfaces, ILC2s are characterized
by their responsiveness to the predominately epithelial cell-derived cytokines IL-25, IL33 and TSLP (Barlow and McKenzie, 2014; Kim et al., 2013b; Monticelli et al., 2012;
Spits and Cupedo, 2011). In vivo and in vitro evidence suggests that IL-33 and/or IL-25
are the primary signals for ILC2 activation at most tissue sites, with TSLP playing a more
minor role in amplifying ILC2 effector function by promoting cell survival (Barlow et al.,
2013; Halim et al., 2012; Salimi et al., 2013).
While the initial reports describing the role of intestinal ILC2s in anti-helminth
immunity implicated involvement of both IL-33 and IL-25 signaling (Moro et al., 2010;
Neill et al., 2010; Price et al., 2010), subsequent characterization of ILC2s in the lung
and lymphoid organs has indicated that IL-33, not IL-25, is the dominant signal for
inducing ILC2 proliferation and cytokine effector function (IL-5 and IL-13) (Barlow et al.,
2013; Saenz et al., 2013). These studies suggest that cues from the local tissue
microenvironment may instruct the cytokine-responsiveness of ILC2 populations. In
addition, the relative ability of these cytokines to promote ILC2 responses may also
depend upon mouse strain genetics. Supporting this, recent work by two groups
examining skin ILC2 responses during atopic dermatitis revealed that the role of TSLP
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versus IL-33/IL-25 signaling in eliciting ILC2 responses and regulating disease
progression was influenced by the genetic background of the mouse strain used
(C57BL/6 versus Balb/c) (Kim et al., 2013a; Salimi et al., 2013). Interestingly,
examination of genetically modified mice lacking all three cytokines IL-33, IL-25 and
TSLP demonstrated that development of ILC2s was largely unaffected although their
functional cytokine capacity was severely impaired (Van Dyken et al., 2014), indicating
that these epithelial cell-derived cytokines primarily serve as activation signals but are
not essential for cell development and maintenance.
While these studies collectively shed light on the cytokine regulation of ILC2
function at multiple tissue sites, examination of ILC2 functionality has largely been
restricted to measuring their production of the classic type 2 cytokines IL-5 and IL-13.
How IL-33 versus IL-25 signaling may influence other aspects of ILC2 effector function,
such as expression of growth factors, remains unknown. Furthermore, it is unclear
whether these cytokines elicit homogenous populations of cytokine-expressing ILC2s or
whether there is heterogeneity in the cytokine profile of ILC2s that may reflect their proinflammatory versus tissue-protective functions. Studies in Chapter 3 and 4 of this
thesis will examine the relative ability of these cytokines to elicit production of the growth
factor AREG in ILC2s and influence tissue repair in the lung and intestine.

1.5 ILC2s regulate immunity, inflammation and tissue homeostasis in the lung and
intestine
The presence of a population of ILCs that is constitutive in human and murine
respiratory tissue raises questions about their potential involvement in regulation of
immunity, inflammation or tissue homeostasis in the lung. The following sections will

	
  

19	
  

discuss the emerging evidence that ILC2s serve as crucial mediators of inflammatory
airway disease primarily through their production of the classical type 2 cytokines.

1.5.1 ILC2s promote development of airway hyper-reactivity
Airway inflammation is commonly triggered by a wide variety of allergic stimuli,
such as pollen or animal dander, and is characterized by high levels of IgE, type 2
cytokines, mucus production and eosinophilia (Broide, 2008; Corren, 2011; Crosby and
Waters, 2010; Doherty and Broide, 2007). Additionally, a second type of non-allergic
inflammation can arise following respiratory viral infection (Broide, 2008; Doherty and
Broide, 2007), but the cellular and molecular mechanisms underlying this type of airway
hyper-reactivity (AHR) response are much less understood. Recently lung ILC2s were
implicated in playing a pathologic role in promoting AHR following viral infection. In this
model, infection with influenza A virus subtype H3N1 induced acute airway inflammation
independently of adaptive immunity but dependent on the IL-33-IL-33R pathway and
ILC2s. (Chang et al., 2011). IL-13 has been shown to promote epithelial cell proliferation
in multiple settings of airway injury or inflammation (Broide, 2008; Crosby and Waters,
2010; Doherty and Broide, 2007; Rock and Hogan, 2011) and IL-13 expression by ILC2s
appeared to be essential for infection induced-AHR responses, as adoptive transfer of
wildtype, but not IL-13-deficient ILC2s, was sufficient to drive AHR responses in IL-13deficient hosts (Chang et al., 2011).
In addition to regulating virus-induced airway hyper-reactivity, further studies
have now defined roles for ILC2s in promoting allergic inflammation in response to a
wide variety of allergens. Intranasal challenge with either OVA antigen, recombinant IL25 or IL-33 protein resulted in the accumulation of IL-13-expressing ILC2s in the lung
and the development of AHR was dependent upon ILC2-intrinsic IL-13 (Barlow et al.,
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2012). A similar dependence on ILC2-derived IL-13 was also observed in an AHR model
using NKT glycolipid antigen (Kim et al., 2012). Exposure to the protease allergen
papain similarly induced ILC2s, eosinophilic infiltration and mucus production in the
airways (Halim et al., 2012), providing further evidence that ILC2-derived cytokines are
central to the promotion of chronic airway inflammation in multiple models (Fig. 3).
Expression of IL-13 in cooperation with IL-4 drives alternative activation of macrophages
(termed AAMacs) that have been implicated as important regulators of lung tissue
fibrosis in settings of allergic airway inflammation and chronic pulmonary fibrosis
disorders like COPD (Byers and Holtzman, 2011; Moreira and Hogaboam, 2011). Using
intranasal administration of chitin, lung ILC2s were recently shown to be required for
optimal polarization of AAMacs (Van Dyken et al., 2014), illustrating another mechanism
by which ILC2s can modulate development of airway inflammation. In addition to IL-5
and IL-13, IL-9 has been linked to a wide array of allergic disorders, although the cellular
sources and regulation of IL-9 expression remains controversial (Noelle and Nowak,
2010; Wilhelm et al., 2012). In response to papain exposure, ILC2s became a
predominant early source of IL-9 (Wilhelm et al., 2011). Although IL-9 production by
ILC2s was transient and dissipated soon after allergen challenge, antibody-mediated
blockade of IL-9 activity demonstrated a crucial role for autocrine IL-9 in promoting
optimal IL-5 and IL-13 expression (Fig 3). While collectively these studies implicate
ILC2s as important initiators of airway inflammation and hyper-reactivity to a broad array
of environmental insults, further investigation is required to define the differential
contributions of IL-5, IL-13 and IL-9 in ILC2-dependent regulation of allergic and nonallergic virally-induced airway inflammation.
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1.5.2 ILC2s regulate pulmonary immunity
The lung circulates over 10,000 liters of air every day, thereby being exposed to a
multitude of pathogens with the potential to invade the epithelium and cause disease
(Hallstrand et al., 2014; Holgate, 2011; Lambrecht and Hammad, 2014). Breach of the
epithelial barrier by viral, bacterial or parasitic pathogens requires coordinated efforts by
the innate and adaptive immune systems to contain the infection, clear the infected cells
and eliminate pathogen replication (Gorski et al., 2012; Hallstrand et al., 2014; Rackley
and Stripp, 2012). Currently there is no evidence to suggest that ILC2s directly regulate
anti-bacterial immunity in the lungs although this area merits further investigation. The
respiratory epithelium is also a frequent target of viral infections and the question of
whether ILC2s can influence anti-viral immunity will be addressed in Chapter 2
employing infection with influenza A virus. Lastly, there is some indication that ILC2s
may modulate anti-parasitic immunity during the transient pulmonary phase of infection.
Although adult helminth worms reside in the gut, the larvae must first migrate through
the lung parenchyma before being coughed up and swallowed to complete maturation
within the intestine (Allen and Maizels, 2011; Anthony et al., 2007). The cells and
effector mechanisms involved in regulating expulsion of the parasites from the lung
remain poorly defined. In two studies, Liang et al. and Yasuda et al. observed that IL-5
and IL-13-producing ILCs accumulated in the lung in response to two helminth parasites,
Nippostrongylus brasiliensis or Strongyloides venezuelensis (Liang et al., 2012; Yasuda
et al., 2012). Given the known role of IL-5-elicited eosinophils in parasite killing and
expulsion, it conceivable that IL-5 produced by the activated ILCs may aid in parasite
clearance (Yasuda et al., 2012) (Fig 3).
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1.5.3 ILC2s promote restoration of lung tissue homeostasis
The ability of ILC2s to regulate restoration of airway tissue homeostasis in response to
influenza virus-induced damage will be a central focus of Chapters 2 and 3 of this
thesis. Since the completion of these thesis studies, however, additional evidence has
emerged implicating ILCs in another model of pathogen-induced lung damage. During
infection with the helminth parasite Nippostrongylus brasiliensis, larval passage through
the lung results in severe acute tissue damage and triggers development of chronic type
inflammation and emphysematous pathology that persists for weeks after the parasite
leaves the respiratory tract (Allen and Maizels, 2011; Anthony et al., 2007). The cellular
and molecular factors that promote repair of the damaged lung and ultimately become
dysregulated to cause chronic inflammation are largely unknown. Since both IL-13 and
AREG are potent inducer of epithelial hyperplasia characteristic of both injury repair
responses and chronic pulmonary fibrosis (Crosby and Waters, 2010; Doherty and
Broide, 2007; Rock and Hogan, 2011), it is conceivable that ILC-derived IL-13 and/or
AREG may regulate remodeling and chronic inflammation of the injured lung. Supporting
this, depletion of ILC2s during N. brasiliensis resulted in reduced IL-13 and AREG levels
that correlated with impaired lung function and increased severity of the emphysematous
pathology (Turner et al., 2013). Further studies are needed to dissect the relative
contribution of IL-13+ and AREG+ ILC2s in regulating restoration of tissue homeostasis in
response to diverse patterns of injury.
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1.5.4 Role of ILC2s in regulating intestinal immunity, inflammation and tissue
repair

ILC2s were originally described as crucial early innate sources of the type 2 cytokines
IL-5 and IL-13 during infection with the intestinal helminth parasite Nippostrongylus
brasiliensis (Moro et al., 2010; Neill et al., 2010; Price et al., 2010). Employing immunodeficient mice or mice with disruptions in IL-25 or IL-33 cytokine signaling, these studies
demonstrated conclusively that ILC2s were both necessary and sufficient to mediate
parasite expulsion from the intestine. However, whether or not ILC2s play a role in
immunity against intestinal bacterial or viral infections remains an unanswered question.
Further, in comparison to the multitude of studies demonstrating the role of lung ILC2s in
promoting inflammation (reviewed in section 1.5.1), there is currently little evidence
supporting involvement of ILC2s in the development or progression of inflammatory
intestinal diseases such as IBD. One study utilizing an oxazolone-induced intestinal
injury model where type 2 cytokines are known to be pathologic observed that IL-25
elicited IL-13+ ILC2s correlated with disease severity (Camelo et al., 2012), although the
precise requirement for these cells in development of disease was not directly tested.
Finally, there is no information on whether ILC2s may play a beneficial, tissue-protective
role during inflammatory disease to regulate repair of the damaged tissue. Chapter 4 of
this thesis will explore the potential role of ILC2s and the IL-33-AREG-EGFR pathway in
tissue repair following acute intestinal injury.

1.5.5 Crosstalk between ILC2s and the adaptive immune system
ILCs are remarkably rare immune cells, vastly outnumbered by their conventional T cell
counterparts at barrier surfaces and lymphoid organs of both mice and man (Barlow and
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McKenzie, 2014; Kim et al., 2013b; Monticelli et al., 2012; Spits and Cupedo, 2011).
Since the ILC family shares many transcriptional and phenotypic characteristics with
CD4 T cell subsets, currently there are limited techniques available to selectively
manipulate ILC function without affecting conventional T cells. As a result, the majority of
studies investigating ILC function have been limited to utilizing immuno-deficient Rag-/mice that lack an adaptive immune system. While these studies have yielded useful
information on the innate role of ILCs, the critical question of how ILCs may interact with
the adaptive immune system to regulate immunity, inflammation and/or tissue repair
remains relatively unexplored. Understanding the cross-regulation between ILCs and the
adaptive immune system is essential for translating the mechanistic insights gained in
the murine studies to potential therapeutic targets in human disease.
Interplay between ILCs and adaptive T and B cells can potentially occur via direct
cell-cell contact mechanisms or indirectly through secretion of cytokine and chemokine
effector molecules that act on secondary cell types. In the case of ILC2s, reports have
provided evidence for both direct and indirect cross-regulation with T and B cells of the
lung and intestine. In the setting of intestinal anti-helminth immunity, adipose tissueassociated ILC2s were originally described as sources of IL-6 that promote B1 cell
proliferation and antibody responses in the intestine during helminth infection (Moro et
al., 2010). More recently, direct interactions between MHCII-expressing ILC2s and CD4
T cells have been shown to be essential for expulsion of the parasites from the intestine
while production of IL-2 from T cells reciprocally augments proliferation of MHCII+ ILC2s
(Oliphant et al., 2014). In the context of airway inflammation, T cell-derived IL-2 was also
shown to be important for ILC2 cytokine effector function, as ILC2-intrinsic IL-9 during
papain allergen exposure was reduced in the absence of IL-2 from T cells (Wilhelm et
al., 2011). Conversely, ILC2s have been proposed to indirectly augment CD4 T cell
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responses during airway inflammation by secreting IL-13 that enhances dendritic cell
migration to the lymph node to promote Th2 cell differentiation (Halim et al., 2014).
These initial studies provide evidence of critical crosstalk between ILC2s and the
adaptive immune system that influences the function of these cells during immunity and
inflammation. Continued examination and greater understanding of the extent of the
interplay between these cell types may aid in predicting the clinical implications of
targeting these cells during human health and disease.

1.5.6 Role of ILC2s in human disease
Allergic airway diseases affect over 300 million people worldwide (Broide, 2008; Corren,
2011), representing a significant global public health burden. While there is some clinical
evidence showing an association between elevated levels of IL-5 and IL-13 and
incidence of allergic airway disorders in human patients (Broide, 2008; Corren, 2011;
Doherty and Broide, 2007; Wilson and Wynn, 2009), the potential contribution of ILCs to
the development and/or progression of allergic inflammation in humans remains poorly
defined. The ability of ILC2s to secret high levels of Th2 cell-associated cytokines, and
their role in murine models of AHR indicate that ILC2s could be an attractive potential
target for improved immuno-therapies. Supporting a role for ILC2s in human allergic
airway disorders, Mjosberg and colleagues found elevated numbers of CRTH2+ ILC2s in
the nasal polyps of patients with chronic rhinosinusitis, an allergic type 2 inflammatory
disease characterized by high levels of circulating IgE and eosinophilia (Mjosberg et al.,
2011). Based on these observations, it is possible that high amounts of IL-5 produced by
CRTH2+ ILC2s within the nasal polyps can contribute to the characteristic eosinophilia
observed in this disease. Consistent with this hypothesis, patients with rhinosinusitis
polyps have higher levels of IL-5 and IL-13 transcripts than patients without polyps
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(Mjosberg et al., 2011), suggesting that CRTH2+ ILC2s may be an important target in the
development of new therapeutic strategies to ameliorate allergic airway inflammation. In
the setting of chronic lung inflammation and fibrosis, little is known about whether ILC2s
are dysregulated. One recent study has reported elevated CRTH2+ ILC2s in the BAL
fluid of patients with Idiopathic Pulmonary Fibrosis (IPF) (Hams et al., 2014), although
the functional potential of these cells was not examined. Importantly, the potential
influence of ILC2s on development or progression of human inflammatory diseases is
not limited to the airways. Dysregulated ILC2 responses have also been observed in
patients suffering from inflammatory conditions at other barrier surfaces, including skin
from patients with atopic dermatitis (Kim et al., 2013a), although the potential role of
ILC2s in intestinal inflammatory disease is unknown.

1.6 Murine models of tissue damage at barrier surfaces
In this thesis, two models of epithelial tissue damage will be employed to test the
potential contribution of ILC2s, IL-33-IL-33R signaling and AREG-EGFR interactions.

1.6.1 Influenza A virus infection of the respiratory tract
Infection with influenza A virus is a significant public health burden, with seasonal
outbreaks causing at least 36,000 deaths and more than 200,000 hospitalizations every
year in the United States (Clark and Lynch, 2011; Medina and Garcia-Sastre, 2011;
Molinari et al., 2007). As a member of the enveloped single stranded (ss)RNA family
Orthomyxoviridae, influenza A virus targets the epithelial cells of the respiratory tract for
replication and eventually spreads to infect dendritic cells and macrophages in the lung
(Iwasaki and Pillai, 2014; Jamieson et al., 2013; Peiris et al., 2010). Sensing of virus
infection by the epithelia and innate immune system involves recognition by TLR7, RIG-I
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and the NLRP3 inflammasome, resulting in a cascade of pro-inflammatory cytokines and
chemokines to recruit and activate the host innate and adaptive immune systems
(Iwasaki and Pillai, 2014; Peiris et al., 2010; Ranjan et al., 2009; Ueki et al., 2013). In
particular, generating a production type 1 interferon response is crucial for host recovery.
During this robust immune response, the airway epithelium becomes severely damaged
due to direct necrosis from the viral replication as well as secretion of inflammatory
mediators like IFNγ, TNFα and MIP-1α that elicit strong immune cell infiltration (Iwasaki
and Pillai, 2014; Peiris et al., 2010; Ueki et al., 2013).
While generation of CD8 T cell memory and long-lived antibody responses is
critical for protection against secondary infection, it has become increasingly clear that
successful repair of the damaged epithelia is equally important for ensuring host
recovery. As such, recovery from respiratory infections such as Influenza A virus
consists of three main phases: clearance of the virus, elimination of virus-induced
inflammation and initiation of epithelial remodeling responses to restore lung tissue
homeostasis and barrier integrity. Failure to adequately repair the damaged lung tissue
has been associated with elevated risk of secondary bacterial infections, particularly in
pandemic outbreaks such as the H1N1 strain in 2009 where loss of epithelial repair
mechanisms was shown to be a primary determinant of the severity of disease
pathogenesis (Peiris et al., 2010).
Despite the importance of tissue repair in host recovery, relatively little is known
about the cellular and molecular factors that regulate these processes in the context of
virus infection. Released by infected epithelial cells, TGFβ can induce proliferation of
fibroblasts to release collagen and matrix proteins to build a new foundation for epithelial
progenitor cells to expand upon (Iwasaki and Pillai, 2014; Peiris et al., 2010).
Additionally, production of IL-22 by NK cells was reported to promote regeneration of
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tracheal epithelial cells, although IL-22 appears not to affect repair of the epithelial cells
in the lower airways and parenchyma (Guo and Topham, 2010; Monticelli et al., 2011).
Whether cytokines and growth factors produced by type 2 innate immune cells, such as
IL-13 and AREG, can modulate epithelial repair following influenza virus infectioninduced damage is unknown and will be explored in Chapters 2 and 3 of this thesis.

1.6.2 Dextran sodium sulfate-induced intestinal inflammation
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammation of the intestinal
mucosa that results in impaired epithelial barrier integrity and a failure to regulate
mucosal wound healing (Hisamatsu et al., 2013; Kaser et al., 2010; Krishnan et al.,
2011; Neurath, 2014; Strober et al., 2007). There are multiple genetic and inducible
models of intestinal injury that are designed to mimic some of the features of human IBD
(Melgar et al., 2008; te Velde et al., 2007; Wirtz et al., 2007), although no model can
completely recapitulate the complexity of this multi-factorial human disease. Studies in
this thesis will utilize the dextran sodium sulfate (DSS)-induced model of acute intestinal
damage and inflammation. Oral administration of DSS in the drinking water is toxic to
epithelial cells at the base of the colon crypts, leading to barrier leakage and subsequent
exposure to commensal bacteria that results in epithelial damage and increased
expression of pro-inflammatory cytokines that activate immune cell populations (Melgar
et al., 2008; Perse and Cerar, 2012; te Velde et al., 2007). Symptoms of DSS-induced
intestinal injury include lethargy, weight loss and bloody stool that can eventually result
in death. Depending upon the dose, molecular weight and duration of DSS
administration, the mice can develop acute or chronic inflammation with varying degrees
of mucosal lesions and immune infiltrate, making DSS an attractive model to examine
multiple stages of disease severity (Melgar et al., 2005; Melgar et al., 2008; te Velde et
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al., 2007; Wirtz et al., 2007). Tissue injury specifically during acute DSS exposure, as
employed in Chapter 4, is characterized by goblet cell depletion with accompanying loss
of mucins, epithelial degeneration and necrosis, loss of crypt architecture and extensive
immune cell infiltration consisting primarily of neutrophilia (Melgar et al., 2005; Melgar et
al., 2008; te Velde et al., 2007; Wirtz et al., 2007). Importantly, unlike other intestinal
injury models such as T cell transfers into immuno-deficient mice, the progression of
DSS-induced intestinal inflammation does not require the adaptive immune response
(Perse and Cerar, 2012).
Notably, expression of IL-33 and its receptor ST2 has been shown to be
dysregulated in patients diagnosed with IBD (Kobori et al., 2010; Lopetuso et al., 2012;
Pastorelli et al., 2011; Pastorelli et al., 2010). However, whether IL-33 plays a tissueprotective or pathologic role in the colonic intestinal mucosa during disease is
controversial (Duan et al., 2012; Garcia-Miguel et al., 2013; Grobeta et al., 2012; Imaeda
et al., 2011; Lopetuso et al., 2012; Pastorelli et al., 2011; Pushparaj et al., 2013;
Sedhom et al., 2013) and the mechanisms which act downstream of IL-33 to regulate
disease severity are poorly understood. Additionally, the etiology of IBD has been linked
to multiple growth factor pathways, including EGFR-associated family members
(Hisamatsu et al., 2013; Lu et al., 2014; Neurath, 2014; Sipos et al., 2010; Yan et al.,
2011). Collectively, these attributes make DSS a useful model to assess the contribution
of ILC2s to intestinal inflammation and tissue repair. In Chapter 4 of this thesis, I will
employ oral administration of 3% DSS to induce acute intestinal injury over a one week
period and assess the role of the IL-33-ILC2-AREG pathway in regulating intestinal
inflammation and repair of the barrier.
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1.7 Outline of the thesis
The focus of this thesis will be to explore how populations of innate lymphoid cells
orchestrate restoration of tissue homeostasis at epithelial barrier surfaces of the lung
and intestine in response to acute tissue damage. Chapter 2 will characterize the
population of ILCs constitutively present in the respiratory tract of humans and mice and
examine whether lung ILC2s can influence airway epithelial barrier integrity and tissue
homeostasis following influenza virus-induced pulmonary damage. The mechanism of
ILC-mediated tissue repair will be examined in Chapter 3 through interrogation of the
role of the AREG-EGFR growth factor pathway in host recovery from influenza virus
infection. Lastly, data presented in Chapter 4 will explore the relevance of this pathway
in sites outside the lung and uncover an IL-33-dependent innate immune mechanism of
intestinal tissue repair dependent on AREG-EGFR interactions. Collectively, the data
presented in this thesis reveal a conserved innate mechanism of barrier repair by which
the

mammalian

immune

system

responds

to

damage

microenvironment to promote restoration of tissue homeostasis.
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Figure 1: The type 2 immune response at barrier surfaces
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Figure 1: The type 2 immune response at barrier surfaces
At mucosal surfaces, a single layer of epithelial cells serves as a critical barrier between
the host immune system and outside envrionmental stimuli. Upon exposure to
pathogens or allergens, epithelial cells release cytokine signals such as Interleukin (IL)25, IL-33 and thymic stromal lymphopoietin (TSLP) to elicit and activate the innate and
adaptive immune cells of the type 2 inflammatory response. While activation of these
cells is essential for host protective immunity and tissue repair to restore homeostasis,
dysregulation of the type 2 immune response can result in development of pathologic
chronic inflammation and tissue fibrosis.
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Figure 2: The ILC family
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Figure 2: The ILC family
The innate lymphoid cell (ILC) family is composed of three main groups that all derive
from Id2+ ILC precursors. Group 1 ILCs (orange) require T-bet, IL-7 and IL-15 for
development and respond to IL-12 to produce IFNγ. Group 2 ILCs (green) are comprised
of Nuocytes (Nuo), Natural Helper (NH) cells, Innate Type 2 Helper (Ih2) cells and lungresident ILCs that express GATA3 and depend upon RORα, TCF-1 and Gfi1 for
development. Upon IL-25, IL-33 and/or TSLP stimulation, Group 2 ILCs can produce IL5, IL-13, IL-9 and amphiregulin (Areg). Group 3 ILCs (blue) consist of a heterogeneous
population of RORγt-dependent ILCs that respond to IL-23, IL-1β and AhR ligands to
express IL-22 and/or IL-17A.
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Figure 3: ILC2s regulate immunity, inflammation and tissue homeostasis in the
lung
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Figure 3: ILC2s regulate immunity, inflammation and tissue homeostasis in the
lung
Contact with allergens, viruses or parasitic helminth worms causes inflammation of the
airway epithelium, resulting in production of IL-33, IL-25 and/or TSLP (red arrow) that
activates Group 2 ILCs to express a variety of effector cytokines that can drive either
pathologic airway hyper-reactivity (AHR) responses (blue arrow) or can promote
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beneficial tissue-protective responses to repair the damaged epithelium (green arrow).
IL-5-mediated recruitment of eosinophils and IL-13-mediated epithelial cell/goblet cell
proliferation can coordinately drive AHR responses. IL-9 acts in an autocrine manner to
promote optimal IL-5/IL-13 expression in ILC2s. ILC2-derived IL-13 also influences
differentiation of alternatively-activated macrophages and polarization of Th2 CD4 T
cells (via DCs).

Additionally, data presented in Chapters 2 and 3 of this thesis

demonstrate that ILC2 expression of amphiregulin (Areg) can promote epithelial cell
proliferation to repair injured airway epithelia that has been damaged by virus infection
(green arrow).
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Chapter 2
Innate lymphoid cells promote lung tissue homeostasis
after influenza virus infection

2.1 Abstract
Innate lymphoid cells (ILCs), an emerging family of heterogeneous innate immune cells,
reside at barrier surfaces and appear to represent the innate counterpart to the CD4
helper T cell lineage. Previous studies have demonstrated a critical role for these cells in
orchestrating immunity and inflammation in the intestine but whether ILCs can influence
immune responses or tissue homeostasis at other mucosal sites remains poorly
characterized. Data presented in this Chapter identify a population of lung-resident ILCs
in mice and human airways that expressed CD90, CD25, CD127 and T1/ST2.
Development of lung ILCs was critically dependent on the transcriptional factor Id2 but
independent of commensal microbial-derived signals. Lung ILCs produced IL-5 and IL13 in response to the predominantly epithelial cell-derived cytokine IL-33, thereby
demonstrating a functional profile reminiscent of recently identified natural helper cells
and nuocytes (Group 2 ILCs “ILC2s”) that reside in the intestine and fat-associated
lymphoid clusters. Strikingly, murine ILCs accumulated in the lung following influenza
virus infection and depletion of ILCs or blockade of IL-33-IL-33R signaling resulted in
loss of airway epithelial barrier integrity, decreased lung function and impaired airway
tissue remodeling. Collectively, these results demonstrate a novel role for lung ILCs and
the IL-33-IL-33R pathway in restoring airway epithelial integrity and tissue homeostasis
following influenza virus-induced tissue damage.
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2.2 Introduction
Maintenance of epithelial barrier function at mucosal sites such as the intestine
and respiratory tract is critical to limit exposure to environmental stimuli, commensal
bacteria and invading pathogens (Artis, 2008; Sonnenberg et al., 2010; Turner, 2009).
Recent studies have highlighted multiple roles for innate lymphoid cells (ILCs) in
regulating immunity and/or inflammation at the intestinal barrier (Saenz et al., 2010a;
Spits and Di Santo, 2011).
ILCs are an emerging, diverse family of immune cells that are heterogeneous in
their tissue location, cytokine production and effector functions (Saenz et al., 2010a;
Spits and Di Santo, 2011). Although the lineage relationships between these
heterogeneous ILC populations are still being fully elucidated and is an area under
intense investigation, they are hypothesized to originate from a common Id2-dependent
progenitor cell (Rankin and Belz, 2011; Spits and Di Santo, 2011). Based on their
differential expression of the transcription factors T-bet, GATA3 and RORγt, mouse ILCs
can be functionally divided into three main populations. Group 1 ILCs (ILC1) express the
transcription factor T-bet and produce IFNγ (Bernink et al., 2013; Klose et al., 2014).
GATA3+ Group 2 ILCs (ILC2) express the TH2 cell-associated cytokines IL-4, IL-5 and
IL-13, and are composed of nuocytes, natural helper cells (NHCs) and innate helper type
2 cells (Ih2). These cells are activated in response to the epithelial cell-derived cytokines
IL-25 and/or IL-33 and can promote TH2 cytokine-dependent protective immunity against
intestinal helminth parasites (Moro et al., 2010; Neill et al., 2010; Price et al., 2010;
Saenz et al., 2010b). Lastly, RORγt+ Group 3 ILCs (ILC3) include CD4+ lymphoid tissue
inducer (LTi) cells, NKp46+ ILCs and a population of CD4- NKp46- ILCs, all of which
express interleukin 17A (IL-17A) and/or IL-22 and can promote intestinal immunity
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and/or inflammation (Buonocore et al., 2010; Satoh-Takayama et al., 2008; Sonnenberg
et al., 2011; Spits and Di Santo, 2011; Takatori et al., 2009). Although these
phenotypically distinct ILC populations have been identified in intestinal and lymphoid
tissue compartments of mice, whether ILCs are present at barrier surfaces in humans
and whether they influence immune responses or tissue homeostasis in the respiratory
tract is unclear.
Respiratory infections, such as influenza virus, cause significant damage to the
lung epithelium as a consequence of direct virus-mediated cell death and indirect
immunopathology caused by immune cell activation (Gorski et al., 2012; Peiris et al.,
2010). It is now well appreciated that successful recovery from respiratory viral infections
involves not only virus clearance, but also appropriate remodeling of the injured tissue to
restore airway barrier integrity and lung function. Repair and remodeling of damaged or
inflamed tissue is a complex process involving many factors, including cytokines,
chemokines, growth factors and extracellular matrix proteins that restore tissue
homeostasis after injury (Crosby and Waters, 2010; Rock and Hogan, 2011). Failure to
either appropriately initiate or resolve these repair responses can have detrimental
effects, including loss of tissue integrity or function and promotion of chronic
inflammation or tissue fibrosis (Crosby and Waters, 2010; Rock and Hogan, 2011).
However, the cellular and molecular regulators of tissue remodeling following injury or
infection at mucosal tissues such as the lung are poorly understood.
Here in Chapter 2, we employ infection with the H1N1 PR8 strain of influenza
virus and identify a previously unrecognized role for ILCs in promoting restoration of
tissue homeostasis in the lung. In mice, lung-resident ILCs were Lin- and expressed cell
surface markers associated with nuocyte and NHC populations (ILC2s), including CD90,
CD25, CD127 and T1/ST2 and produced IL-5 and IL-13 in response to IL-33 stimulation.
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An analogous population of Lin- lung ILC2s was also present in bronchoalveolar lavage
fluid and lung parenchyma of humans. ILC2s accumulated in the lung of wild-type (WT)
or Rag1-/- mice following experimental influenza virus infection and depletion of CD90+
ILCs or blockade of IL-33-IL-33R signaling in influenza virus-infected mice resulted in
severely decreased lung function, loss of airway epithelial integrity and impaired
respiratory tissue remodeling. Collectively, these data identify the presence of ILC2s in
the lung of both humans and mice and demonstrate a crucial role for murine lung ILC2s
in regulating airway epithelial integrity and orchestrating pulmonary tissue homeostasis
following experimental influenza virus infection.

2.3 Methods
2.3.1 Mice
C57BL/6 wild-type (WT) mice and Rag1-/- were purchased from the Jackson Laboratory.
All mice were maintained in specific pathogen-free facilities at the University of
Pennsylvania. All protocols were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee (IACUC), and all experiments were performed
according to the guidelines of the University of Pennsylvania IACUC. Germ-free mice
were maintained in plastic isolator units, fed autoclaved feed and water, and routinely
monitored to ensure absence of microbial contamination.	
   Generation of Id2-deficient
mice and fetal liver chimeras have been described previously (Cannarile et al., 2006;
Monticelli et al., 2009). 	
   For generation of Id2-deficient bone marrow chimeras, 10-20 x
106 bone marrow cells from Id2+/+ or Id2-/- fetal liver chimeras were transferred i.v. into
irradiated hosts (900 RAD) of a different congenic marker. All chimeras were placed on
antibiotic drinking water (Sulfamethoxazole and Trimethoprim, Hi-Tech Pharmacal Co.)
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for two weeks following irradiation and were allowed to reconstitute for 10 weeks prior to
analysis.

2.3.2 Flow cytometry
Single cell suspensions were stained with a combination of the following monoclonal
fluorescently conjugated antibodies: FITC-conjugated T1/ST2 (DJ8; MD Bioproducts).
PE-conjugated ICOS (7E.17G9), Sca-1 (D7), c-kit (2B8), NKp46 (29AI.4), Siglec F (E502440; BD Pharmigen). PerCP-Cy5.5-conjugated CD3 (17A2), CD5 (53-73), CD27
(LG.7F9), NK1.1 (PK136), TCRβ (H57-597), CD11b (MI/70), CD11c (N418), B220 (RA36B2). APC-conjugated CD44 (IM7), c-kit (2B8), CD90.1 (HIS51). eFluor-450-conjugated
CD127 (A7R34), CD45.1 (A20). PE-Cy7-conjugated CD25 (PC61.5). Alexa 700conjugated CD90.2 (30-H12) and Ly6G (1A8; Biolegend). e-Fluor-780-conjugated
CD11b (MI/70), CD11c (N418), TCRβ (H57-597), B220 (RA3-6B2), CD45.2 (104). PETexas Red-conjugated CD4 (GK1.5; Abcam). All antibodies were purchased from
eBioscience unless specified otherwise. For measurement of intracellular cytokine
expression, stimulated cells were surface stained with a combination of the antibodies
listed above, fixed and permeabilized using a commercially available kit (eBioscience),
and stained with IL-5 APC (TRFK5; BD Pharmigen), IL-13-PE (eBio13A; eBioscience),
IL-17A PE (TC11-18H10; BD Pharmigen), or IL22-02 (from Pfizer Inc.) conjugated to
Alexa Fluor 647 according to manufacturer's instructions (Molecular Probes). For
measurement of intracellular RORγt, cells were fixed, permeabilized and stained with
RORγt PE (AFKJS-9; eBioscience)

For all stains, dead cells were excluded from

analysis by means of an Aqua viability stain (Invitrogen LIVE/DEAD). Samples were
acquired on a BD LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo
software (v9.2, Tree Star).
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2.3.3 Isolation of cells from mouse lung tissue
Lungs were perfused with 10 ml PBS through the right ventricle of the heart prior to
removal. Lungs were then cut into small pieces using scissors and digested with 1 mg/ml
Collagenase D (Roche) in PBS for 30-45 min at 37 °C with vortexing every 10 min.
Samples were mashed through 70 µm cell strainers, washed with DMEM media
(supplemented with 10% FBS, 1% L-glutamine (GIBCO), 1% Pencillin/Streptomycin
(GIBCO)), and any remaining red blood cells were lysed. Single cell suspensions were
used for subsequent flow cytometry staining.

2.3.4 Analysis of human BAL fluid and lung
Human bronchoalveolar lavage samples were obtained as residual material from clinical
procedures from nine patients undergoing routine surveillance bronchoscopies during
the first year following lung transplant.	
  Patients were on a regimen of immunomodulatory
drugs following lung transplant, including tacrolimus and prednisone in addition to either
mycophenolate or azathioprine. Use of human BAL samples for research purposes was
approved by the University of Pennsylvania IRB and carried out in accordance with
protocols for use of residual clinical material with waiver of consent.
Human lung tissue was obtained from cadaver organ donors in collaboration with
the New York Organ donor network (NYODN, New York, NY). Consent was obtained for
use of lung tissue from human cadavers for research purposes. Lung tissue was cut into
small pieces with a curved scissor and subsequently incubated at 37 °C with shaking for
1 h in collagenase solution (1 mg/ml Collagenase D, 1 mg/ml Trypsin Inhibitor and 25
µg/ml DNAse I). The tissue was then mechanically dissociated using a gentleMACS
Dissociator (Miltenyi Biotech) and strained with a wire mesh tissue sieve. Remaining
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connective tissue was then removed by passing the cell suspension through a syringe
column fitted with glass wool.

Lymphocytes were subsequently separated by

centrifugation through Ficoll (LSM, Invitrogen).
For analysis of ILC populations, single cell suspensions of BAL fluid and lung
parenchyma were stained with the following monoclonal antibodies for flow cytometric
analysis: ST2 FITC (B4E6; MD Bioproducts), CD3 PerCP-Cy5.5 (SK7; BD Pharmigen,
intracellular staining), CD11b APC (MI/70; eBioscience), CD19 eFluor 450 (HIB19;
eBioscience), CD25 PE-Cy7 (M-A251) BD Pharmigen), CD56 Alexa Fluor 700 (CMSSB;
BD Pharmigen), CD127 eFluor 780 (eBioRDR5; eBioscience), CD11c PE-Cy5 (B-ly6)
BD Pharmigen) and TCRαβ PE-Cy5 (IP26; eBioscience), live/dead aqua stain
(Invitrogen). Samples were acquired on a BD LSRII flow cytometer (BD Biosciences)
and analyzed using FlowJo software (v9.2, Tree Star).

2.3.5 RNA isolation and Real-Time Quantitative PCR
RNA was isolated from purified populations of CD90+ CD25+ lung ILCs, CD90+ CD4+
splenic LTi cells or B220+ splenic B cells, sorted using a BD FACSAria (BD Biosciences)
cell sorter. RNA was isolated using RNeasy mini kit according to manufacturer’s
instructions (QIAGEN). cDNA was generated using Superscript reverse transcription
(Invitrogen).

Real-time quantitative PCR (qRT-PCR) was performed on cDNA using

SYBR green master mix (Applied Biosystems) and commercially available primer sets
(QIAGEN).

Reactions were run on a real-time PCR system (ABI7500; Applied

Biosystems). Samples were normalized to β-actin and displayed as a fold induction
relative to expression seen in purified B cells (Id2 and Rorc) or naïve lung tissue (Areg,
Il5 and Il13).
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2.3.6 Cytokine ELISA
CD90+ CD25+ T1/ST2+ lung ILCs were sort-purified from the lungs of C57BL/6 mice
using a BD FACSAria cell sorter. 2 x 104 lung ILCs were cultured in DMEM complete
media in the presence of 10 ng/ml rmIL-7, 10 ng/ml rIL-2, and/or 30 ng/ml rmIL-33 (for
measurement of IL-5, IL-13 and amphiregulin) or 50 ng/ml rmIL-23 (for measurement of
IL-17A) for four days (all recombinant cytokines obtained from R&D Systems).
Supernatants were collected after 4 days of culture. For measurement of amphiregulin in
whole tissue, lung tissues from naïve or PR8 influenza-infected mice were homogenized
in sterile PBS and centrifuged to remove cell debris. Measurement of IL-5, IL-13 and IL17A

were

performed

using

commercially

available

ELISA

kits

(eBioscience).

Amphiregulin was measured using DuoSet ELISA Kit (R&D Systems).

2.3.7 Influenza infection, antibody treatments and cytokine administration
For infections with PR8 influenza virus, C57BL/6 or Rag1-/- mice were anaesthetized with
2.5% Avertin i.p. and infected with 0.5 LD50 PR8-GP33 virus (recombinant virus
expressing the LCMV epitope GP33) in 25µl volume administered intransally. PR8-GP33
influenza virus was grown and titered as previously described(Decman	
   et	
   al.,	
   2010).	
  

The replication and pathogenicity of this recombinant PR8 strain was not substantially
different from nonrecombinant virus39.	
  	
  
For monoclonal antibody treatments, anti-CD90.2 mAb (30H12) and anti-NK1.1
mAb (PK136) were purchased from BioXCell (West Lebanon, NH). Anti-IL-33R mAb
(anti-ST2 clone 245707) was purchased from R&D Systems. All mAb treatments were
administered i.p. every 3 days at a dose of 200 µg/mouse starting on the day prior to
infection.
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For cytokine treatments, recombinant murine IL-13 or amphiregulin (R&D
Systems) was administered i.p. every 2 days at a dose of 5-10 µg starting on the day of
infection.

2.3.8 ILC adoptive transfer
1x105 Lin- CD90+ CD25+ T1-ST2+ ILCs were sort-purified from the lungs of naïve CD90.1
wild-type mice and transferred intravenously into anti-CD90.2 mAb-treated Rag1-/- mice
at day 0 and day 5 post influenza virus infection (0.5 LD50 PR8).

2.3.9 Lung histological sections
Left lobes of lungs were perfused and fixed with 4% paraformaldehyde, embedded in
paraffin, and 5 µm sections were used for staining with H&E.

2.3.10 Measurement of Pulse Oximetry
The MouseOxTM Pulse-oximeter (Starr Life Sciences) was used to measure blood SpO2
in PR8-infected mice during the course of infection. A depilatory agent (Nair, Church &
Dwight Co.) was applied to the neck of anesthetized mice 2 days prior to influenza
infection to remove hair and delay future hair growth. For readings, the oximeter clip was
placed on the neck and percent SpO2 was measured each second over several minutes,
data shown is average of SpO2 readings recorded over 3-5 min per mouse.

2.3.11 Measurement of BAL fluid protein concentration
Bronchoalveolar lavage fluid was collected from naïve or PR8-infected mice using the
following method. A small cut was made in the trachea and a thin tube was inserted.
Lungs were lavaged using 500 µl PBS and fluid was immediately placed on ice. BAL
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fluid was spun down to pellet cells and cell-free supernatant was collected.
Measurement of total protein was performed using a Micro BCA protein assay (Pierce
Thermo Scientific) according to manufacturer’s instructions.

2.3.12 Influenza virus quantification
Lung tissue was homogenized and RNA was isolated using RNeasy mini kit according to
manufacturer’s instructions (QIAGEN). cDNA was generated using MultiScribe reverse
transcription (Invitrogen).

Real-time quantitative PCR (qRT-PCR) was performed on

cDNA using FAM/TAM system (Applied Biosystems). Primers and Taqman probe were
generated that were specific for M1 protein of PR8-GP33 influenza virus. Reactions
were run on a real-time PCR system (ABI7500; Applied Biosystems).

Viral RNA

concentration (ng per gram of lung tissue) in each sample was determined by
comparison to a standard curve of PR8-GP33 virus RNA concentrations and converted
to µl of virus per gram of lung tissue. The TCID50 of PR8-GP33 per µl of virus was
determined with a plaque assay on Madin-Darby canine kidney (MDCK) cell monolayers
as previously described39. The TCID50 per µl of virus was then multiplied by the µl of
virus present in the lung tissue to determine the TCID50 equivalence.

2.3.12 Statistical analysis
Results represent the mean ± SEM unless indicated otherwise. Statistical significance
was determined by unpaired Student’s t test. Statistical analyses were performed using
Prism GraphPad software v5.0. (*,P < 0.05; **, P < 0.01; ***, P < 0.001).
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2.4 Results
2.4.1 Lung-resident ILCs phenotypically resemble natural helper cells and
nuocytes
To examine whether ILCs are present at extra-intestinal mucosal sites, we performed
flow cytometric analysis of cells isolated from the lung tissues of naive wild-type
C57BL/6 or Rag1-/- mice. We identified a population of lineage negative (Lin-) cells that
lacked expression of lineage markers associated with T cells (CD3, CD5, TCRβ, CD27),
B cells (B220), macrophages (CD11b), dendritic cells (CD11c) or NK cells (NK1.1).
These Lin- cells expressed CD90 (Thy1), CD25 (IL-2Rα) and CD127 (IL-7Rα) (Fig. 4A),
a pattern of surface marker expression consistent with ILCs (Saenz et al., 2010a; Spits
and Di Santo, 2011). Further examination of these Lin- CD90+ CD25+ lung ILCs revealed
a lack of expression of either CD4 or NKp46 (Fig. 4B), thus distinguishing lung-resident
ILCs from conventional ILC3 subsets (CD4+ LTi cells or NKp46+ ILCs (Spits and Di
Santo, 2011)). However, lung ILCs did express the activation markers CD44 and ICOS
as well as Sca-1 and c-kit (Fig. 4B), similar to the phenotype of nuocytes and
NHCs(Moro et al., 2010; Neill et al., 2010). Furthermore, CD90+ CD25+ lung ILCs
expressed the IL-33R subunit T1/ST2 (Fig. 4B). This Lin- population of ILCs was a
relatively rare population, totaling 2-3 x104 cells in naïve mice, representing 0.4-1% of
total live cells in the lung (Fig. 4C). Collectively, these data indicate that lung-resident
ILCs most closely resemble nuocytes and NHCs, which were originally reported to be
present in secondary lymphoid tissue and fat-associated lymphoid clusters (FALCs)
(Moro et al., 2010; Neill et al., 2010). Collectively, these cell populations are now
referred to as Group 2 ILCs (ILC2s).
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2.4.2 ILCs are present in human lung and airways
Recent studies have described heterogeneous populations of ILC3 LTi-like cells and
NKp46+ cells that express IL-17A and/or IL-22 located in human lymphoid tonsil and
Peyer’s patch tissues (Cella et al., 2009; Cella et al., 2010; Crellin et al., 2010b; Cupedo
et al., 2009; Hughes et al., 2010). However, whether human ILC populations exist at
other barrier surfaces such as the respiratory tract and what surface markers they
express had not yet been examined. Similar to findings in mice, we identified a Linpopulation of cells in previously healthy human lung parenchymal tissue from organ
donors that lacked expression of markers for T cells (CD3, TCRαβ), dendritic cells
(CD11c), NK cells (CD56), macrophages (CD11b) or B cells (CD19), but that expressed
CD127 (IL-7Rα) (Fig. 5A). The Lin- CD127+ ILC population in the lung parenchyma
expressed CD25 (IL-2Rα) and the IL-33R subunit ST2 (Fig. 5B), consistent with the cell
surface phenotype of the lung-resident ILC population found in mouse lung (Fig. 5A,B)
and previously identified members of the ILC2 subset including murine nuocytes and
NHCs (Moro et al., 2010; Neill et al., 2010). To determine if an analogous ILC2
population exists in the airway, we examined bronchoalveolar lavage (BAL) fluid from
lung transplant recipients. Similar to the population of ILC2s found in lung parenchyma,
we identified a Lin- CD127+ ILC population that also expressed CD25 and ST2 in BAL
fluid from 7 of 9 lung transplant recipients examined (Fig. 5C,D). Thus, these data
provide evidence of NHC/nuocyte-like ILC2 populations in human respiratory tissue.

2.4.3 Lung-resident ILCs produce IL-5 and IL-13 but not IL-22
Recent studies demonstrated that nuocytes and NHCs can be activated by IL-33 alone
or in combination with IL-7 to produce IL-5 and IL-13 (Moro et al., 2010; Neill et al.,
2010). While stimulation of sort-purified CD90+ CD25+ T1/ST2+ lung ILCs with IL-2 and
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IL-7 had no apparent effect on IL-5 or IL-13 cytokine secretion, the addition of IL-33
resulted in elevated production of both IL-5 and IL-13 (Fig. 6A,B). Unlike CD4+ splenic
LTi (ILC3) cells (Fig 6C) or NKp46+ ILC3s (Satoh-Takayama et al., 2008; Sonnenberg et
al., 2011; Takatori et al., 2009), CD90+ CD25+ lung ILCs expressed minimal IL-22 or IL17A in response to IL-23 stimulation (Fig. 6C,D). Consistent with in vitro IL-33
stimulation, administration of recombinant (r)IL-33 in vivo resulted in an elevated
frequency of lung-resident ILCs that produced the TH2 cell-associated cytokines IL-5 and
IL-13, but not the TH1 cell-associated cytokine interferon-γ (IFN-γ) (Fig. 6E). Taken
together, these results indicate that ILCs in the respiratory tract share a cell surface
phenotype and cytokine profile that most closely resembles nuocytes and NHCs (ILC2s).

2.4.4 Lung ILC development requires Id2 but not commensal microbial-derived
signals
Members of the ILC family including LTi cells, NKp46+ ILCs and NHCs share a
developmental requirement for the transcriptional regulator Id2 (Boos et al., 2007; Moro
et al., 2010; Satoh-Takayama et al., 2010; Yokota et al., 1999). To examine the
influence of Id2 on the development of lung-resident ILCs, expression of Id2 was
examined in sort-purified lung CD90+ CD25+ ILCs. Quantitative analysis of Id2 mRNA
expression revealed comparable abundance of Id2 mRNA in lung-resident ILCs and
conventional splenic CD4+ LTi (ILC3) cells (Fig. 7A), a population known to be Id2dependent (Boos et al., 2007; Satoh-Takayama et al., 2010; Yokota et al., 1999).
Consistent with a developmental requirement for Id2, lung resident CD90+ CD25+ ILCs
were not detectable in chimeric mice deficient in Id2 (Fig. 7B), thereby developmentally
linking this cell population to the Id2-dependent ILC family.
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Based on their expression of the transcription factor RORγt, GATA3 and T-bet,
ILCs can be divided into multiple populations, one of which is critically dependent on
RORγt for development (LTi cells, NKp46+ ILCs) and the others that are RORγtindependent (including nuocytes and NHCs) (Spits and Di Santo, 2011). Compared to
splenic LTi cells, lung ILCs did not express abundant RORγt (Rorc) mRNA (Fig. 7C) or
protein (Fig. 7D, providing further evidence that lung ILCs are more closely related to
nuocytes and NHCs (ILC2s) than LTi or NKp46+ ILC populations (ILC3s).
Signals derived from commensal bacterial communities have also been
implicated in the development and/or activation of several ILC subsets (Sanos et al.,
2009; Satoh-Takayama et al., 2008; Sawa et al., 2011). To test whether live commensal
bacterial-derived signals influenced the development of lung-resident ILCs, we examined
ILCs in the lungs of conventional (CNV) or germ-free (GF) C57BL/6 mice. CNV and GF
mice had similar frequencies (Fig. 8A-B), total numbers (Fig 8C), and surface phenotype
of lung ILCs (Fig. 8D), indicating that development of lung ILCs is dependent on Id2 but
independent of signals derived from live commensal bacteria.

2.4.5 Influenza virus induces ILC responses in the lung
ILCs have been shown to mediate anti-bacterial or anti-helminth immunity in the
intestine (Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al., 2010b;
Satoh-Takayama et al., 2008; Sonnenberg et al., 2011); however, the functional
significance of ILCs in regulating immunity and/or inflammation in the lung is not well
understood. To investigate whether lung ILCs can influence immunity, inflammation or
tissue homeostasis in the lung, we utilized a model of respiratory infection with mouseadapted H1N1 influenza virus A/Puerto Rico/8/34 (PR8). Wild-type mice control viral
replication and recover following infection with this dose of PR8 (0.5 LD50 or ~300
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TCID50) and although Rag1-/- mice are unable to clear infection and eventually succumb
within 12-14 days, the early ILC response and pathologic consequences of infection,
including the decline in lung function and lung immunopathology, were similar in
immunocompetent and immunodeficient hosts (Fig 9A-C). In response to intranasal PR8
infection, CD90+ CD25+ ILCs accumulated in the lung parenchyma in both wild-type
C57BL/6 and Rag1-/- mice (Fig. 9D-F). Taken together, these data demonstrate that
ILCs respond to influenza virus infection in the lung in the presence or absence of the
adaptive immune system, suggesting a potential role for lung ILCs in regulating innate
immunity, inflammation and/or tissue homeostasis in the lung.

2.4.6 ILC depletion impairs lung function and tissue repair
While both cellular and humoral arms of the adaptive immune system have been shown
to be crucial for immunity to respiratory viruses, the influence of innate cell populations
on anti-viral immunity in the lung remains poorly understood (Kohlmeier and Woodland,
2009). To examine the influence of lung ILCs on innate immunity to influenza virus,
isotype or anti-CD90.2 depleting monoclonal antibodies (mAb) were administered in vivo
to PR8-infected Rag1-/- mice (Fig 10A). As some NK cells can also express CD90.2
upon activation, an additional group of mice was treated with anti-NK1.1 mAb to allow
direct comparison of anti-CD90.2-mediated depletion of ILCs versus anti-NK1.1mediated depletion of NK cells.

Administration of anti-CD90.2 antibody effectively

depleted the CD90+ CD25+ population of ILCs in the lung (Fig. 10B). Depletion of
CD90.2+ ILCs or NK1.1+ NK cells did not affect viral loads in the lung compared to
isotype treated mice (Fig. 10C), suggesting that neither NK cells nor ILCs directly
contribute to innate control of viral replication. However, mice that received anti-CD90.2
mAb exhibited a substantially lower mean body temperature at day 10 post infection
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(p.i.) (Fig. 10D), indicating exaggerated thermo-dysregulation and morbidity in the
absence of CD90.2+ ILCs. Strikingly, depletion of CD90.2+ ILCs resulted in significantly
decreased lung function as measured by pulse oximetry (Pulse Ox), reaching average
blood oxygen saturation levels below 54% in anti-CD90.2 treated mice at day 9 p.i.
compared to 76% in isotype-treated controls (Fig. 10E). Furthermore, depletion of
CD90.2+ ILCs significantly impaired epithelial integrity, as measured by increased total
protein concentration in the BAL fluid compared to isotype or anti-NK1.1 treated mice
(Fig. 10F).
Influenza is a cytopathic virus that replicates preferentially in airway epithelial
cells and causes severe acute injury to the respiratory epithelium (Kohlmeier and
Woodland, 2009). Although isotype-treated or NK cell-depleted Rag1-/- mice eventually
succumb to infection between day 13-14 due to the absence of an adaptive immune
response (data not shown), they generated hyperplastic epithelial and goblet cell
responses essential for repair of the damaged airway epithelial barrier (Fig. 11A-B). In
contrast to isotype or anti-NK1.1 mAb treatment, depletion of CD90.2+ ILCs resulted in
an impaired ability to generate hyperplastic epithelial cell responses (Fig. 11C) and led
to substantial epithelial degeneration and necrosis (black arrows), including in many
cases the complete sloughing of the bronchiolar epithelial lining (Fig. 11C-D). This
epithelial necrosis was unlikely to be due to anti-CD90.2 mAb treatment affecting the
epithelia directly, as bronchioles in anti-CD90.2 mAb-treated naïve mice had normal
epithelial cell lining (Fig. 11E) similar to untreated naïve mice (Fig. 11F). Collectively,
these observations indicate a critical role for CD90.2+ ILCs in promoting airway epithelial
integrity and restoring tissue homeostasis in the lung following acute viral infection.
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2.4.7 Lung ILCs are sufficient to restore airway integrity
CD90 is expressed on a number of hematopoietic and non-hematopoietic cell lineages
(Bradley et al., 2009). To directly test whether lung-resident ILCs were the cell
population responsible for promoting tissue remodeling following influenza virus
infection, we performed adoptive transfer experiments of congenically disparate CD90.1+
lung ILCs into PR8-infected, anti-CD90.2-depleted Rag1-/- mice. This system allowed for
the selective depletion of endogenous CD90.2+ ILCs while leaving the transferred
population of CD90.1+ lung ILCs unaffected. Analysis of lung tissue by flow cytometry at
10 days p.i. indicated that while anti-CD90.2 mAb effectively abolished host CD90.2+ ILC
responses in treated mice (Fig. 12A), a population of donor CD90.1+ ILCs could be
detected (Fig. 12B). CD90.2-depleted mice receiving transferred CD90.1+ ILCs exhibited
higher mean body temperature at day 10 p.i. compared to mice receiving anti-CD90.2
mAb alone, suggesting that adoptively transferred ILCs can ameliorate influenza-virus
induced morbidity (Fig. 12C). Additionally, analysis of blood oxygen saturation levels
revealed that delivery of CD90.1+ lung ILCs effectively restored lung function to levels
equivalent to isotype-treated mice (Fig. 12D). Similar to isotype-treated controls (Fig
12E), anti-CD90.2 treated mice receiving CD90.1+ ILCs exhibited regions of epithelial
proliferation within the bronchioles (Fig. 12G, black arrows) indicative of a beneficial
tissue remodeling response, which was largely absent in mice receiving anti-CD90.2
treatment alone (Fig. 12F, gray arrows). Collectively, these data provide evidence that
the lung ILC population, not another CD90-expressing cell type, was critical for
promoting respiratory tissue remodeling following influenza virus infection.
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2.4.8 ILC-mediated repair is independent of IL-13

Previous studies demonstrated that IL-13 can promote epithelial cell and goblet
cell proliferation as well as epithelial mucin production in the context of airway
inflammation and fibrosis (Crosby and Waters, 2010; Doherty and Broide, 2007; Wilson
and Wynn, 2009). To test the hypothesis that ILC-derived IL-13 may be required to
promote tissue homeostasis following influenza virus infection, rIL-13 was administered
to anti-CD90.2-treated Rag1-/- mice. Although IL-13 protein could be detected in BAL
fluid (Fig. 13A) and goblet cell hyperplasia was observed in the bronchioles of rIL-13treated animals confirming biological activity of the rIL-13 cytokine in the lung (Fig. 13B,
black arrows), anti-CD90.2-depleted mice receiving rIL-13 had severely decreased blood
oxygen saturation levels similar to mice receiving anti-CD90.2 mAb alone (59%
compared to 62%, respectively) (Fig 13C). Furthermore, mice receiving anti-CD90.2
alone or in combination with rIL-13 suffered severe influenza-induced morbidity,
succumbing to infection four days earlier than isotype-treated mice (day 9 vs. day 13 p.i.)
(data not shown). Taken together, these results indicate that rIL-13 is not sufficient to
restore lung function in ILC-depleted mice, suggesting that lung ILCs may employ IL-13independent mechanisms to promote lung tissue homeostasis.

2.4.9 IL-33-IL-33R signaling is critical for lung ILC responses
Given the ability of lung ILCs to respond to IL-33 stimulation (Fig. 6B,E) and previous
studies demonstrating that IL-33 is upregulated in the lung during influenza virus
infection (Chang et al., 2011; Le Goffic et al., 2011b), we next sought to test whether IL33–IL-33R signaling was required for ILC-dependent maintenance of airway epithelial
integrity. Anti-IL-33R (anti-T1/ST2) mAb or PBS was administered to wild-type mice
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following influenza virus infection. Blockade of IL-33–IL-33R signaling resulted in a
significant decrease in both frequency and total cell number of CD90+ CD25+ ILCs in the
lungs of anti-IL-33R treated mice compared to PBS treated controls (Fig. 14A-C).
Additionally, lung function was severely impaired, with blood oxygen saturation levels
reaching 68% in anti-IL-33R treated mice compared to 79% in PBS treated controls (Fig.
14D). Histological examination of lung parenchyma revealed regions of epithelial cell
necrosis and bronchial degeneration within the airways of anti-IL-33R treated mice at
day 10 p.i. (Fig. 14E-F) indicative of severe damage to the airway epithelial barrier
similar to the results observed when ILCs were depleted with anti-CD90.2 mAb (Fig.
12C). Taken together, these results confirm the ILC depletion studies and further
demonstrate that a treatment that severely impairs lung ILC responses can compromise
tissue repair and lung function in wild-type mice.

2.5 Discussion
A number of studies have identified heterogeneous ILC populations in the murine and
human intestine and implicated a role for these cell populations in regulating immunity
and inflammation in the gut (Saenz et al., 2010a; Spits and Di Santo, 2011). The data
presented in this Chapter identify a population of ILCs constitutively present in the
respiratory tract of humans and mice and demonstrate a novel function for murine lung
ILCs in regulating airway epithelial barrier integrity and tissue homeostasis following
influenza virus-induced pulmonary damage.
The ILC family in mice is remarkably heterogeneous and includes at least three
main cell subsets found in lymphoid and intestinal tissues that exhibit distinct
developmental requirements and patterns of effector cytokine expression (Saenz et al.,
2010a; Spits and Di Santo, 2011). While the nomenclature of ILC family members has
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been greatly complicated by the simultaneous discovery of similar cell types across
multiple laboratories, the current dogma classifies ILCs into three main subsets, ILC1,
ILC2 and ILC3 (Spits et al., 2013). In this Chapter, we show that the development of
lung-resident ILCs in mice is Id2-dependent and that these cells express a panel of cell
surface markers characteristic of the Group 2 ILC subset (ILC2s), including CD90,
CD25, CD127 and the IL-33R T1/ST2. Furthermore, lung-resident ILCs produced IL-5
and IL-13 in response to IL-33 stimulation, but notably did not make high amounts of IL22 or IL-17A following culture with IL-23. The cell surface phenotype and cytokine profile
of these lung-resident ILCs indicate that they most closely resemble NHCs or nuocytes,
cell types originally identified within the gut-associated lymphoid tissue and fatassociated lymphoid clusters and now referred to as ILC2s (Moro et al., 2010; Neill et
al., 2010; Saenz et al., 2010a; Spits and Di Santo, 2011). Since the completion of
studies outlined in this Chapter, new reports have emerged demonstrating the existence
of phenotypically similar ILC2 populations throughout multiple anatomical sites, including
skin and adipose tissue (Hams et al., 2013; Kim et al., 2013a; Roediger et al., 2013;
Salimi et al., 2013). While these cells share common phenotypic and developmental
requirements, the extent to which each population may possess distinct activation and
functional characteristics unique to each tissue microenvironment remains incompletely
understood.
In humans, previous studies identified RORγt+ ILC3 populations in the tonsils and
Peyer’s patches that share a phenotype and cytokine profile similar to murine LTi cells
and NKp46+ ILC3s (Cella et al., 2009; Cella et al., 2010; Crellin et al., 2010b; Cupedo et
al., 2009; Hughes et al., 2010). In this report, we provide the first identification of an ILC
population in the human respiratory tract and lung parenchyma. Human lung ILCs
expressed CD25, CD127 and ST2 (IL-33R), indicating they are a nuocyte/NHC-like ILC2
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population. Therefore, like murine ILCs, the human ILC family exhibits heterogeneity in
tissue distribution, phenotype and functional capacity across different tissue sites.
Examining other lymphoid and mucosal-associated tissues may lead to the identification
of additional ILC-like cells and provide critical insight into the regulation of human ILC
populations. Since the publication of the data in this Chapter 2, there has been a
multitude of studies identifying ILC2s in BAL from patients with Idiopathic Pulmonary
Fibrosis (IPF) (Hams et al., 2014), polyps from patients with allergic rhinosinusitis
(Mjosberg et al., 2012), skin from patients with atopic dermatitis (Kim et al., 2013a), and
blood from asthmatic patients (Bartemes et al., 2014). Importantly, however, the tissue
distribution, phenotype and function of ILC2s in non-diseased human tissue remains
largely unexplored and would provide critical ‘baseline’ information for understanding
how these cells become dysregulated during disease.
While previous studies have implicated murine ILC2s in promoting TH2 cytokinedependent anti-helminth immunity (Moro et al., 2010; Neill et al., 2010; Saenz et al.,
2010a; Spits and Di Santo, 2011), in this Chapter we identify a role for ILCs in repairing
airway epithelial integrity and maintaining lung tissue homeostasis. While this study
utilizes influenza virus as a model of severe lung injury, it is important to note that lung
injury is a key feature of many diseases besides viral infections, for example COPD,
ARDS, Sarcoidosis, asthma, allergy and others (Crosby and Waters, 2010; Rock and
Hogan, 2011). Despite the high incidence of lung damage occurring in these diseases,
the cellular and molecular mechanisms involved in effective versus ineffective lung
repair and tissue remodeling remain poorly understood. The identification of lung ILCs
as an important cell type regulating tissue homeostasis not only implicates a new
hematopoietic cell type in orchestration of non-hematopoietic cell repair/regeneration,
but also reveals previously unappreciated functions for the ILC2 lineage. Whether ILC2
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act directly on airway epithelial cells to direct cellular proliferation and differentiation or
whether they require interactions with other immune cells to orchestrate tissue repair will
be addressed in Chapter 3.
The TH2 cell cytokines IL-5 and IL-13 have also been shown to mediate epithelial
cell and goblet cell hyperplasia in the lung (Broide, 2008; Doherty and Broide, 2007;
Wilson and Wynn, 2009). Although lung-resident ILCs were capable of producing high
amounts of IL-5 and IL-13 in response to IL-33 stimulation and IL-33-IL-33R signaling
was required for repair from influenza virus-induced lung damage, the administration of
IL-13 failed to restore lung function or promote respiratory tissue remodeling in influenza
virus-infected ILC-depleted mice. These data indicate a critical distinction between the
tissue repair functions of lung ILCs and the previously described roles other ILC2
populations (nuocyte and NHC) that are reported to act primarily through IL-13dependent mechanisms (Chang et al., 2011; Moro et al., 2010; Neill et al., 2010; Price et
al., 2010). It is currently unclear whether this difference indicates a minor role for IL-13
in the disease context examined here or additional heterogeneity in the functional
diversity of ILC populations in the lungs. It is important to note that ILC-derived IL-13
might play a more prominent role in other airway disease contexts. For example, a
recent report found a role for ILC2-derived IL-13 using a different H3N1 influenza virus
infection model that causes airway hyperreactivity early during infection (Chang et al.,
2011). In those studies, however, the ILC2-produced IL-13 contributed to airway
hyperreactivity suggesting that in some settings the type 2 cytokines produced by lung
ILC populations might have detrimental effects. Supporting this, the importance of ILC2derived IL-13 has also recently been demonstrated in multiple allergic, non-viral models
of airway inflammation (Barlow et al., 2012; Barlow et al., 2013; Bartemes et al., 2012;
Halim et al., 2012; Wilhelm et al., 2011).
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The impact of lung ILC-derived cytokines and tissue remodeling proteins might
depend on the pattern of lung injury (i.e. different pathogenesis of infectious or
inflammatory disease) or other environmental factors. Nonetheless, the identification of a
major pathway of tissue repair coordinated by lung ILCs suggests that these cells, and
their products, could be targets for therapeutic manipulation in settings of lung infection,
injury and chronic inflammation. Future studies are needed to define the mechanisms by
which ILCs regulate tissue repair and to examine whether functionally distinct subtypes
of ILCs exist in the respiratory tract; this question will be the focus of Chapter 3. It is
interesting to note that IL-33, as a key alarmin cytokine made by epithelial and immune
cell lineages, can activate lung ILCs and IL-33-IL-33R signaling was essential for
recovery from influenza virus infection, indicating that a degree of crosstalk exists
between the damaged tissue and the ILC population that initiates the repair process.
Chapter 3 will explore the extent of this crosstalk between epithelial cells and ILCs and
elucidate the molecular mechanisms employed by ILCs to promote tissue restoration.
In summary, the results presented in this report identify a previously
unrecognized role for lung ILCs in promoting airway epithelial integrity and lung tissue
homeostasis. In light of these new findings, targeting ILC responses in the airway and
other tissues may offer new therapeutic potential in the clinical management of tissue
damage or chronic inflammation.
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Figure 4: ILCs in the lung phenotypically resemble nuocytes and NHCs
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Figure 4: ILCs in the lung phenotypically resemble nuocytes and NHCs
(A) Identification of lung ILCs in C57BL/6 wild-type (WT) and Rag1-/- mice by flow
cytometry as CD90+ CD25+ CD127+ lineage (Lin) negative cells lacking expression of the
follow markers: (CD3, CD5, NK1.1, CD27, TCRβ antibodies on the y-axis, B220, CD11b,
CD11c antibodies on the x-axis). (B) Expression of cell surface markers on Lin- CD90+
CD25+ lung ILCs in C57BL/6 WT (blue line) and Rag1-/- mice (red line) compared to
isotype controls (gray shaded). (C) Absolute number of CD90+ CD25+ ILCs in naïve WT
or Rag1-/- lung. Data is representative of more than three experiments, n = at least 4 WT
or Rag1-/- mice.
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Figure 5: Lin- CD127+ CD25+ ST2+ ILCs in human lung and airways
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Figure 5: Lin- CD127+ CD25+ ST2+ ILCs in human lung and airways
(A,C) Flow cytometric gating strategy for identifying CD127+ Lin- ILCs (CD3- TCRαβCD11c- CD11b- CD19- CD56-) in human lung parenchyma tissue (lower lobe) (A) or
bronchoalveolar lavage (BAL) fluid (C), plots gated on live cells. (B,D) Expression of
CD25 and ST2 on lineage negative CD127+ human lung parenchyma cells (B) and BAL
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cells (D) (black line) compared to FMO controls (gray shaded). FMO = fluorescence
minus one. For examination of human BAL, data shown is representative of 7 of 9 lung
transplant recipient patients examined. Data from lung parenchyma is representative of
more than four cadaver tissue donors.
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Figure 6: Lung ILCs resemble nuocytes/natural helper cells in cytokine profile

A

C

B

D

E

Figure 6: Lung ILCs resemble nuocytes/natural helper cells in cytokine profile
(A) Flow cytometry plots of pre-sort and post-sort purity of CD90+ CD25+ T1-ST2+ WT
lung ILCs, gated on live, lineage negative cells. (B) IL-5 and IL-13 cytokine secretion
from flow sorted CD90+ CD25+ T1-ST2+ lung ILCs cultured with IL-2 + IL-7 alone or in
combination with IL-33 for four days, measured by ELISA. (A-B) Data is representative
of three independent experiments, n = 3 replicates, each replicate consisting of ILCs
sorted from 5 pooled lungs. (C) Intracellular cytokine staining for IL-22 and IL-17A in LinCD90+ CD25+ lung ILCs or spleen CD90+ CD4+ LTi cells from WT mice, stimulated with
50 ng/ml rIL-23 (12 h) + PMA and Ionomycin (4 h). (D) IL-17A cytokine secretion from
flow sorted CD90+ CD25+ T1-ST2+ lung ILCs or spleen CD90+ CD4+ LTi cells cultured

	
  

63	
  

with IL-2 + IL-7 alone or in combination with IL-23 for four days, measured by ELISA.
Data is representative of two independent experiments, n = 3 replicates, each replicate
consisting of ILCs sorted from 3 pooled lungs or spleens.

(E) Intracellular cytokine

staining in Lin- CD90+ CD25+ lung ILCs from WT mice treated with 500 ng rIL-33 for 7
days in vivo and stimulated with PMA + Ionomycin (4 hours) ex vivo. (C,E) Data is
representative of 2 or more experiments, n = 3-4 mice.
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Figure 7: Lung ILCs require Id2 for development but do not express RORγt
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Figure 7: Lung ILCs require Id2 for development but do not express RORγt
(A,C) mRNA expression of Id2 (A) or RORc (C) in sort purified Lin- CD90+ CD25+ lung
ILCs and Lin- CD90+ CD4+ splenic LTi cells, normalized to β-actin and shown relative to
expression levels in purified B220+ B cells. n = 3 replicates, each replicate consisting of
spleens (LTi cells) or lungs (ILCs) pooled from 5 C57BL/6 WT mice. (B) Flow cytometry
plots of CD90+ CD25+ lung ILCs in WT or Id2-deficient bone marrow chimeras sacrificed
10 weeks post reconstitution, gated on live Lin- donor cells. Data is representative of 3
experiments, n = 2-4 Id2+/+ or Id2-/- chimeras. (D) Flow cytometry plot of RORγt
expression in CD90+ CD25+ lung ILCs (dashed black line) or CD90+ CD4+ LTi cells (solid
black line) compared to isotype antibody control (gray shaded). Data is representative of
at least 3 experiments with n = 2-4 mice.
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Figure 8: Lung ILCs develop independently of commensal microbial signals
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Figure 8: Lung ILCs develop independently of commensal microbial signals
(A) Representative flow cytometry plots, total frequency, and absolute cell number of
lung Lin- CD90+ CD25+ ILCs in conventional C57BL/6 (CNV) or germ-free (GF) mice. (B)
Cell surface expression of c-kit, CD127, and T1-ST2 on Lin- CD90+ CD25+ lung ILCs in
CNV (blue line) or GF (red line) mice compared to isotype controls (gray shaded). Data
is representative of 2 independent experiments. Data shown are the mean ± SEM, n = 35 CNV or GF mice.
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Figure 9: Induction of lung ILC responses in influenza virus-infected wildtype and
Rag1-/- mice
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Figure 9: Induction of lung ILC responses in influenza virus-infected wildtype and
Rag1-/- mice
(A-C) WT C57BL/6 or Rag1-/- were infected 0.5 LD50 PR8 i.n. and assessed for weight
loss (A) and lung function by pulse oximetry (B). (C) Lung histological sections from
naïve, WT or Rag1-/- mice at day 10 p.i., stained with H&E. Representative flow
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cytometry plots (D) and frequency (E-F) of Lin- CD90+ CD25+ ILCs in the lung
parenchyma of naïve or intranasally infected (0.5 LD50 PR8) C57BL/6 WT mice (day 16
p.i.) (E) and Rag1-/- mice (day 10 p.i.) (F). Data shown is combination of 5 experiments, n
= 3-5 mice per experiment. Scale bar = 100 µm. Data shown are the mean ± SEM. **
P < 0.01.
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Figure 10: Depletion of CD90+ ILCs during influenza infection results in reduced
lung function and compromised epithelial integrity
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Figure 10: Depletion of CD90+ ILCs during influenza infection results in reduced
lung function and compromised epithelial integrity
(A) Experimental schematic of Rag1-/- mice infected with 0.5 LD50 PR8 i.n. on D0 and
treated with 200 µg of isotype, anti-NK1.1, or anti-CD90.2 mAb i.p. on D-1, D2, D5 and
D8 p.i. and sacrificed day 10 p.i. (B) Representative flow cytometry plots of Lin- CD90+
CD25+ ILCs in the lungs of antibody-treated Rag1-/- at day 10 p.i. (C) PR8 viral copies
per gram of lung tissue at day 10 p.i. from infected, untreated WT mice or from infected,
antibody-treated Rag1-/- mice, measured by quantitative PCR and expressed as TCID50
per gram, dashed line = limit of detection. (D) Body temperature measured in naïve mice
and infected Rag1-/- at day 10 p.i. (E) Percentage blood oxygen saturation (SpO2) over
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the course of PR8 infection. (F) Quantification of total protein present in the
bronchoalveolar lavage (BAL) fluid at day 10 p.i., Data is representative of 3 or more
independent experiments n = 3-4 mice per group. Data shown are the mean ± SEM. *
P < 0.05, ** P < 0.01, *** P < 0.001.
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Figure 11: Lung ILC depletion impairs airway epithelial repair after influenza virus
infection
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Figure 11: Lung ILC depletion impairs airway epithelial repair after influenza virus
infection
(A-F) H&E staining of lung tissue from PR8-infected isotype (A), anti-NK1.1 (B), or antiCD90.2 (C) treated Rag1-/- mice, day 10 p.i. Scale bar, 50 µm. (A,B) Black arrows
indicate goblet cell hyperplasia and white arrows indicate epithelial cell hyperplasia. (C)
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Black arrows denote regions of epithelial shedding/necrosis within the bronchioles. (D)
Histological score of respiratory epithelial degeneration. H&E stained lung sections from
day 10 p.i. PR8-infected antibody-treated Rag1-/- mice were blindly graded on a scale of
0-10 for degree of bronchial/bronchiolar epithelial degeneration and necrosis. (E-F) H&E
staining of lung tissue from anti-CD90.2 treated naive mice (E) and untreated naive mice
(F). Scale bar = 50 µm. Data is representative of 3 or more independent experiments n =
3-4 mice per group. Data shown are the mean ± SEM. *** P < 0.001.
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Figure 12: Adoptive transfer of lung-resident ILCs promotes tissue remodeling in
anti-CD90.2-depleted mice
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Figure 12: Adoptive transfer of lung-resident ILCs promotes tissue remodeling in
anti-CD90.2-depleted mice
(A-G) Rag1-/- mice were infected with 0.5 LD50 PR8 i.n. on D0 and treated with 200 µg of
isotype or anti-CD90.2 mAb i.p. on D-1, D2, D5, and D8 p.i. and sacrificed day 10 p.i.
One group of anti-CD90.2-treated mice also received 1 x 105 FACS-sorted Lin- CD90.1+
CD25+ T1/ST2+ lung ILCs i.v. at D0 and D5 p.i. (A-B) Flow cytometry plots of
endogenous Lin- CD90.2+ CD25+ ILCs (A) and donor Lin- CD90.1+ T1/ST2+ ILCs (B) in
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the lungs of antibody-treated Rag1-/- at day 10 p.i.. (C) Body temperature measured in
naïve mice and infected Rag1-/- at day 10 p.i. (D) Percentage blood oxygen saturation
(SpO2) over the course of PR8 infection. (E-G) H&E staining of lung tissue from PR8infected isotype (E), anti-CD90.2 (F), or anti-CD90.2 + CD90.1 lung ILCs (G) treated
Rag1-/- mice, day 10 p.i. Scale bar, 50 µm. Black arrows indicate epithelial cell
hyperplasia and gray arrows denote regions of epithelial shedding/necrosis within the
bronchioles. Scale bar = 50 µm. (A-G) Data is representative of 2 independent
experiments n = 3-4 mice per group. Data shown are the mean ± SEM. * P < 0.05, ** P <
0.01, *** P < 0.001.	
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Figure 13: Administration of recombinant IL-13 fails to restore lung function in
ILC-depleted mice
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Figure 13: Administration of recombinant IL-13 fails to restore lung function in
ILC-depleted mice
(A-C) Rag1-/- mice were infected with 0.5 LD50 PR8 influenza virus and treated with
isotype mAb, anti-CD90.2 mAb or anti-CD90.2 + rIL-13 (5-10 µg i.p. every 2 days
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starting at D0). (A) Measurement of IL-13 protein in the BAL fluid, N.D. not detected. (B)
Histological analysis of lung tissue from antibody-treated mice at 10 days p.i. Black
arrows denote regions of goblet cell hyperplasia. Scale bar = 50 µm. (C) Measurement
of blood oxygen saturation levels by pulse oximetry. Data is representative of 2
independent experiments, n = 4 mice. Data shown are the mean ± SEM. * P < 0.05
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Figure 14: Blockade of IL-33R signaling impairs lung function and airway repair.
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Figure 14: Blockade of IL-33R signaling impairs lung function and airway repair.
(A-F) C57BL/6 WT mice received 200 µg anti-IL-33R (ST2) mAb or PBS every 3 days
following infection with 0.5 LD50 PR8. Representative flow cytometry plots (A) and
frequency and cell number (B,C) of CD90+ CD25+ ILCs in the lung of antibody-treated
WT mice at 10 days p.i. (D) Pulse oximetry measurement of blood oxygen saturation
levels. (E-F) H&E staining of lung tissue from PR8-infected PBS-treated mice (E) or antiIL-33R-treated mice (F) at day 10 p.i. Black arrows indicate epithelial cell hyperplasia
and gray arrows denote regions of epithelial shedding/necrosis within the bronchioles.
Scale bar = 100 µm. Data is representative of 3 independent experiments n = 3-4 mice
per group. Data shown are the mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.	
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Chapter 3
The amphiregulin-epidermal growth factor receptor pathway orchestrates
repair of airway epithelial cells

3.1 Abstract
In Chapter 2 we demonstrated that ILC2s could promote tissue homeostasis following
influenza virus-induced lung injury, although the mechanisms underlying ILC-dependent
tissue repair remain undefined. In this Chapter we identify that lung ILC2s express
multiple genes associated with tissue repair pathways, including the epidermal growth
factor family member amphiregulin (AREG). AREG was increased during influenza virusinduced lung injury and ILC depletion during infection resulted in decreased AREG
expression, reduced lung function and impaired airway remodeling. IL-33, not IL-25,
promoted expression of AREG in lung ILCs and administration of AREG effectively
restored airway tissue remodeling in ILC-depleted mice, suggesting that ILC-intrinsic
AREG is a central mediator of epithelial repair. Supporting this, chemical or genetic
inhibition of the endogenous EGFR-AREG pathway during influenza virus infection
resulted in severely impaired lung function and a failure to restore airway tissue
homeostasis, leading to increased host mortality. Mechanistically, infection with
influenza virus induced EGFR activation specifically in bronchiolar airway epithelial Clara
cells in an ILC2-dependent manner, suggesting that ILC2s directly orchestrate repair of
the airway epithelial barrier to promote host recovery. Taken together, these data
uncover novel innate pathway critical for host recovery from influenza virus infection in
which cytokine signals from the injured tissue instruct ILC2-mediated repair of the airway
epithelial barrier via AREG-EGFR signaling.
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3.2 Introduction

The mammalian barrier surfaces of the skin, lung and intestinal tract are continually
exposed to microbial, physical and environmental insults, which can lead to tissue injury
and inflammation (Artis, 2008; Maloy and Powrie, 2011; Rescigno, 2011). The processes
of tissue repair and remodeling that occur following acute injury or infection require a
delicate balance between promoting beneficial regenerative responses that support
epithelial cell proliferation while also acting to limit these responses once the tissue has
been adequately repaired (Crosby and Waters, 2010; Rackley and Stripp, 2012; Turner,
2009). The failure to initiate or resolve these repair responses can have detrimental
effects on the host, resulting in either loss of tissue integrity and function or promotion of
chronic inflammation and fibrosis, as observed in multiple inflammatory diseases of the
respiratory tract including chronic obstructive pulmonary disease (COPD), idiopathic
pulmonary fibrosis (IPF) and Sarcoidosis (Crosby and Waters, 2010; Kaser et al., 2010;
Wilson and Wynn, 2009). Therefore, delineating the mechanisms that direct tissue repair
and remodeling could identify new therapeutic targets to improve treatment of multiple
chronic inflammatory diseases.
A degree of crosstalk exists between the epithelial barrier and the mammalian
immune system in which damaged epithelial cells release cytokine signals such as
interleukin (IL)-25, IL-33 and thymic stromal lymphopoetin (TSLP) that activate sentinel
immune cell populations (Oliphant et al., 2011; Saenz et al., 2010a; Ziegler and Artis,
2010). Reciprocally, the immune system is integral to orchestrating epithelial repair and
maintenance of tissue homeostasis at these barrier sites, providing key cytokines and
growth factors that modulate epithelial cell function. For example, cytokines associated
with type 2 inflammatory responses such as IL-13 can directly impact barrier function by
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inducing epithelial cell proliferation, differentiation and survival (Akiho et al., 2005; Chiba
et al., 2009; Shim et al., 2001). More broadly, the evolution of type 2 immune responses
has been proposed to have originated as a host-protective response in mediating wound
healing following tissue damage by parasites (Allen and Maizels, 2011; Gause et al.,
2013; Maizels et al., 2009), although the precise mechanisms underlying type 2 immune
cell-driven tissue repair are not yet fully understood.
It is now well appreciated that host recovery from cytopathic viruses like influenza
A requires not only viral clearance mediated by the adaptive immune system, but also
successful tissue repair of the damaged lung tissue in order to restore epithelial barrier
integrity (Fukushi et al., 2011; Kohlmeier and Woodland, 2009; Peiris et al., 2010;
Rackley and Stripp, 2012). However, the factors that regulate this process are poorly
understood. In Chapter 2 we demonstrated a critical role for lung ILC2s in promoting
tissue homeostasis following influenza virus-induced lung injury, although the precise
mechanism underlying ILC-dependent tissue repair remained undefined. In this Chapter,
we identify that lung ILC2s express multiple genes associated with tissue repair
pathways, including the epidermal growth factor family member amphiregulin (AREG).
AREG was increased during influenza virus-induced lung injury and ILC depletion during
infection resulted in decreased AREG expression, reduced lung function and impaired
airway remodeling while addition of recombinant AREG could restore these defects in
ILC-depleted mice. Further, endogenous AREG-EGFR interactions were essential for
epithelial repair and host recovery from influenza virus-induced lung damage, revealing
a previously unrecognized role for EGFR signaling during respiratory viral infection.
Remarkably, ILC2-intrinsic AREG expression alone was sufficient to restore tissue
homeostasis, revealing a critical non-redundant role for these innate cells. Virus-induced
lung damage resulted in activation of EGFR specifically in the bronchiolar airway
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epithelial Clara cells, not in the alveolar epithelium, suggesting that ILC2-derived AREG
may act directly on the airway barrier to orchestrate restoration of tissue homeostasis.
Taken together, these data indicate a critical role for group 2 ILCs in mediating lung
tissue homeostasis though an IL-33-AREG-EGFR axis and suggest that ILCs serve as a
key link between the signaling pathways of Type 2 inflammation and tissue repair.

3.3 Methods
3.3.1 Mice
C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Rag1-/and EGFRvel/+ mice were purchased from the Jackson Laboratory and bred in house.
Areg-/- mice were provided by Dietmar Zaiss (University of Edinburgh, UK) and had been
backcrossed to C57BL/6 for over 14 generations before arrival. All mice were maintained
in specific pathogen-free facilities at the University of Pennsylvania. All protocols were
approved by the University of Pennsylvania Institutional Animal Care and Use
Committee (IACUC), and all experiments were performed according to the guidelines of
the University of Pennsylvania IACUC.

3.3.2 Flow Cytometry
Single cell suspensions were stained with a combination of the following monoclonal
fluorescently conjugated antibodies: FITC-conjugated FceR1; PE-conjugated CD127;
PerCP-Cy5.5-conjugated CD3, CD5, NK1.1, CD11b; biotinylated T1/ST2 (IL-33R) (MD
Bioproducts); APC streptavidin; eFluor-450-conjugated CD127; PE-Cy7-conjugated
CD25; Alexa 700-conjugated CD90.2 (Biolegend); e-Fluor-780-conjugated CD11c,
TCRβ, B220; PE-Texas Red-conjugated CD4, CD11b (Invitrogen); eFluor 605NC CD45;
eFluor 650NC CD45, CD4. All antibodies were purchased from eBioscience unless
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specified otherwise. For measurement of intracellular cytokine expression, cells were
isolated ex vivo and stimulated with PMA and ionomycin for four hours in the presence
of brefeldin A. Cells were subsequently surface stained with a combination of the
antibodies listed above, fixed and permeabilized using a commercially available kit (BD
Cytofix/Cytoperm, BD Biosciences), and stained with IL-13 FITC (eBioscience), IL-5 PE
(eBioscience) and AREG Alexa Fluor 647 (AREG rat anti-mouse monoclonal mAb (clone
206220, R&D Systems) conjugated to Alexa Fluor 647 according to manufacturer's
instructions (Molecular Probes)). For measurement of intracellular transcription factor
expression, cells were isolated directly ex vivo, stained with antibodies against surface
antigens,

fixed

and

permeabilized

according

to

manufacturer’s

instructions

(Foxp3/Transcription Factor Staining Buffer Set, eBioscience) and stained with GATA3
PE (eBioscience) and Foxp3 eFluor 450 (eBioscience). For all stains, dead cells were
excluded from analysis by means of a viability stain (Live/Dead Fixable Aqua stain,
Invitrogen). Samples were acquired on a BD LSRII flow cytometer (BD Biosciences) and
analyzed using FlowJo software (v9.2, Tree Star).

3.3.3 Isolation of cells from mouse lung tissue
Lungs were perfused with 10 ml PBS through the right ventricle of the heart prior to
removal. Lungs were then cut into small pieces using scissors and digested with 1 mg/ml
Collagenase D (Roche) in PBS for 30-45 min at 37 °C with vortexing every 10 min.
Samples were mashed through 70 µm cell strainers, washed with DMEM media
(supplemented with 10% FBS, 1% L-glutamine (GIBCO), 1% Pencillin/Streptomycin
(GIBCO)), and any remaining red blood cells were lysed. Single cell suspensions were
used for subsequent flow cytometry staining.
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3.3.4 RNA isolation and Real-Time Quantitative PCR
RNA was isolated from purified populations of CD90+ CD25+ lung ILCs, CD90+ CD4+
splenic LTi cells or B220+ splenic B cells, sorted using a BD FACSAria (BD Biosciences)
cell sorter. RNA was isolated using RNeasy mini kit according to manufacturer’s
instructions (QIAGEN). cDNA was generated using Superscript reverse transcription
(Invitrogen).

Real-time quantitative PCR (qRT-PCR) was performed on cDNA using

SYBR green master mix (Applied Biosystems) and commercially available primer sets
(QIAGEN).

Reactions were run on a real-time PCR system (ABI7500; Applied

Biosystems). Samples were normalized to β-actin and displayed as a fold induction
relative to expression seen in naïve lung tissue (Areg, Il5 and Il13).

3.3.5 ELISA
CD90+ CD25+ T1/ST2+ lung ILCs were sort-purified from the lungs of C57BL/6 mice
using a BD FACSAria cell sorter. 2 x 104 lung ILCs were cultured in DMEM complete
media in the presence of 10 ng/ml rmIL-7, 10 ng/ml rIL-2, and/or 30 ng/ml rmIL-33 (for
measurement of IL-5, IL-13 and amphiregulin) or 50 ng/ml rmIL-23 (for measurement of
IL-17A) for four days (all recombinant cytokines obtained from R&D Systems).
Supernatants were collected after 4 days of culture. For measurement of amphiregulin in
whole tissue, lung tissues from naïve or PR8 influenza-infected mice were homogenized
in sterile PBS and centrifuged to remove cell debris. Amphiregulin protein levels were
measured using DuoSet ELISA Kit (R&D Systems) and normalized to tissue weight.

3.3.6

Influenza

virus

infection,

antibody

administration
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treatments

and

EGFR

inhibitor

For infections with PR8 influenza virus, C57BL/6 wildtype, EGFRvel/+, EGFR+/+ or Areg-/mice were anaesthetized with Avertin i.p. and infected with 0.5 LD50 PR8-GP33 virus
(recombinant virus expressing the LCMV epitope GP33) in 25µl volume administered
intransally. PR8-GP33 influenza virus was grown and titered as previously described
(Decman et al., 2010). The replication and pathogenicity of this recombinant PR8 strain
was not substantially different from nonrecombinant virus (Decman et al., 2010).	
   For
monoclonal antibody treatments, anti-CD90.2 mAb (30H12) was purchased from
BioXCell (West Lebanon, NH) and administered i.p. every 3 days at a dose of 200
µg/mouse starting on the day prior to infection. Anti-AREG mAb (clone 206220, R&D
Systems) was administered in sterile PBS intraperitoneally (i.p.) every 2 days at a dose
of 300 µg/mouse starting on the day of infection. For chemical inhibition of EGFR
signaling, AG1478 (Calbiochem) was reconstituted in 100% DMSO to aid in
solubilization and further diluted in 1 ml sterile PBS for injection. 10 mg/kg of AG1478 or
vehicle control was administered i.p. every 2 days starting at the time of PR8 infection.

3.3.7 In vivo cytokine treatments
For examination of intracellular cytokine production, 300 ng of recombinant murine IL-25
or IL-33 (carrier-free, R&D Systems) in sterile PBS was administered intraperitoneally
(i.p.) into C57BL/6 wildtype mice daily for six days and cytokine expression was
assessed on day seven. For cytokine treatments during influenza infection, recombinant
murine IL-13 or amphiregulin (R&D Systems) was administered i.p. every 2 days at a
dose of 5-10 µg starting on the day of infection.

3.3.8 ILC2 adoptive transfer

	
  

84	
  

C57BL/6 wild-type mice were treated i.p. with IL-7 complexes (2 µg rIL-7 + 15 µg anti-IL7 M25 antibody) every 2 days for 1 week. Recombinant murine IL-7 (carrier-free) was
purchased from R&D Systems, and anti-human IL-7 M25 antibody was kindly provided
by Amgen Inc. Lin- CD45+ CD90+ CD25+ T1/ST2+ ILC were sort-purified from the lungs
of IL-7 complex-treated mice using a BD FACSAria and 1 x 105 ILC2 were transferred
intravenously into Areg-/- mice on days 0, 4 and 7 after PR8 infection.

3.3.9 Tissue histological sections
For PR8 influenza experiments, left lobes of lungs were inflated and fixed with 4%
paraformaldehyde, embedded in paraffin, and 5 µm sections were used for staining with
hematoxylin

and

eosin

or

were

used

for

immunohistochemical

staining

of

phosphorylated EGFR (p-EGFR, Tyr1068). In brief, slides were deparaffinized with
xylene and changes of 100%, 95%, 80%, 70% ethanol followed by water. Endogenous
peroxidase activity was removed using 180 ml methanol with 3 ml of 30% hydrogen
peroxide. Antigen retrieval was performed in 1 mM EDTA buffer pH 8 in a microwave
oven. Blocking of non-specific binding was achieved with Avidin D-Biotin blocking
reagent kit (Vector Elite Laboratories) and incubation in 5% goat serum. Primary
antibody (phospho-EGFR Tyr1068 XP rabbit mAb (Cell Signaling)) was diluted 1:800 in
diluent (SignalStain Antibody Diluent, Cell Signaling). Isotype control rabbit IgG XP mAB
(Cell Signaling) was used at an equivalent concentration. Slides were then incubated
with rabbit anti-biotin secondary antibody diluted in goat serum block solution. Slides
were incubated with HRP-conjugated Avidin Biotin Complex reagent (Vector Elite
Laboratories) and signal was developed using DAB Substrate Kit for Peroxidases. Slides
were counter-stained with hematoxylin, rehydrated with ethanol and mounted with a
coverslip for imaging.
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3.3.10 Measurement of Pulse Oximetry
As previously described (Monticelli et al., 2011), the MouseOxTM Pulse-oximeter (Starr
Life Sciences, Oakmont PA) was used to measure blood SpO2 in PR8-infected mice
during the course of infection. A depilatory agent (Nair, Church & Dwight Co.) was
applied to the neck of anesthetized mice 2 days prior to influenza infection to remove
hair and delay future hair growth. For readings, the oximeter clip was placed on the neck
and percent SpO2 was measured each second over several minutes. Data shown are
the average of steady SpO2 readings recorded over 3-5 minutes per mouse.

3.3.11 Measurement of protein in BAL fluid
Bronchoalveolar lavage fluid was collected from naïve or PR8-infected mice using the
following method: a small cut was made in the trachea, a thin tube was inserted, the
lungs were lavaged using 500 µl PBS, and fluid was immediately placed on ice. BAL
fluid was spun down to pellet cells and cell-free supernatants were collected.
Measurement of total protein was performed using a Micro BCA protein assay (Pierce
Thermo Scientific) according to manufacturer’s instructions.

3.3.12 Microarray gene expression profiling
Lin- CD90+ CD25+ ILCs and Lin- CD90+ CD4+ LTi cells were sorted from the lungs
(ILC2) and spleens (LTi cell) of naïve C57BL/6 wild-type mice. Four biological replicates
were collected, each consisting of 15,000-20,000 cells sorted from 6 pooled lungs (ILCs)
or 10 pooled spleens (LTi cells) to >97% purity. Cells were sorted directly into TRIzol LS
(Invitrogen). mRNA was isolated, amplified, and hybridized to Affymetrix GeneChips
(Mouse Gene 1.0ST).
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3.3.13 Data Normalization and Differential Gene Expression Profiling
Affymetrix Power Tools software was used to process and quantile normalize fluorescent
hybridizaiton signals using the Robust Multichip Averaging (RMA) method (Irizarry et al.,
2003). Transcripts were log2 normalized and technical replicates were averaged for foldchange analysis. Using the ClassNeighbors module of GenePattern, genes were ranked
by the signal-to-noise ratio and class-biased genes were identified by permutation
testing (Reich et al., 2006). Genes were considered differentially expressed if the foldchange was > 2, P < 0.05.

3.3.14 GO Enrichment Analysis
Differentially expressed genes (fold-change >2) in both the naïve lung ILC2 and naïve
splenic ILC3 (LTi) transcriptional profiles were uploaded to the Database for Annotation,
Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) (Huang da
et al., 2009), and Fischer’s exact test was used to identify significantly enriched Gene
Ontology (GO, http://www.geneontology.org) terms (Huang da et al., 2009). (Full list of
enriched genes for specific GO terms listed in available in Table 1).

3.3.15 Gene Set Enrichment Analysis (GSEA)
Gene Set Enrichment Analysis (GSEA) was performed using the Broad Institute program
(http://www.broadinstitute.org/gea/index.jsp) as described previously (Subramanian et
al., 2005). Published gene expression arrays of whole lungs divided into either “control”
or “LPS-treated” groups were downloaded from Gene Expression Omnibus (GEO,
www.ncbi.nlm.nih.gov/geo/)_ENREF_34	
   (Altemeier et al., 2005). The normalized
enrichment score (NES) and q-value were calculated for enrichment of the top 100
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differentially expressed genes from the ILC naïve data sets (as previously defined using
the ClassNeighbors signal-to-noise ratio) between the publically accessible gene arrays
(described above). (Leading-edge genes listed in Table 2.)

3.3.16 Statistical analysis
Results represent the mean ± SEM unless indicated otherwise. Statistical significance
was determined by unpaired Student’s t test. Statistical analyses were performed using
Prism GraphPad software v5.0. (*,P < 0.05; **, P < 0.01; ***, P < 0.001).

3.4 Results
3.4.1 Wound healing genes are enriched in ILCs
To investigate potential mechanisms by which lung ILC2s influence maintenance of
airway epithelial integrity or restoration of lung tissue homeostasis, we performed
genome-wide transcriptional profiling of lung-resident ILC2s. CD90+ CD25+ lung ILC2s
and CD90+ CD25+ CD4+ splenic ILC3s (also referred to as adult lymphoid tissue inducer
(LTi) cells) were sort-purified from the lungs or spleens of naïve C57BL/6 mice and
mRNA isolated from these populations was then hybridized to Affymetrix GeneChips for
genome-wide transcriptional profiling. Examination of the top 100 genes differentially
expressed in lung ILC2s compared to spleen ILC3s illustrated substantial differences
between these two ILC populations (Fig. 15A). Splenic ILC3 cells were characterized by
high expression of CD4, CCR6, IL-23R and RORγt, in agreement with previous studies
(Sonnenberg et al., 2011; Takatori et al., 2009), while the top transcripts in the lung ILCs
included the ST2 receptor IL1Rl1, IL-25 receptor IL-17Rb, and the cytokines IL-2 and IL5 (Fig. 15B). In addition, within the top 100 genes expressed in lung ILC2s, there was
striking expression of multiple genes associated with tissue remodeling, including genes
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encoding the extracellular matrix proteins decorin, asporin and dermatopontin as well as
epidermal growth factor family members like amphiregulin (Fig. 15B). Analysis of the
differentially expressed genes between lung ILC2 versus splenic ILC3 populations using
the Database for Annotation, Visualization and Integrated Discovery (DAVID) revealed a
transcriptional signature of lung ILC2s that was significantly enriched in pathways
regulating wound healing, immune defense responses, inflammatory responses and cell
proliferation (Fig. 15C and Table 1). In contrast, splenic ILC3s were significantly
enriched in processes associated with hematopoietic and lymphoid organ development,
immune responses, and cell activation (Fig. 15C and Table 1).
Gene Set Enrichment Analysis (GSEA) was then employed to compare the gene
expression signature of lung ILC2s with previously reported models of lung damage or
inflammation. Direct comparison of the lung ILC2 gene set with a previously published
data set examining the effects of lipopolysaccharide (LPS)-induced acute lung injury
(Altemeier et al., 2005) revealed enrichment of the transcriptional signatures of lung
ILC2s in the LPS-treated group compared to PBS-treated controls, consistent with a
signature of tissue damage and wound repair (Fig. 15D). Further analysis of the
transcripts which most contributed to the bias toward the LPS-treated group (denoted by
the ‘leading edge’) revealed the presence of the gene amphiregulin (Areg). Thus, this
epidermal growth factor, which was highly expressed in the lung ILC2 gene expression
profile, is one of the strong “driver genes” in this enrichment pattern (Fig. 15D and Table
2). Collectively, these results represent the first genome-wide transcriptional profiling of
lung ILC2s and demonstrate clear gene signatures of wound healing in the lung ILC2
population.
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3.4.2 IL-33, but not IL-25, stimulates ILC2-intrinsic amphiregulin expression
Amphiregulin is a member of the EGF family of growth factors that has been implicated
in regulating tissue remodeling and repair in the context of acute epithelial injury and
asthma (Dolinay et al., 2006; Enomoto et al., 2009; Fukumoto et al., 2010). Quantitative
qPCR analysis confirmed the microarray results demonstrating high expression of
amphiregulin mRNA by lung ILC2s compared to splenic ILC3s (Fig. 16A). Further,
stimulation of sort-purified CD90+ CD25+ T1-ST2+ lung ILC2s with IL-2 and IL-7 in
combination with IL-33 resulted in elevated production of amphiregulin protein compared
to culture with IL-2 and IL-7 alone (Fig. 16B). In addition to IL-33, previous studies have
also demonstrated that IL-25 can activated ILC2s to produce IL-5 and IL-13 (Monticelli et
al., 2012; Spits and Cupedo, 2011). However, the differential role of these two cytokines
in eliciting AREG expression in ILC2s is unknown. To address this question, we
developed a new staining protocol to allow the first single cell analysis of intracellular
expression of AREG in ILCs. Wildtype (WT) mice were treated in vivo with PBS,
recombinant (r)IL-25 or rIL-33 and lung cells were assessed for expression of AREG, IL5 and IL-13 by intracellular cytokine staining. Flow cytometric analysis of gated lineage
negative (Lin-) CD45+ CD90+ T1/ST2+ lung ILC2s revealed minimal expression of AREG,
IL-5 or IL-13 in PBS-treated mice (Fig. 16C). Although administration of rIL-25 resulted
in increased IL-5 and IL-13 expression in lung ILC2s consistent with previous reports
(Barlow et al., 2013; Bartemes et al., 2012), there was no detectable effect on the
frequency of AREG-expressing ILC2s (Fig. 16C). In striking contrast to PBS or rIL-25
treatment, rIL-33 elicited robust lung ILC2 responses that consisted of distinct
heterogeneous populations of ILC2s expressing AREG, IL-5 and/or IL-13 (Fig. 16C).
Furthermore, multivariate analysis of the composition of cytokine producers within the
lung ILC population revealed that rIL-33 treatment induced a greater proportion of single-
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(green pie slice), double- (yellow slice) and triple- (red slice) cytokine-expressing cells
compared to PBS or rIL-25 treatment (Fig. 16D). Further examination of the cytokine
distribution among these single, double and triple cytokine producers revealed that the
majority of IL-33-elicited ILC2s expressed AREG (black arc surrounding the pie graph)
compared to IL-5 (gray arc) or IL-13 (brown arc) (Fig. 16D). Collectively, these data
reveal remarkable heterogeneity in the cytokine profile of lung ILC2s and demonstrate a
dominant role for the cytokine IL-33, but not IL-25, in eliciting robust AREG expression
from lung ILC2 in vivo.

3.4.3 Recombinant AREG restores lung function in ILC-depleted mice
Analysis of lung parenchyma tissue in Rag1-/- mice at 10 days post-influenza virus
infection revealed a significant increase in amphiregulin mRNA (Fig. 17A) and protein
expression (Fig. 17B) compared to naïve controls, indicating that AREG expression is
upregulated in the lung following influenza virus infection and airway damage. Analysis
of lung tissue from anti-CD90.2 treated mice revealed reduced amphiregulin mRNA in
the absence of CD90.2+ ILCs (Fig. 17C), indicating that lung ILC2s are a major source
of AREG in vivo and that secretion of this protein may be one mechanism by which ILCs
promote airway epithelial integrity and restore lung function.
To directly test whether delivery of AREG could promote airway epithelial
integrity

and

restore

lung

function

following

influenza

virus-induced

damage,

recombinant AREG was administered to anti-CD90.2 treated PR8-infected Rag1-/- mice
(Fig. 17D). Mice receiving recombinant AREG exhibited substantially higher mean body
temperatures (Fig. 17E) and significantly improved lung function compared to antiCD90.2 treated controls, reaching blood oxygen saturation levels comparable to isotypetreated mice at day 9 p.i. (78% vs 80%, respectively) (Fig. 17F). Additionally, mice
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treated with recombinant amphiregulin exhibited diminished amounts of total protein
present in the BAL fluid compared to anti-CD90.2-treated controls (Fig. 17G) and
histologic analysis of lungs from anti-CD90.2-depleted mice receiving recombinant
AREG revealed regions of epithelial cell hyperplasia and goblet cell proliferation (black
arrows) within the bronchial airways indicating that recombinant AREG treatment
promoted restoration of airway epithelial integrity and lung tissue homeostasis (Fig. 17HJ). Collectively, these data provide both in vitro and in vivo evidence implicating
amphiregulin as one mechanism by which ILCs can promote tissue homeostasis
following influenza virus infection.

3.4.4 Endogenous AREG is required for recovery from influenza virus-induced
lung damage
IL-33 acts as an alarmin when released upon epithelial cell damage during inflammation
and infection, as occurs with pathogens like Influenza A virus (Le Goffic et al., 2011a;
Monticelli et al., 2011). While treatment with exogenous AREG in influenza-infected
Rag1-/- mice following depletion of ILCs could restore lung epithelial repair (Fig 17)
whether physiologic levels of endogenous AREG are important for lung tissue repair and
host recovery in the presence of functional adaptive immune responses remains
unknown. To test this, we employed a monoclonal antibody (mAb)-mediated approach
that neutralizes endogenous AREG in vivo. Wildtype mice were infected intranasally with
0.5 LD50 H1N1 PR8 virus and 300 µg of anti-AREG mAb was administered every 2 days
starting at the time of infection. Mice were monitored over the course of infection for
parameters of influenza virus-induced morbidity. Strikingly, neutralization of AREG in
mice infected with PR8 virus was associated with impaired lung function as measured by
decreased blood oxygen saturation levels (PulseOX) (Fig. 18A) as well as increased
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protein levels in the bronchoalveolar lavage (BAL) fluid (Fig. 18B) indicative of impaired
airway epithelial integrity.
Additionally, histological examination of lung sections from mice treated with
isotype antibodies revealed regions of epithelial hyperplasia within the bronchiolar
airways indicative of mounting a beneficial tissue remodeling response (Fig. 18C).
However, upon AREG neutralization, there was a failure to efficiently mount this tissue
reparative response, and many airway bronchioles exhibited complete sloughing of the
bronchial epithelial lining (Fig. 18C). The failure to promote restoration of the airway
epithelial barrier correlated with increased host mortality, as anti-AREG mAb-treated
mice succumbed to infection within 2 weeks while isotype-treated controls survived (Fig.
198D). Collectively these results demonstrate an essential physiologic role for
endogenous AREG in regulating lung tissue homeostasis and indicate that a single
growth factor is a critical component of host survival from influenza virus-induced lung
damage.

3.4.5 ILC2-intrinsic AREG is sufficient to restore airway epithelial repair in the
presence of adaptive immunity
While ILC2s are the predominant innate source of AREG in the lung during influenza
virus infection (Fig. 17), amphiregulin expression is not exclusively restricted to innate
cells (Burzyn et al., 2013; Zaiss et al., 2006). Therefore, we next sought to test whether
ILC2-intrinsic AREG expression alone was sufficient to restore airway epithelial repair
and tissue homeostasis in a lymphocyte-sufficient setting. To generate sufficient
numbers of ILC2s to perform adoptive transfers, we expanded the cells in vivo using
immune complexes consisting of anti-IL-7 and recombinant IL-7, a strategy previously
used to expand Group 3 ILCs (Schmutz et al., 2009). Administration of anti-IL-7-rIL-7
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complexes to wildtype mice resulted in robust expansion of ILC2s in the lung by both
frequency (Fig. 19A) and cell number (Fig. 19B). Sort-purified lung ILC2s were then
transferred into AREG-deficient (Areg-/-) hosts during influenza virus infection, and mice
were examined for parameters of influenza virus-induced morbidity. Although there was
no intrinsic impairment in lung ILC2 accumulation in Areg-/- mice following influenza virus
infection (Fig. 20A), consistent with our anti-AREG neutralization studies, mice deficient
in AREG exhibited severely reduced lung function compared to their WT counterparts
(Fig. 20B). Strikingly, adoptive transfer of AREG-sufficient ILC2s into Areg-/- mice was
sufficient to restore blood oxygen saturation levels equivalent to levels observed in WT
mice (Fig. 20B). Additionally, Areg-/- mice receiving AREG-sufficient ILC2 cells had
reduced protein in the BAL fluid (Fig. 20C) and exhibited regions of epithelial cell
hyperplasia in the bronchiolar airways similar to wildtype mice that were largely absent in
Areg-/- mice (Fig. 20D). Taken together, these results indicate that ILC2-intrinsic AREG
is sufficient to promote airway epithelial remodeling and maintenance of tissue
homeostasis in the presence of adaptive immunity.

3.4.6 Influenza virus-induced lung damage is associated with bronchiolar airway
epithelial cell-intrinsic EGFR activation in vivo
Amphiregulin binds to EGFR, inducing a signaling cascade that can lead to the
proliferation and differentiation of epithelial cells (Burgel and Nadel, 2004; Nadel, 2001).
However, the in vivo cellular targets of EGFR activity in response to cytopathic
respiratory pathogens such as influenza virus are unknown. In order to interrogate which
epithelial cell lineages may be responsive to ILC2-derived AREG in the context of lung
injury, we performed immunohistochemical staining for phosphorylated EGFR (p-EGFR)
tyrosine kinase activity (Fig. 21A-C). Naïve mouse lungs exhibited little to no p-EGFR
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activity in the bronchiolar (BR) airway epithelial cells (Fig. 21D,E), in the endothelial cells
lining the blood vessels (BV) (Fig. 21D), or the alveolar type 2 pneumocytes in the lung
parenchyma (Fig. 21D,F). However, upon infection with influenza virus, EGFR activity
was strongly enhanced, as illustrated by bright p-EGFR staining in the non-ciliated Clara
cells that comprise the bronchiolar airway epithelial lining (Figure 21G,I). Furthermore,
the cellular pattern of EGFR activity appeared to be largely restricted to the bronchiolar
epithelial cells, with only very minor levels of p-EGFR detected on cells within the lung
parenchyma alveolar spaces (Fig. 21H). Collectively, these results demonstrate that
EGFR activity is strongly upregulated in vivo following influenza-virus induced lung
damage and suggest that the primary cellular targets of virus-induced EGFR activation
are bronchiolar airway, not alveolar, epithelial cells.

3.4.7 ILC depletion abolishes EGFR activity in lung airway epithelial cells
To test whether ILC2s can influence EGFR activation in the airways during influenza
virus infection, we utilized the antibody-mediated ILC depletion approach in Rag1-/- mice
that was introduced in Chapter 3. Consistent with the results observed in wildtype
C57BL/6 mice (Fig. 21), there was no detectable EGFR phosphorylation in the lungs of
naïve Rag1-/- mice although EGFR activity was strongly induced upon influenza virus
infection primarily in the bronchiolar airway epithelium (Fig. 22A-B). Remarkably,
antibody-mediated depletion of CD90.2+ ILC2s completely abolished EGFR activity in
the airways of influenza virus-infected Rag1-/- mice at day 10 post infection, as indicated
by the absence of phosphorylated EGFR staining in the airway epithelium of antiCD90.2-treated mice compared to their isotype-treated counterparts (Fig. 22B-C). These
results reveal a critical, non-redundant role for ILC2s in regulating EGFR activity in the
bronchiolar airway epithelium following influenza virus-induced lung damage.
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3.4.8 Constitutive or temporal disruption in EGFR signaling during influenza virus
infection results in reduced lung function, impaired airway epithelial remodeling
and increased host mortality
While the data above provide insight into the cellular targets of the ILC2-AREG-EGFR
pathway, the in vivo functional significance of EGFR signaling during respiratory viral
infection has never been examined. To test whether the EGFR signaling pathway is
critical for recovery from influenza virus-induced lung damage in vivo, we utilized mice
with a dominant negative mutation in the EGFR tyrosine kinase domain (called velvet)
that have reduced EGFR activity (Du et al., 2004). Although mice heterozygous for the
velvet mutation (EGFRvel/+) had no intrinsic defect in ILC2 accumulation in the lung (Fig.
23A),

EGFRvel/+

exhibited

severe

influenza

virus-induced

morbidity,

including

exacerbated weight loss (Fig. 23B), reduced blood oxygen saturation levels (Fig. 24C)
and elevated BAL fluid protein (Fig. 23D) compared to their littermate controls.
Furthermore, although naïve EGFRvel/+ mice had a normal bronchiolar airway
epithelial lining under steady-state conditions (Fig. 23E), upon exposure to influenza
virus-induced damage EGFRvel/+ mice exhibited sloughing of the epithelial lining and
failure to initiate proliferative epithelial remodeling responses (Fig. 23F), suggesting that
EGFR signaling is critical for generating a hyperplastic epithelial response to restore the
damaged airway barrier. Similar to mice deficient in AREG, EGFRvel/+ exhibited
increased host mortality, succumbing to infection within 2 weeks (Fig. 23G). Notably,
temporal disruption of EGFR signaling during the course of infection using the selective
EGFR tyrosine kinase inhibitor AG1478 (Hartmann et al., 2009) resulted in a similar
phenotype to that observed in the genetic EGFRvel/+ model, whereby wildtype mice
treated with AG1478 had impaired lung function (Fig. 24A) and a failure to generate
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epithelial remodeling responses in the airways (Fig. 24B), resulting in eventual host
mortality (Fig. 24C). Collectively, these data reveal that EGFR signaling is an essential
component of the epithelial remodeling response that restores tissue homeostasis
following virus-induced injury.

3.5 Discussion
It is now well appreciated that host recovery from cytopathic viruses like influenza
A requires not only viral clearance, but also successful tissue repair of the damaged lung
tissue in order to restore epithelial barrier integrity (Fukushi et al., 2011; Kohlmeier and
Woodland, 2009; Peiris et al., 2010; Rackley and Stripp, 2012). However, the factors
that regulate this process are poorly understood.	
   In the previous Chapter 2, we
demonstrated that ILC2s were critical for epithelial repair during influenza infection. Here
we identify that lung ILC2s express a transcriptional gene signature associated with
wound healing pathways, including the epidermal growth factor family member AREG,
and that exogenous AREG could promote lung tissue homeostasis in a lymphocytedeficient setting. These data illustrate a novel innate pathway of lung tissue repair but
also provoke fundamental questions regarding the relevance of the endogenous ILC2AREG pathway in the presence of a functional adaptive immune system. The second
part of this Chapter demonstrates that physiologic levels of a single growth factor,
AREG, are essential for promoting tissue homeostasis and ultimately influencing host
morbidity and mortality. Additionally, we provide the first in vivo evidence for EGFR
signaling regulating lung epithelial repair and host recovery from a respiratory viral
infection. Remarkably, ILC2-intrinsic AREG expression alone was sufficient to restore
airway epithelial reparative responses in AREG-deficient mice, highlighting an essential
role for an innate immune cell-derived growth factor in regulating epithelial cell function.
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IL-33 acts a cytokine ‘alarmin’ that is released rapidly upon epithelial cell damage
to activate resident immune cell populations of the lung and intestine (Garcia-Miguel et
al., 2013; Le et al., 2013; Ohno et al., 2012). Our data demonstrate that IL-33 is a potent
in vivo stimulus for inducing AREG expression in ILC2s compared to another epithelial
cell-derived cytokine IL-25. Intriguingly, single cell analysis revealed that IL-33 elicited
distinct populations of polyfunctional ILC2s that expressed IL-5, IL-13 and/or AREG
simultaneously, identifying a previously unrecognized degree of potential functional
heterogeneity in ILC2s that may reflect their differential roles in regulating proinflammatory versus tissue-protective responses at barrier surfaces.
EGFR is widely expressed in epithelial cell lineages across multiple tissues sites
although the cellular pattern of EGFR activity depends upon the nature of the
inflammatory stimulus (Burgel and Nadel, 2004, 2008; Nadel and Burgel, 2001).
Therefore, in this study we sought to examine the cellular sources of EGFR activity to
provide insight into the mechanism by which the IL-33-ILC2-AREG pathway influences
tissue repair. In the case of the lung airways, respiratory viruses can influence EGFR
activity on stromal cells in vitro (Eierhoff et al., 2010; Ueki et al., 2013), but the in vivo
cellular targets of EGFR signaling during influenza virus infection have never been
examined. In this Chapter we demonstrate that EGFR activity is strongly and selectively
upregulated in the Clara cells lining the bronchiolar airway epithelium, with little to no
activity in the parenchyma alveolar epithelial cells. Combined with the in vivo
requirement for EGFR signaling to promote airway epithelial remodeling responses,
these data are consistent with a model in which ILC2-derived AREG acts on bronchiolar
airway epithelial Clara cells or on a facultative airway progenitor stem cell population to
promote cellular proliferation to restore the airway epithelial barrier, although further
studies are needed to test this directly. Strikingly, data in this Chapter demonstrated that
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depletion of ILCs was sufficient to completely abolish EGFR phosphorylation in the
airways of influenza virus-infected mice, thereby revealing an essential and nonredundant role for ILC2s in regulating EGFR activity in the airways. Collectively, these
data shed new light on the cellular and molecular mechanisms that regulate lung tissue
remodeling and repair during infection-induced injury. The question of whether this
pathway may be conserved in settings of non-infectious tissue damage at extrapulmonary barrier surfaces will be the focus of Chapter 4.
Taken together, these data highlight a mechanism by which the innate immune
system responds to cytokine cues from damaged epithelia at mucosal surfaces to
orchestrate repair and restoration of tissue homeostasis through the AREG-EGFR
pathway. These findings could have important implications for clinical treatment of
inflammatory diseases of the respiratory tract. For example, pharmaceutical grade
EGFR inhibitors are a widely used therapeutic treatment for multiple diseases, including
cancers of the lung and intestine (Busser et al., 2011a; Hartmann et al., 2009; Iyer and
Bharthuar, 2010). Notably, there have been reports of fatal interstitial lung disease of
unknown etiology occurring in lung cancer patients treated with EGFR inhibitors (Chou
et al., 2010; Makris et al., 2007; Wang et al., 2013). Given the role of endogenous EGFR
signaling in regulating lung tissue repair in murine models, it is possible that the
inhibition of EGFR signaling may disrupt lung tissue regenerative responses in these
patients and potentially contribute to development of disease, provoking the need for
caution in utilizing these therapies. In contrast, in some circumstances such infection
with cytopathic pathogens, the targeted promotion of the ILC2-AREG-EGFR pathway to
promote epithelial repair may have therapeutic benefit in improving clinical outcomes in
multiple chronic infectious and inflammatory diseases of the respiratory tract.
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Figure 15: Global gene expression profiling of lung-resident ILC2s reveals strong
enrichment for genes regulating wound healing pathways 	
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Figure 15: Global gene expression profiling of lung-resident ILC2s reveals strong
enrichment for genes regulating wound healing pathways 	
  
(A-D) CD90+ CD25+ ILC2s and CD90+ CD4+ ILC3s cells were FACS-sorted from the
lung (ILC2s) or spleen (ILC3s) of naïve C57BL/6 WT mice. mRNA was isolated,
amplified, and hybridized to Affymetrix gene chips for microarray analysis. (A) Heat map
representing gene expression profiles of the top 100 differentially expressed genes in
lung ILC2s versus spleen ILC3s. Red = high expression, blue = low expression. (B) Heat
map of key genes highly expressed in lung ILC2s or spleen ILC3s. Red = high
expression, blue = low expression (C) Gene expression signatures of ILC2s and ILC3
(genes differentially expressed by two-fold or greater) were examined using Database
for Annotation, Visualization and Integrated Discovery (DAVID) to identify enriched Gene
Ontology terms describing biological processes. Shaded boxes represent significant
enrichment (light gray P > 0.05, black P < 0.0004). (D) Gene Set Enrichment Analysis
comparing the lung ILC2 gene expression signature with a previously published data set
examining the effects of LPS-induced acute lung injury. Analysis of the top transcripts in
the LPS-treated group shows presence of amphiregulin (Areg) (highlighted by arrow).
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Table 1: GO term gene list enriched in lung ILC2 and splenic ILC3 gene expression
signatures

Lung ILC2 Enriched
regulation of
cell
proliferation
CSF2
CAV1
FOSL2
FGF7
PTGS2
CSF1
PPARG
NFKBIA
CD24A
SCGB1A1
TGFB1
ADA
CDH5
LIF
SPRY2
GPC3
GATA3
BCL11B
CALCRL
MYC
DPT
KLF5
IRS2
AR
IL6
SPARC
PROX1
HES1
PRKCQ
ADRB2
CDKN1A
RBPJ
KLF4
BMPR1A
NFIB
IL2

defense
response
CXCL1
RARRES2
NFKBID
C3
CXCL3
PPARG
TLR1
CXCL2
C1S
PRDX1
CD24A
TGFB1
CALCA
SH2D1A
CFH
THBS1
NFKBIZ
IL6
IL5
IL1RL1
CCL21A
SERPING1
COTL1
CCL11
HIF1A
PENK
CCR5
CCR4
CXCL15
CCR2
ALOX5
RBPJ
KDM6B

Spleen ILC3 Enriched
response
to
wounding
CXCL1
NFKBID
C3
CXCL3
PPARG
TLR1
CXCL2
GJA1
C1S
TIMP3
CD24A
TGFB1
CALCA
ARG1
CFH
THBS1
NFKBIZ
IL6
IL5
CCL21A
SERPING1
PLAUR
CCL11
THBD
HIF1A
CCR5
CCR4
CXCL15
CCR2
ALOX5
PROS
KDM6B

inflammatory
response

immune
response

CXCL1
NFKBID
C3
CXCL3
CXCL2
TLR1
PPARG
C1S
CD24A
TGFB1
CALCA
CFH
THBS1
NFKBIZ
IL6
IL5
CCL21A
SERPING1
CCL11
HIF1A
CCR5
CCR4
CXCL15
CCR2
ALOX5
KDM6B

IL1F9
IL1R1
SUSD2
PGLYRP1
CD74
TMEM173
FCER1G
CD4
BCL6
CLEC4D
MPA2L
LTB
LTA,
CD7
RAB27A
IGH
IL18R1
IRGM1
IL23R
LY96
IGJ
MYO1F
H2-AB1
VAV1
H2-DMB2
TNFSF8
PSMB9
BTLA,
VAMP7
H2-EB1
PLCG2
H2-AA
GBP4
H2-DMA
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hematopoetic
or lymphoid
organ
development
STAP1
TGFBR1
G6PDX
RORC
VAV1
CD74
HBA-A1
ZFP826
HBA-A2
CXCR5
MFSD7B
PLCG2
CD4
BCL6
HBB-B1
H2-DMA
HDAC9
LTB
LTA
HELLS

cell
activation
FYB
KLRK1
MYO1F
RORC
SKAP2
VAV1
CD74
CXCR5
VAMP7
PLCG2
FCER1G
CD4
BCL6
H2-DMA
HDAC9
RAB27A
LTB
LTA
HELLS

Table 2: Top gene transcripts (“leading edge”) in LPS-treated lung GSEA data set

GSEA leading edge genes
Cxcl2
Tnfaip3
Myc
Csf2
Tiparp
Fgl2
Gadd45b
Cdkn1a
Chd7
Ctla2b
Aim1
Areg
Nr4a1
Ccr2
Ptgir
Skil
Tlr1
Calca
Fosl2
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Figure 16: IL-33 elicits AREG in lung ILC2
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Figure 16: IL-33 elicits AREG in lung ILC2
(A) mRNA expression of amphiregulin (Areg) in sort-purified CD90+ CD25+ T1/ST2+ lung
ILC2s compared to CD90+ CD4+ splenic ILC3s. (B) Production of AREG protein by sort-
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purified lung ILC2s stimulated with IL-2, IL-7, +/- IL-33 for four days, as measured by
ELISA. (C-D) C57BL/6 wildtype (WT) mice were treated i.p. with PBS, 300 ng rIL-25 or
300 ng rIL-33 daily for 6 days. (C) Lung cells were stimulated ex vivo with PMA and
Ionomycin plus brefeldin A for 4 hours and then examined for intracellular cytokine
expression of IL-5, IL-13 and AREG via flow cytometry. Plots gated on Lin- CD45+ CD90+
CD25+ T1/ST2+ lung ILC2. (D) Multivariate analysis of flow cytometric data from (C)
using SPICE Software. Pie slice color indicates number of cytokines (IL-5, IL-13 or
AREG) produced by lung ILC2s (blue = 0, green = 1, yellow = 2, red = 3). Pie arcs
illustrate the distribution of IL-5-, IL-13- and/or AREG-expressing cells within each
population of single (green pie slice), double (yellow pie slice) or triple (red pie slice)
cytokine-producing ILC2s. IL-5 (gray arc), IL-13 (brown arc) and AREG (black arc). Data
is representative of at least 3 independent experiments n = 3-4 mice per group. Data
shown are the mean ± SEM. ** P < 0.01, *** P < 0.001.
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Figure 17: AREG restores lung function, barrier integrity and respiratory tissue
remodeling following influenza virus-induced damage.
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Figure 17: AREG restores lung function, barrier integrity and respiratory tissue
remodeling following influenza virus-induced damage
(A-B) mRNA (A) and protein (B) expression of ammphiregulin in the lung of naïve or
PR8-infected Rag1-/- mice at day 10 p.i. (C) mRNA expression of Areg in the lung of
naïve or PR8-infected Rag1-/- mice receiving isotype or anti-CD90.2 mAb (day 10 p.i.).
(D-J) Rag1-/- mice were infected i.n. with 0.5 LD50 PR8 and treated with isotype, antiCD90.2 mAb, or anti-CD90.2 mAb + 5-10 µg recombinant murine AREG i.p. every 2
days. (D) Representative flow cytometry plots of lung ILC2s in antibody-treated mice. (E)
Body temperature of antibody-treated mice at day 10 p.i. (F) Percentage blood oxygen
saturation in antibody-treated mice. (G) Total protein concentration in BAL fluid at day 10
p.i. (H-J) H&E staining of lung tissue in isotype (H), anti-CD90.2 (I) and anti-CD90.2 +
AREG (J) treated mice at day 10 p.i. Black arrows indicate epithelial cell hyperplasia and
gray arrows denote regions of epithelial shedding/necrosis within the bronchioles. Scale
bar = 50 µm. Data is representative of 2 independent experiments n = 3-4 mice per
group. Data shown are the mean ± SEM. *P < 0.05, ** P < 0.01, *** P < 0.001.
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Figure 18: Endogenous AREG is required for recovery from influenza virusinduced lung damage
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Figure 18: Endogenous AREG is required for recovery from influenza virusinduced lung damage
(A-D) C57BL/6 WT mice were infected with 0.5 LD50 PR8 i.n. and treated with 300 mg
of isotype or anti-AREG mAb i.p.every 2 days starting the day of infection. (A)
Percentage blood oxygen saturation (SpO2) over the course of PR8 infection, as
measured by pulse oximetry. (B) Quantification of total protein present in the
bronchoalveolar lavage (BAL) fluid at day 10 post-infection (p.i.), as determined by BCA
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protein assay. (C) H&E staining of lung tissue from PR8-infected isotype or anti-AREG
treated mice, day 10 p.i. Scale bar, 50 µm or 100 µm (for enlarged images). (D) Percent
survival over the course of infection. Data is representative of 2 independent
experiments n = 3-4 mice per group. Data shown are the mean ± SEM. ** P < 0.01.
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Figure 19: anti-IL-7-rIL-7 complexes elicit ILC2s in vivo
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Figure 19: anti-IL-7-rIL-7 complexes elicit ILC2s in vivo
C57BL/6 wild-type mice were treated i.p. with PBS or IL-7 complexes (2 mg rIL-7 + 15
mg anti-IL-7 M25 antibody) every 2 days for 1 week and assessed for lung ILC2 (A)
frequency and (B) cell number. Frequency of ILC2 gated as percentage of Lin- CD45+
cells. Data are representative of at least 3 independent experiments n = 3-4 mice per
group. Data shown are the mean ± SEM. ***p < 0.001.
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Figure 20: ILC2s are sufficient to restore lung function and tissue repair in AREGdeficient mice following influenza virus-induced lung damage
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Figure 20: ILC2s are sufficient to restore lung function and tissue repair in AREGdeficient mice following influenza virus-induced lung damage
(A-D) Areg-/- or WT C57BL/6 mice were infected with 0.5 LD50 PR8 i.n. and 1 x 105 sortpurified ILC2s from IL-7 complex-treated mice were transferred i.v. into Areg-/- mice at
day 0, day 4 and day 7 p.i. (A) Frequency of T1/ST2+ CD127+ ILC2 in the lungs of naïve
and PR8-infected WT and Areg-/- mice at day 10 p.i., gated on Lin- CD45+ cells. (B)
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Percentage blood oxygen saturation over the course of PR8 infection. (C) Quantification
of total protein present in the BAL fluid at day 10 p.i. (D) H&E staining of lung tissue from
PR8-infected WT, Areg-/- or Areg-/- + ILC2, day 10 p.i. Scale bar, 50 µm or 100 µm (for
enlarged images). Data are representative of 2-3 independent experiments n = 3-4 mice
per group. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01.
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Figure 21: EGFR is selectively activated in the airway bronchiolar epithelial cells
following influenza virus infection
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Figure 21: EGFR is selectively activated in the airway bronchiolar epithelial cells
following influenza virus infection
(A-I) C57BL/6 WT mice were infected with 0.5 LD50 PR8 i.n. and sacrificed at day 10 p.i.
(A-C) Validation of p-EGFR staining in influenza virus-infected lung tissue. Lung sections
from PR8-infected wildtype mice at day 10 post infection and stained without primary
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antibody (A), or with rabbit IgG isotype control antibody (B) or with phosphorylated
EGFR

(p-EGFR)

antibody

(Tyr1068).

(D-I)

Immunohistochemistry

staining

of

phosphorylated EGFR (p-EGFR, Tyr1068) in different anatomical lung sections from
naïve WT mice (D-F) or PR8-infected mice (G-I). BV = blood vessel, BR = bronchiolar
airway. Scale bar, 50 µm or 100 µm (for enlarged images). Data are representative of
more than 3 experiments with n = 3 mice.
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Figure 22: ILC depletion abolishes EGFR activity in lung airway epithelial cells
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Figure 22: ILC depletion abolishes EGFR activity in lung airway epithelial cells
(A-C) Rag1-/- mice were infected with 0.5 LD50 PR8 i.n. and treated with 200 mg of
isotype or anti-CD90.2 mAb i.p. every 2 days starting the day prior to infection. Mice
receiving anti-CD90.2 treatment were also given either sort-purified ILC2 cells (day 0
and day 5 p.i.). Immunohistochemistry staining for phosphorylated EGFR (p-EGFR,
Tyr1068) in paraffin-embedded lung sections from naïve (A), isotype (B), anti-CD90.2
(C), anti-CD90.2 + ILC2 treated mice at day 9 p.i. Data are representative of 2-3
experiments, n = 3-4 mice per group.
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Figure 23: Constitutive disruption in EGFR signaling during influenza virus
infection results in reduced lung function, impaired airway epithelial remodeling
and increased host mortality
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Figure 23: Constitutive disruption in EGFR signaling during influenza virus
infection results in reduced lung function, impaired airway epithelial remodeling
and increased host mortality
(A-G) EGFRvel/+ and EGFR+/+ littermates were infected with 0.5 LD50 PR8 i.n. (A)
Frequency of T1/ST2+ CD127+ ILC2 in the lungs at day 10 p.i., gated on Lin- cells. (B)
Weight loss over the course of infection. (I) Percentage blood oxygen saturation over the
course of infection. (C) Quantification of total protein present in the BAL fluid at day 10
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p.i. (E-F) H&E staining of lung tissue from naïve (E) or from PR8-infected infected (F)
EGFR+/+ and EGFRvel/+ mice at day 10 p.i. Scale bar, 50 µm or 100 µm (for enlarged
images). (G) Percent survival over the course of infection. Data are representative of at
least 3 independent experiments n = 3-4 mice per group. Data shown are the mean ±
SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 24: Temporal disruption in EGFR signaling impairs lung function and
airway epithelial repair following influenza virus infection
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Figure 24: Temporal disruption in EGFR signaling impairs lung function and
airway epithelial repair following influenza virus infection
(A-C) C57BL/6 WT mice were infected with 0.5 LD50 PR8 and treated with 10 mg/kg
EGFR inhibitor AG1478 or vehicle control starting on the day on infection. (A)
Percentage blood oxygen saturation over the course of infection. (B) H&E staining of
lung tissue from PR8-infected WT mice treated with vehicle or AG1478, at day 9 p.i.
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Scale bar, 50 µm or 100 µm (for enlarged images) (C) Percent survival over the course
of infection. Data are representative of at least 3 independent experiments n = 3-4 mice
per group. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Chapter 4
IL-33 promotes an innate pathway of intestinal tissue repair dependent on
amphiregulin-epidermal growth factor receptor interactions

4.1 Abstract
The barrier surfaces of the skin, lung and intestine are constantly exposed to
environmental stimuli that can result in inflammation and tissue damage, as observed in
multiple human chronic inflammatory diseases at these tissue sites. IL-33-dependent
group 2 innate lymphoid cells (ILC2s) are enriched at barrier surfaces and have been
implicated in promoting inflammation, however the mechanisms underlying the tissueprotective roles of IL-33 or ILC2s at surfaces such as the intestine remain poorly defined.
In this Chapter we demonstrate that following activation with IL-33, expression of a
growth factor amphiregulin (AREG) is a dominant functional signature of gut-associated
ILC2s. Utilizing a murine model of intestinal damage and inflammation, we demonstrate
that the numbers of AREG-expressing ILC2s are increased following intestinal injury and
that genetic disruption of the endogenous AREG-epidermal growth factor receptor
(EGFR) pathway results in defective repair of the epithelial barrier and exacerbated
disease. Conversely, therapeutic administration of exogenous AREG was associated
with reduced intestinal inflammation, less severe disease and enhanced tissue repair.
Notably, exogenous AREG could ameliorate disease even in the absence of the
adaptive immune system, revealing a previously unrecognized innate immune
mechanism of intestinal tissue repair. Further, therapeutic treatment with IL-33
preferentially elicited ILC2s and ameliorated intestinal disease severity in an AREGdependent manner, identifying a critical feedback loop in which cytokine cues from
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damaged epithelia activate innate immune cells to express growth factors essential for
the restoration of epithelial barrier function and maintenance of tissue homeostasis.

4.2 Introduction
A single layer of epithelial cells serves to separate the skin, lung and intestinal tracts
from exposure to microbial, physical and environmental insults, which can lead to tissue
injury and inflammation (Artis, 2008; Maloy and Powrie, 2011; Peterson and Artis, 2014;
Rescigno, 2011). Following host infection or injury, a tissue remodeling response is
initiated that serves to repair the damaged cells and restore homeostasis. (Crosby and
Waters, 2010; Rackley and Stripp, 2012; Turner, 2009). In the context of chronic
diseases like inflammatory bowel disease (IBD), the failure to initiate or resolve these
repair responses can have detrimental effects on the host, resulting in loss of tissue
function and promotion of chronic inflammation and fibrosis (Crosby and Waters, 2010;
Kaser et al., 2010; Wilson and Wynn, 2009). Therefore, delineating the cellular and
molecular mechanisms that direct tissue repair and remodeling could identify new
therapeutic targets to improve treatment of multiple chronic inflammatory diseases.
Crosstalk exists between the epithelial barrier and the mammalian immune
system in which damaged epithelial cells release cytokine signals such as interleukin
(IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP) that recruit and activate diverse
immune cell populations (Oliphant et al., 2011; Peterson and Artis, 2014; Saenz et al.,
2010a; Ziegler and Artis, 2010). In particular, elevated expression of IL-33 and its
receptor ST2 has been reported in IBD patients (Kobori et al., 2010; Lopetuso et al.,
2012; Pastorelli et al., 2011; Pastorelli et al., 2010). However, whether IL-33 plays a
pathologic or tissue-protective role during intestinal injury remains controversial (Duan et
al., 2012; Garcia-Miguel et al., 2013; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso

	
  

121	
  

et al., 2012; Pastorelli et al., 2011; Pushparaj et al., 2013; Sedhom et al., 2013), and the
cellular and molecular mechanisms which act downstream of IL-33 to regulate disease
severity are unknown. Additionally, the immune system is essential to orchestrating
epithelial repair and restoration of tissue homeostasis at these barrier sites, producing
cytokines and growth factors that can directly modulate epithelial turnover and/or
differentiation. Recently, amphiregulin (AREG), a ligand of the epidermal growth factor
receptor (EGFR), has emerged as a component of the type 2 inflammatory response in
the context of intestinal helminth infection (Zaiss et al., 2006), influenza virus-induced
lung damage (Jamieson et al., 2013; Monticelli et al., 2011) and muscle injury (Burzyn et
al., 2013). In the context of IBD, dysregulated expression of EGFR family members and
associated ligands has been reported in patients (Sipos et al., 2005; Sipos et al., 2010)
and in murine models of intestinal inflammation (Brandl et al., 2010; Yan et al., 2011).
Despite these advances, however, the cellular sources and functional significance of
specific EGFR ligands during disease remain poorly understood.
In Chapter 2 and 3, we demonstrated that a subset of the innate lymphoid cell
(ILC) family (called group 2 ILCs or ‘ILC2’) were a previously unrecognized cellular
source of AREG in the respiratory tract and that lung ILC2s were critical for restoration of
airway epithelial reparative responses following influenza virus-induced damage
(Monticelli et al., 2011). However, the majority of studies have implicated classical type 2
cytokines IL-5 and IL-13 in ILC2 function in the lung (Barlow et al., 2012; Barlow et al.,
2013; Bartemes et al., 2012; Chang et al., 2011; Halim et al., 2012; Halim et al., 2014;
Kim et al., 2012), skin (Kim et al., 2013a; Kim et al., 2013b; Roediger et al., 2013; Salimi
et al., 2013) and intestine (Camelo et al., 2012; Moro et al., 2010; Neill et al., 2010; Price
et al., 2010) while a role for ILC2-derived growth factors such as AREG has only been
described within the lung. Whether ILC2s at other barrier sites such as the intestine can
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express AREG and what functional significance this may have in regulating intestinal
inflammation and tissue homeostasis remains unknown.
In this Chapter, we demonstrate that AREG production is a dominant functional
signature of gut-associated ILC2s in response to the epithelial cell-derived cytokine IL33. Utilizing the dextran sodium sulfate (DSS) model of intestinal damage and
inflammation where IL-33 is induced, we demonstrate for the first time that AREGexpressing ILC2s are increased in response to intestinal injury. Genetic disruption of the
endogenous AREG-EGFR pathway was associated with impaired epithelial barrier repair
and exacerbated disease while therapeutic administration of AREG limited intestinal
inflammation and decreased disease severity in both lymphocyte-sufficient and
lymphocyte-deficient mice, revealing a previously unrecognized innate immune
mechanism of intestinal repair. Further, therapeutic treatment with IL-33 preferentially
elicited ILC2s and ameliorated intestinal disease severity in an AREG-dependent
manner, revealing one mechanism through which cytokine cues from damaged epithelia
orchestrate immune cells to express growth factors essential for tissue repair and the
restoration of intestinal homeostasis.

4.3 Methods
4.3.1 Mice
C57BL/6 WT mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
Rag1-/- and EGFRvel/+ mice were purchased from the Jackson Laboratory and bred in
house at the University of Pennsylvania. Areg-/- mice were provided by Dietmar Zaiss
(University of Edinburgh, UK) and were backcrossed to C57BL/6 for 14 generations. For
all DSS experiments, mice were either co-housed littermates or had shared soiled
bedding for at least two weeks prior to start of DSS exposure. All mice were maintained
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in specific pathogen-free facilities at the University of Pennsylvania. All protocols were
approved by the University of Pennsylvania Institutional Animal Care and Use
Committee (IACUC), and all experiments were performed according to the guidelines of
the University of Pennsylvania IACUC.

4.3.2 Flow cytometry
Single cell suspensions were stained with a combination of the following monoclonal
fluorescently conjugated antibodies: FITC-conjugated anti-FceR1; PE-conjugated antiCD127;

PerCP-Cy5.5-conjugated

anti-CD3,

anti-CD5,

anti-NK1.1,

anti-CD11b;

biotinylated T1/ST2 (IL-33R) (MD Bioproducts); APC streptavidin; eFluor-450-conjugated
anti-CD127;

PE-Cy7-conjugated

anti-CD25;

Alexa

700-conjugated

anti-CD90.2

(Biolegend); e-Fluor-780-conjugated anti-CD11c, anti-TCRβ, anti-B220; PE-Texas Redconjugated anti-CD4, anti-CD11b (Invitrogen); eFluor 605NC anti-CD45; eFluor 650NC
anti-CD45, anti-CD4. All antibodies were purchased from eBioscience unless specified
otherwise. For measurement of intracellular cytokine expression, cells were isolated ex
vivo and stimulated with PMA and ionomycin for four hours in the presence of brefeldin
A. Cells were subsequently surface stained with a combination of the antibodies listed
above, fixed and permeabilized using a commercially available kit (BD Cytofix/Cytoperm,
BD Biosciences), and stained with anti-IL-13 FITC (eBioscience), anti-IL-5 PE
(eBioscience) and anti-AREG Alexa Fluor 647 (AREG rat anti-mouse monoclonal mAb
(clone 206220, R&D Systems) conjugated to Alexa Fluor 647 according to
manufacturer's instructions (Molecular Probes)). For measurement of intracellular
transcription factor expression, cells were isolated directly ex vivo, stained with
antibodies

against

manufacturer’s
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permeabilized
Factor

Staining

according
Buffer

to
Set,

eBioscience) and stained with anti-GATA3 PE (eBioscience) and anti-Foxp3 eFluor 450
(eBioscience). For all stains, dead cells were excluded from analysis by means of a
viability stain (Live/Dead Fixable Aqua stain, Invitrogen). Samples were acquired on a
BD LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software (v9.2,
Tree Star)

4.3.3 Isolation of cells from mouse tissue
For isolation of cells from lymphoid tissues, tissues were pressed through 70 µm cell
strainers using the plunger of a 3 ml syringe, washed with DMEM Wash Media (DMEM
supplemented with 10% FBS, 1% L-glutamine (GIBCO), 1% Pencillin/Streptomycin
(GIBCO)), and any remaining red blood cells were lysed (ACK Lysis Buffer, GIBCO). For
isolation of cells from lung tissue, lungs were perfused with 10 ml PBS through the right
ventricle of the heart prior to removal. Right lobes of lungs were then cut into small
pieces using scissors and digested with 2 mg/ml Collagenase D (Roche) in PBS for 3045 minutes at 37 degrees with vortexing every 10 minutes. Samples were pressed
through 70 µm cell strainers, washed with DMEM Wash Media, and any remaining red
blood cells were lysed. Single cell suspensions were used for subsequent flow cytometry
staining.

4.3.4 RNA isolation and Real-Time Quantitative PCR
1 cm length of colon tissue distal to the cecum was flushed out with PBS and placed in
RNAlater (QIAGEN). Tissue was homogenized in RLT buffer and RNA was isolated
using RNeasy mini kit according to manufacturer’s instructions (QIAGEN). cDNA was
generated using Superscript reverse transcription (Invitrogen). Real-time quantitative
PCR (qRT-PCR) was performed on cDNA using SYBR green master mix (Applied
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Biosystems) and commercially available primer sets (QIAGEN). Reactions were run on
a real-time PCR system (ABI7500; Applied Biosystems). Samples were normalized to βactin and displayed as a fold induction relative to expression levels in naïve tissue.

4.3.5 DSS administration and pathological scoring
Mice were given 3% (weight/volume) Dextran Sodium Sulfate (DSS) in the drinking
water (molecular weight 36,000-50,000, MP Biomedicals). Mice were monitored daily for
morbidity (piloerection, lethargy), weight loss, and rectal bleeding as previously
described(Troy et al., 2009). Briefly, severity of disease was scored as follows: 1. weight
loss (no change, 0; <5%, 1; 6–10%, 2; 11–20%, 3; >20%, 4); 2. Feces (normal, 0; pasty,
semiformed, 1; sticky, 2; sticky with some blood, 3; completely liquid, bloody, or unable
to defecate after ten minutes, 4); 3. rectal bleeding (no blood, 0; visible blood in rectum,
1; visible blood on fur, 2); 4. general appearance (normal, 0; piloerect, 1; lethargic and
piloerect, 2; lethargic and hunched, 3; motionless and sickly, 4).

4.3.6 In vivo cytokine treatments
For examination of intracellular cytokine production, 300 ng of recombinant murine IL-33
(carrier-free, R&D Systems) in sterile PBS was administered intraperitoneally (i.p.) into
C57BL/6 wildtype mice daily for six days and cytokine expression was assessed on day
seven. For treatment during DSS-induced intestinal inflammation, 10 µg of recombinant
murine AREG or 300-400 ng recombinant murine IL-33 (carrier-free, R&D Systems) was
administered i.p. daily for the duration of the seven days on 3% DSS. Endotoxin levels
were reported to be ≤ 0.00669 EU/µm.
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4.3.7 Tissue histological sections
1 cm of colon tissue distal to the cecum was removed and flushed out with PBS. Colon
tissue was fixed in 4% paraformaldehyde, embedded in paraffin, and 5 µm sections were
used for staining with hematoxylin and eosin (H&E).

4.3.8 Statistical analysis
Results represent the mean ± SEM unless indicated otherwise. Statistical significance
was determined by unpaired Student’s t test unless indicated otherwise. Statistical
analyses were performed using Prism GraphPad software v5.0. (*, p < 0.05; **, p <
0.01; ***, p < 0.001).

4.4 Results
4.4.1 IL-33-elicited ILC2s express AREG in gut-associated lymphoid tissue
Previous studies investigating the roles of ILC2s have implicated classical type 2
cytokines IL-5 and IL-13 in ILC2 function, while the role of ILC2-derived growth factors
such as AREG have only been described within the lung. Whether ILC2s that are found
in tissues other than the respiratory tract can express AREG and what functional
significance this may have in regulating tissue homeostasis of extra-pulmonary barrier
sites such as the intestine is unknown. Further, it is unclear if AREG-producing ILC2s
represent a distinct population of ILC2s from the classical IL-5- and IL-13-expressing
cells. To address these questions, we performed single cell analysis of intracellular
expression of AREG in ILC2s from multiple tissue sites. Wildtype (WT) mice were
treated in vivo with recombinant (r)IL-33 to activate the ILC2s and assessed for
production of AREG, IL-5, and IL-13 in the lung, mesenteric lymph node (mLN) and
Peyer’s Patches (PP). Notably, in all tissue sites examined, IL-33 elicited distinct
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populations of polyfunctional ILC2s that expressed IL-5, IL-13, and/or AREG, revealing a
previously unrecognized degree of potential functional heterogeneity in ILC2s (Fig. 25AC).
Examination of the patterns of effector molecule expression in ILC2s revealed
that the majority of IL-33-elicited ILC2s expressed AREG (black arc surrounding the pie
graph) compared to IL-5 (gray arc) or IL-13 (brown arc), suggesting that AREG
production is a dominant functional signature of ILC2s following IL-33 stimulation.
Notably, multivariate analysis revealed that a greater proportion of ILC2s in the GALT
exhibited triple effector molecule producing-capacity compared to their lung counterparts
(Fig. 25D, red pie slices). Specifically, the mLN contained a significantly higher
proportion of ILC2s that expressed AREG alone and a higher percentage of triple
cytokine-producing cells capable of expressing AREG, IL-5 and IL-13 simultaneously as
compared to the lung (Fig. 25D, black arcs, and Fig. 25E). Collectively, these data
reveal unexpected functional heterogeneity in IL-33-elicited ILC2s and demonstrate that
gut-associated ILC2s express high levels of AREG, provoking the question of whether
the IL-33-ILC2-AREG pathway may play a role in regulating tissue homeostasis or
inflammation at the intestinal barrier.

4.4.2 Enhanced ILC2 responses during DSS-induced intestinal injury and
inflammation
To test the potential contribution of the ILC2-AREG pathway to intestinal inflammation
and repair, we utilized the dextran sodium sulfate (DSS)-induced model of intestinal
damage and inflammation. Oral administration of DSS is toxic to colonic epithelial cells
at the base of the crypts, leading to barrier leakage and subsequent exposure to
commensal bacteria that results in immune cell infiltration and increased expression of
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pro-inflammatory cytokines (Perse and Cerar, 2012). Additionally, progression of DSSinduced intestinal inflammation does not require the adaptive immune response (Perse
and Cerar, 2012), making it a useful model to assess the contribution of innate immune
cells to intestinal inflammation and tissue repair. Consistent with previous reports (Duan
et al., 2012; Grobeta et al., 2012; Pastorelli et al., 2010), IL-33 mRNA expression was
increased in the colon of WT mice in response to DSS-induced intestinal damage (Fig.
26A). The increase in IL-33 expression was associated with an elevation in the
frequency and cell number of Lin- CD45+ CD90+ T1/ST2+ ILC2s in the mLN that drain the
colon during DSS-induced inflammation (Fig. 26B-D). Additionally, the number of ILC2s
expressing AREG was also elevated in response to DSS-induced intestinal damage
(Fig. 26E) provoking the hypothesis that the ILC2-AREG pathway may influence
inflammation or epithelial repair responses following intestinal damage.

4.4.3 Epithelial repair and restoration of tissue homeostasis following DSSinduced intestinal injury requires endogenous AREG-EGFR interactions
To test how the AREG-EGFR pathway influences development of intestinal inflammation
or epithelial cell remodeling, WT and Areg-/- mice were exposed to DSS in the drinking
water for seven days and clinical disease scores (incorporating multiple disease
parameters including weight loss, lethargy and rectal bleeding (Troy et al., 2009)) were
monitored. In comparison to DSS-treated WT mice, Areg-/- mice exhibited increased
weight loss (Fig. 27A), exacerbated colonic shortening (Fig. 27B) and a more severe
disease pathology score (Fig. 27C). Furthermore, histological examination of the colon
tissue revealed that Areg-/- mice exhibited more severe pathological changes within the
intestinal mucosa compared to WT mice, including increased smooth muscle
hyperplasia (red arrows) and greatly enhanced immune cell infiltration (green arrows)
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that resulted in loss of crypt architecture throughout the colon (Fig. 27D).

Taken

together, these data provide the first evidence that a single EGFR ligand AREG is a
critical component of a host-protective tissue repair in response to DSS-induced
intestinal damage.
To test the role of downstream EGFR signaling in limiting intestinal inflammation,
we utilized the EGFRvel/+ mouse model that exhibits reduced EGFR tyrosine kinase
activity (Du et al., 2004). Upon exposure to DSS, EGFRvel/+ mice exhibited increased
weight loss (Fig. 28A), profound colonic shortening (Fig. 28B) and a more severe
pathological disease score (Fig. 28C) compared to littermate controls. Strikingly,
histological examination revealed that in comparison to littermate controls, EGFRvel/+
mice exhibited increased edema (black arrows) and greater immune cell infiltration
(green arrows) that resulted in near complete loss of crypt architecture throughout the
colon (Fig. 28D). Taken together, these results demonstrate a critical role for AREGEGFR signaling in limiting inflammation and regulating epithelial remodeling responses
during DSS-induced intestinal injury.

4.4.4 Exogenous AREG ameliorates DSS-induced intestinal inflammation and
tissue damage
Given the critical role of the endogenous AREG-EGFR signaling pathway in regulating
inflammation and epithelial remodeling during DSS-induced intestinal damage, we
sought to test whether therapeutic administration of recombinant AREG (rAREG) could
limit or ameliorate DSS-induced intestinal inflammation. Wildtype mice were exposed to
DSS in the drinking water and rAREG was administered in vivo daily while mice were
monitored for clinical disease parameters. WT mice treated with rAREG exhibited
reduced weight loss (Fig. 29A) and improved pathological disease score (Fig. 29B)
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compared to PBS-treated controls. Furthermore, histological examination of colonic
tissue revealed reduced inflammatory infiltrates (green arrows) and improved restoration
of epithelial architecture with goblet cell responses (blue arrows) (Fig. 29C), suggesting
a role for AREG in limiting disease severity in response to DSS-induced intestinal
damage.
In the intestine, EGFR is primarily expressed on epithelial cells (Yan et al., 2011)
although recent evidence suggests it can also be expressed on some hematopoietic
cells, including T regulatory (Treg) cells (Zaiss et al., 2013). Amphiregulin enhances
Treg function, raising the possibility that exogenous rAREG ameliorates intestinal
inflammation through its actions on the adaptive immune system. To test this, Rag1-/mice were exposed to DSS and treated daily with rAREG.

Similar to the results

observed with wildtype mice (Fig. 29A-C), rAREG treatment of DSS-exposed Rag1-/mice resulted in decreased weight loss (Fig. 30A), a significant improvement in colitis
disease score (Fig. 30B), reduced inflammation in the colon and restoration of goblet
cell responses in the crypts (blue arrows) (Fig. 30C). Taken together, these results
demonstrate that administration of exogenous AREG can limit intestinal damage and
ameliorate disease severity independently of the adaptive immune system.

4.4.5 Therapeutic administration of recombinant IL-33 preferentially elicits ILC2
responses during intestinal injury
Expression of IL-33 and its receptor ST2 has been shown to be dysregulated in patients
diagnosed with IBD (Kobori et al., 2010; Lopetuso et al., 2012; Pastorelli et al., 2011;
Pastorelli et al., 2010). However, whether IL-33 plays a tissue-protective or pathologic
role in the colonic intestinal mucosa during disease remains controversial (Duan et al.,
2012; Garcia-Miguel et al., 2013; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso et
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al., 2012; Pastorelli et al., 2011; Pushparaj et al., 2013; Sedhom et al., 2013) and the
cellular and molecular mechanisms which act downstream of IL-33 to regulate disease
severity are poorly understood. Given the ability of IL-33 to elicit AREG production by
ILC2s and the protective role of AREG in limiting DSS-induced intestinal inflammation,
we sought to test whether therapeutic treatment with recombinant IL-33 (rIL-33) could
ameliorate inflammation or promote tissue repair through induction of the ILC2-AREG
pathway. WT or Areg-/- mice were exposed to DSS and treated with rIL-33 or PBS daily
and monitored for ILC2 responses and clinical disease parameters. Flow cytometric
analysis of the mLN revealed that treatment with rIL-33 elicited a robust 16-20 fold
expansion of a lineage negative (Lin-) cell population in both WT and Areg-/- mice (Fig.
31A-B). Further examination of this Lin- population revealed induction of CD90+ T1/ST2+
ILC2s at comparable frequencies in WT and Areg-/- mice (Fig. 31C-D).
CD4+ Th2 cells can also express IL-33R (Le et al., 2013) and can express AREG
mRNA in the context of anti-helminth intestinal immunity (Zaiss et al., 2006), raising the
possibility that IL-33 may induce Th2 cell responses during intestinal inflammation.
However, total CD4+ T cell frequencies were unaffected by rIL-33 treatment (Fig. 31E).
Additionally, comparative analysis of GATA3+ CD4- ILC2 and GATA3+ CD4+ Th2 cell
induction during DSS revealed that rIL-33 preferentially induced ILC2s while having a
minimal effect on Th2 cell responses (Fig. 31F). This preferential accumulation
corresponded to an average 47-fold increase in the frequencies of ILC2s versus a 4-fold
change in CD4+ Th2 cells (Fig. 31G). Furthermore, the IL-33-mediated induction of ILC2
responses was associated with a significant increase in colonic AREG mRNA
expression over levels observed in mice treated with PBS (Fig. 31H). Taken together,
these data demonstrate that rIL-33 preferentially induces a robust ILC2 response and
results in enhanced colonic expression of amphiregulin.
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4.4.6 Therapeutic administration of recombinant IL-33 ameliorates intestinal
disease severity in an AREG-dependent manner
Strikingly, therapeutic administration of rIL-33 to WT mice resulted in decreased weight
loss (Fig. 32A), reduced colonic shortening (Fig. 32B) and improved pathological
disease score (Fig. 32C) compared to PBS-treated mice. In contrast, severe weight loss,
profound colonic shortening and elevated disease score (Fig. 32A-C) was still evident in
IL-33-treated Areg-/- mice, indicating that IL-33-mediated disease amelioration was
dependent on AREG. Histological examination of the colon revealed that in contrast to
PBS-treated animals (Fig. 32D), WT mice given rIL-33 exhibited enhanced goblet cell
responses in the crypts (Fig. 32E, blue arrow) and restoration of normal colonic
architecture without excessive immune cell infiltration. The restoration of crypt
architecture and goblet cell responses were dependent upon AREG, as Areg-/- mice
treated with rIL-33 exhibited severe disruption of colonic crypt architecture with poor
goblet cell responses, robust immune cell infiltration (green arrow), edema (black arrow)
and smooth muscle hyperplasia (red arrow) (Fig. 32G), similar to Areg-/- mice treated
with PBS alone (Fig. 32F). Notably, amelioration of disease was not associated with an
enhancement in Treg responses, as PBS- and rIL-33-treated WT and Areg-/- mice had
equivalent frequencies of Tregs (Fig. 33A-B), supporting a role for IL-33 in eliciting an
innate AREG-EGFR-dependent repair process in the intestine.

4.5 Discussion
Crosstalk between the epithelium and the immune system is essential for maintaining
tissue homeostasis at barrier surfaces of the skin, lung and intestine (Artis, 2008; Maloy
and Powrie, 2011; Peterson and Artis, 2014; Rescigno, 2011). ILC2s are enriched at

	
  

133	
  

these barrier sites and previous studies have largely focused only on the role of the
classical type 2 cytokines IL-5, IL-9 and IL-13 in regulating pro-inflammatory functions of
ILC2s. Specifically in the intestine, ILC2s were originally described as critical innate
sources of IL-13 that promoted immunity to helminth parasites (Moro et al., 2010; Neill et
al., 2010; Price et al., 2010). However, the ability of gut-associated ILC2s to express
growth factors such as AREG and whether these cells can serve a tissue-protective
function during intestinal injury has never been tested.
This Chapter provides new insight into the tissue-reparative functions of ILC2s in
the intestinal tract and implicates the AREG-EGFR signaling pathway as a critical
mechanism by which ILC2s may limit inflammation and promote epithelial repair during
DSS-induced intestinal injury. Further, we identify that therapeutic IL-33 treatment
preferentially elicits ILC2s and ameliorated intestinal disease severity in an AREGdependent manner, identifying a critical feedback loop in which cytokine signals from
damaged epithelia orchestrate innate immune cell responses and promote expression of
growth factors essential for restoration of epithelial barrier function and tissue
homeostasis. Notably, a previous study utilizing an oxazolone-induced intestinal injury
model where type 2 cytokines are known to be pathologic observed that IL-25 elicited IL13+ ILC2s correlated with disease severity (Camelo et al., 2012), suggesting that under
some circumstances ILC2s can serve pro-inflammatory functions during intestinal injury.
This potential dual function of ILC2s in intestinal injury parallels the role of gut RORγt+
group 3 ILCs, where their production of pro-inflammatory cytokines IFNγ and IL-17A can
drive intestinal colitis disease in some settings (Buonocore et al., 2010; Geremia et al.,
2011), while conversely in other models their expression of IL-22 can serve to promote
restoration of tissue integrity (Aujla et al., 2008; Mielke et al., 2013b; Sanos et al., 2011;
Sonnenberg et al., 2010; Sonnenberg et al., 2011; Zheng et al., 2008).
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IL-33 acts a cytokine ‘alarmin’ that is released rapidly upon epithelial cell damage
to activate resident immune cell populations of the lung and intestine (Garcia-Miguel et
al., 2013; Le et al., 2013; Ohno et al., 2012). Expression of IL-33 and its receptor ST2
has been shown to be dysregulated in IBD patients (Kobori et al., 2010; Lopetuso et al.,
2012; Pastorelli et al., 2011; Pastorelli et al., 2010). However, whether IL-33 plays a
tissue-protective or pathologic role in the colonic intestinal mucosa during disease
remains controversial (Duan et al., 2012; Garcia-Miguel et al., 2013; Grobeta et al.,
2012; Imaeda et al., 2011; Lopetuso et al., 2012; Pastorelli et al., 2011; Pushparaj et al.,
2013; Sedhom et al., 2013), and the cellular and molecular mechanisms which act
downstream of IL-33 to regulate disease severity are unknown. We identify the ILC2AREG-EGFR axis as one mechanism by which IL-33 orchestrates tissue repair in the
intestine. Importantly, this AREG-dependent protection was evident in lymphocytesufficient and lymphocyte-deficient mice and was not associated with enhanced Treg
frequencies, highlighting a previously unappreciated role for the innate immune system
in regulating tissue repair in the intestine.
Dysregulated expression of EGFR family members and associated ligands has
been reported in patients diagnosed with IBD (Sipos et al., 2005; Sipos et al., 2010) and
in murine models of intestinal inflammation (Brandl et al., 2010; Yan et al., 2011).
Additionally, therapeutic administration of a single EGFR ligand reduced disease
severity and inflammation in a clinical trial (Sinha et al., 2003). However, despite these
advances, the cellular sources of specific EGFR ligands during disease and the
functional significance of individual ligands in limiting intestinal inflammation or regulating
mucosal tissue repair during disease remain poorly characterized. Our data identifying
AREG as a single ligand that is both necessary and sufficient for limiting disease
severity and promoting tissue repair provides a critical conceptual advance in our
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understanding of EGFR-mediated regulation of intestinal biology. Remarkably, in the
steady-state AREG-deficient mice exhibit few physiological abnormalities besides
impaired mammary development (Luetteke et al., 1999), suggesting that other EGFR
ligands or alternative growth factors can compensate for the absence of AREG to
maintain tissue homeostasis. In contrast, under inflammatory conditions when the
epithelial barrier is damaged, the data presented in Chapters 3 and 4 indicate that innate
immune cell-derived AREG becomes a critical factor in orchestrating restoration of
epithelial barrier function and tissue homeostasis at multiple barrier surfaces. The
identification of ILC2s as a previously unrecognized hematopoietic cellular source of
AREG in the intestine indicates that manipulation of the AREG-EGFR pathway could
provide therapeutic benefit in the treatment of intestinal inflammatory diseases.
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Figure 25: IL-33-elicited ILC2s express AREG in gut-associated lymphoid tissue
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Figure 25: IL-33-elicited ILC2s express AREG in gut-associated lymphoid tissue
(A-E) C57BL/6 WT mice were treated i.p. with 300 ng rIL-33 daily for 6 days. Cells were
isolated from the lung, mesenteric lymph node (mLN) and Peyer’s Patches (PP) on day
7, stimulated ex vivo with PMA and Ionomycin plus brefeldin A for 4 hours and then
examined for intracellular cytokine expression of IL-5, IL-13 and AREG via flow
cytometry. (A) Frequency of CD90+ T1/ST2+ ILC2 in the lung, mLN and PP after rIL-33
treatment, gated on Lin- CD45+ cells. (B) Frequency of Lin- CD45+ CD90+ T1/ST2+ ILC2s
expressing IL-5 and AREG in rIL-33-treated WT mice. (C) Frequency of Lin- CD45+
CD90+ T1/ST2+ ILC2s expressing IL-13 and AREG in rIL-33-treated WT mice. (D)
Multivariate analysis of flow cytometric data from (B-C) using SPICE Software. Pie slice
color indicates number of cytokines (IL-5, IL-13 or AREG) produced by lung ILC2s (blue
= 0, green = 1, yellow = 2, red = 3). Pie arcs illustrate the distribution of IL-5-, IL-13and/or AREG-expressing cells within each population of single (green pie slice), double
(yellow pie slice) or triple (red pie slice) cytokine-producing ILC2s. IL-5 (gray arc), IL-13
(brown arc) and AREG (black arc). (E) Frequency of total ILC2 in lung, mLN and PP
expressing AREG alone or expressing AREG, IL-5 and IL-13 simultaneously. Data are
representative of at least 3 independent experiments n = 3-4 mice per group per
experiment. Data shown are the mean ± SEM. *p < 0.05
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Figure 26: Epithelial remodeling during DSS-induced intestinal inflammation is
associated with enhanced ILC2 responses
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Figure 26: Epithelial remodeling during DSS-induced intestinal inflammation is
associated with enhanced ILC2 responses
(A-E) C57BL/6 WT mice were exposed to 3% (weight/volume) dextran sodium sulfate
salt (DSS) in the drinking water for 7 days. (A) mRNA expression levels of IL-33 in
colonic tissue from mice on DSS or normal water, normalized to β-actin and shown
relative to expression levels in mice on normal water. Frequency (B-C) and cell number
(D) of CD90+ T1/ST2+ ILC2 in the colonic draining mesenteric lymph nodes (mLN), gated
on Lin- CD45+ cells. (E) mLN cells from water or DSS-treated mice were briefly
stimulated ex vivo with PMA and Ionomycin plus brefeldin A for 4 hours and assessed
for total number of AREG-expressing ILC2s, as determined by intracellular cytokine
staining. Data are representative of at least 3 independent experiments, n = 3-4 mice per
group per experiment. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01, ***p <
0.001.
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Figure 27: Epithelial remodeling during DSS-induced intestinal inflammation
requires endogenous AREG
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Figure 27: Epithelial remodeling during DSS-induced intestinal inflammation
requires endogenous AREG
(A-D) WT or Areg-/- mice were administered 3% DSS in the drinking water and assessed
on day 7 for weight loss (A), colon length (B) and pathological disease score (C). (D)
H&E staining of colon sections from WT or Areg-/- mice after 7 days of DSS exposure.
Green arrows denote regions of cellular infiltrate and red arrows denote thickening and
hyperplasia of the smooth muscle lining. Scale bar, 100 µm. Data are representative of
at least 3 independent experiments, n = 3-4 mice per group per experiment. Data shown
are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 28: EGFR signaling is critical for limiting inflammation and promoting
epithelial remodeling during DSS-induced intestinal injury
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Figure 28: EGFR signaling is critical for limiting inflammation and promoting
epithelial remodeling during DSS-induced intestinal injury
(A-B) EGFRvel/+ and EGFR+/+ littermates were exposed to 3% DSS in the drinking water
for 7 days and assessed for weight loss (A), colon length (B) and pathological disease
score (C). (D) H&E staining of colon sections from EGFRvel/+ or EGFR+/+ mice after 7
days of DSS exposure. Green arrows denote regions of cellular infiltrate and black
arrows denote areas of edema. Scale bar, 100 µm. Data are representative of at least 3
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independent experiments, n = 3-4 mice per group per experiment. Data shown are the
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 29: Therapeutic administration of AREG ameliorates DSS-induced
intestinal inflammation and tissue damage
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Figure 29: Therapeutic administration of AREG ameliorates DSS-induced
intestinal inflammation and tissue damage
C57BL/6 WT mice were exposed to 3% DSS in the drinking water for 7 days and treated
with PBS or 10 µg recombinant (r)AREG intraperitoneally (i.p.) daily starting on the initial
day of DSS exposure. Mice were examined for weight loss (A) over the course of
treatment and pathological disease score (B was assessed on day 7. (C) H&E staining
of colon tissue from PBS or rAREG-treated mice on day 7. Blue arrows indicated goblet
cell hyperplasia, green arrows denote regions of cellular infiltrate and black arrows
denote areas of edema. Scale bar, 100 µm. Data are representative of 2-3 independent
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experiments, n = 4 mice per group per experiment. Data shown are the mean ± SEM. *p
< 0.05, ***p < 0.001.
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Figure 30: AREG ameliorates DSS-induced intestinal inflammation and promotes
tissue repair in the absence of adaptive immunity
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Figure 30: AREG ameliorates DSS-induced intestinal inflammation and promotes
tissue repair in the absence of adaptive immunity
Rag1-/- mice were exposed to 3% DSS in the drinking water for 7 days and treated with
PBS or 10 µg recombinant (r)AREG intraperitoneally (i.p.) daily starting on the initial day
of DSS exposure. Mice were examined for weight loss (A) over the course of treatment
and pathological disease score (B) was assessed on day 7. (C) H&E staining of colon
tissue from PBS or rAREG-treated mice on day 7. Blue arrows indicated goblet cell
hyperplasia, green arrows denote regions of cellular infiltrate and black arrows denote
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areas of edema. Scale bar, 100 µm. Data are representative of 2-3 independent
experiments, n = 4 mice per group per experiment. Data shown are the mean ± SEM. *p
< 0.05, **p < 0.01.

	
  

146	
  

Figure 31: Therapeutic administration of recombinant IL-33 preferentially elicits
ILC2 responses during intestinal injury
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Figure 31: Therapeutic administration of recombinant IL-33 preferentially elicits
ILC2 responses during intestinal injury
C57BL/6 WT or Areg-/- mice were exposed to 3% DSS in the drinking water for 7 days
and administered PBS or 400 ng recombinant (r)IL-33 i.p. daily starting on the day of
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initial DSS treatment. Frequency of CD45+ Lin- cells (A,B) and CD45+ Lin- CD90+
T1/ST2+ ILC2s (C,D) in the colonic draining mesenteric lymph nodes (mLN) of WT and
Areg-/- mice at day 7 following PBS or rIL-33 treatment. Lineage antibodies include
NK1.1, CD11b, CD11c, FcεR1, CD3, CD5, TCRβ, B220. (E) Frequency of total CD4+ T
cells in the colonic draining mesenteric lymph node (mLN), gated on CD45+ cells. (F)
Frequency of GATA3+ CD4- ILC2s and GATA3+ CD4+ Th2 cells in the mLN of WT mice
on 3% DSS treated with PBS or rIL-33, plots are gated on CD45+ cells. (G) Fold
increase in relative frequency of GATA3+ CD4- ILC2s and GATA3+ CD4- Th2 cells
following rIL-33 treatment during DSS. (H) mRNA expression levels of AREG in the
colon tissue of PBS or rIL-33-treated WT and Areg-/- mice after 7 days of DSS exposure,
normalized to β-actin and shown relative to expression levels in WT mice on normal
water. Data are representative of 2 independent experiments, n = 4 mice per group per
experiment. Data shown are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 32: Therapeutic administration of recombinant IL-33 limits intestinal
inflammation and promotes tissue repair in an AREG-dependent manner
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Figure 32: Therapeutic administration of recombinant IL-33 limits intestinal
inflammation and promotes tissue repair in an AREG-dependent manner
C57BL/6 WT or Areg-/- mice were exposed to 3% DSS in the drinking water for 7 days
and administered PBS or 400 ng recombinant (r)IL-33 i.p. daily starting on the day of
initial DSS treatment. Weight loss (A), colon length (B) and pathological disease score
(C) of PBS and rIL-33-treated WT and Areg-/- mice on DSS. (D-G) H&E staining of colon
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tissue after 7 days of DSS exposure. Blue arrows denote goblet cell hyperplasia, green
arrows indicate regions of severe cellular infiltrate, red arrows indicate hyperplasia of the
smooth muscle lining and black arrows denote areas of edema. Scale bar, 100 µm. Data
are representative of 2 independent experiments, n = 4 mice per group per experiment.
Data shown are the mean ± SEM. **p < 0.01, ***p < 0.001.

	
  

150	
  

Figure 33: Regulatory T cell frequency is unaltered following rIL-33 treatment
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Figure 33: Regulatory T cell frequency is unaltered following rIL-33 treatment
C57BL/6 WT or Areg-/- mice were exposed to 3% DSS in the drinking water for 7 days
and administered PBS or 400 ng recombinant (r)IL-33 i.p. daily starting on the day of
initial DSS treatment. Flow cytometry plots (A) and frequency (B) of CD45+ CD4+ CD25+
Foxp3+ regulatory T cells (Tregs) in the draining mesenteric lymph node (mLN). Data are
representative of 2 independent experiments, n = 4 mice per group per experiment. Data
shown are the mean ± SEM.
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Chapter 5
Summary, Discussion and Future Directions

5.1 The expanding ILC family
Recent work over the past several years has shed light on the development, regulation
and effector function of this novel family of immune cells that play vital roles in balancing
host-protective immunity and pathologic inflammation barrier surfaces. Data presented in
Chapters 2 and 3 of this thesis identify a novel ILC population in the respiratory tract of
humans and mice and implicate these cells as critical drivers of epithelial cell repair to
restore tissue homeostasis following acute injury. Our studies suggest that lung ILCs
phenotypically and functionally resemble members of the Group 2 ILC (ILC2) subset,
previously indentified in the intestinal tract and fat-associated lymphoid clusters and
referred to as natural helper (NH) cells, nuocytes or innate helper type 2 (Ih2) cells
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010). While the biological distinctions
between NH cells, nuocytes and Ih2 cells remain a point of controversy, the striking
similarities in cell surface phenotype, developmental requirements and effector cytokine
expression between the three populations strongly suggest that these cells are part of a
single subset that exists in multiple anatomical locations and exhibits some degree of
functional heterogeneity. Transient differences in reported cell surface expression of
activation markers (such as c-Kit or Sca-1) between these three cell populations could
be the result of varying degrees of maturation/differentiation governed by environmental
cues in distinct tissue microenvironments. Furthermore, there is very little known about
the trafficking patterns and chemokine receptor expression profiles of ILCs, raising the
possibility that some ILCs (or their less differentiated progenitors) may circulate
throughout the bloodstream or lymph, migrating into different anatomical sites in
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response to infectious or inflammatory cues, while other ILCs may remain tissueresident sentinels at barrier sites. Since the completion of studies outlined in this thesis,
new reports have emerged demonstrating the existence of phenotypically similar ILC2
populations throughout multiple anatomical sites, including skin, liver and adipose tissue
(Hams et al., 2013; Kim et al., 2013a; McHedlidze et al., 2013; Roediger et al., 2013;
Salimi et al., 2013). While these cells appear to share common phenotypic and
developmental requirements, the extent to which each population may possess distinct
activation and functional specialization unique to each tissue microenvironment remains
incompletely understood and merits further investigation.

5.2 Identification of the AREG-EGFR pathway as a key component of immune cellmediated tissue repair
Amphiregulin (AREG) was originally discovered as a growth factor associated with
proliferation of mammary cancer cell lines (Berasain and Avila, 2014; Busser et al.,
2011b). Although AREG is just one of several ligands of the epidermal growth factor
receptor (EGFR) family, it is now appreciated as a central regulator of cellular
proliferation and differentiation for a diverse array of non-hematopoietic cell lineages
including epithelial cells, endothelial cells, fibroblasts, smooth muscle cells, keratinocytes
and osteoclasts (Berasain and Avila, 2014; Busser et al., 2011b; Kataoka, 2009).
However, it was only been the past several years that AREG has been recognized as a
modulator of hematopoietic cell function. First reported as a new component of the type
2 cytokine franchise produced by Th2 CD4 T cells to expel parasites from the intestine
(Zaiss et al., 2006), AREG is now considered to be an effector molecule of multiple cells
types associated with type 2 immunity, including basophils, eosinophils, mast cells and
regulatory T cell (Tregs) (Burgel et al., 2001; Matsumoto et al., 2009; Meulenbroeks et
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al., 2014; Qi et al., 2010; Zaiss et al., 2013). However, it would be short-sighted to
assume that AREG is solely an effector molecule of the type 2 immune response. Due to
the lack of a comprehensive assessment of AREG expression in innate and adaptive
murine cells, it is unclear whether AREG could also be induced during type 1 or type 17
immune responses. Notably, examination of human AREG expression in T cells
indicates that AREG can be induced in both CD4 and CD8 cells irrespective of prior in
vitro polarization (Qi et al., 2012). Taken together with our data in Chapters 3 and 4
demonstrating a dominant role for the cytokine alarmin IL-33 in inducing ILC2-intrinsic
AREG expression, these data suggest that regulation of AREG production is more likely
dependent on instruction from local environmental cues rather than programmed early in
lineage specification.
It is surprising that under homeostatic conditions, mice lacking AREG are
reported to exhibit few physiological abnormalities besides impaired mammary
development while mice with genetic deletions in EGFR die in utero (Luetteke et al.,
1999). Furthermore, mice that are only heterozygous for mutations that reduce EGFR
activity still exhibit profound abnormalities in skin and mammary tissues where EGFR
expression is strongest (Berasain and Avila, 2014; Du et al., 2004; Luetteke et al., 1999),
illustrating the essential role of EGFR signaling in prenatal development. These data
suggest that the other EGFR ligand family members can compensate for the absence of
AREG to maintain tissue homeostasis during early development and postnatal
homeostatic conditions in the adult mouse. Supporting this, reports of growth retardation
and spontaneous intestinal abnormalities have only been reported in mice that are
genetically deficient in multiple EGFR ligands simultaneously (AREG, EGF, TGFα)
(Troyer et al., 2001).
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In contrast, under inflammatory conditions when the epithelial barrier is
damaged, the data presented in Chapters 3 and 4 of this thesis indicate that innate
immune cell-derived AREG becomes a critical factor in orchestrating restoration of
epithelial barrier function and tissue homeostasis at multiple barrier surfaces (Fig. 34).
Future studies are needed to investigate the possibility that additional EGFR ligand
family members (or non-EGFR growth factors) may also contribute to ILC2-mediated
tissue repair. Nonetheless, the data presented in this thesis identifying ILC2s as a
previously unrecognized hematopoietic cellular source of AREG and demonstrating an
essential role of the AREG-EGFR pathway during tissue repair suggest that
manipulation of this innate axis could provide therapeutic benefit in the treatment of
multiple inflammatory diseases of the respiratory and intestinal tracts.

5.3 Heterogeneity in ILC2 functionality in response to epithelial cytokines
In Chapter 2 we demonstrate that IL-33, but not another epithelial cell-derived cytokine
IL-25, is a robust, in vivo signal for inducing AREG expression in ILC2s. Intriguingly, IL33 elicited distinct populations of polyfunctional ILC2s that expressed IL-5, IL-13 and/or
AREG simultaneously, illustrating a previously unrecognized degree of functional
heterogeneity in ILC2s. As IL-33 is upregulated in diverse inflammatory conditions of
allergy, infection, or non-infectious tissue injury (Garcia-Miguel et al., 2013; Le Goffic et
al., 2011a; Oboki et al., 2011; Ohno et al., 2012; Smith, 2011), it is tempting to speculate
that this functional heterogeneity may reflect the differential roles that IL-33-elicited
ILC2s play in the context of inflammation or tissue repair. For example, IL-5 and IL-13
are critical for development of ILC2-mediated allergic and virus-induced airway
inflammation (Barlow et al., 2013; Chang et al., 2011; Halim et al., 2012; Kim et al.,
2012) but data presented in Chapter 2 and elsewhere (Monticelli et al., 2011) indicate
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that these cytokines are dispensable for ILC2-mediated tissue repair during influenza
virus infection. Conversely, ILC2 single cytokine producers expressing AREG alone may
be the critical ILC2 population regulating restoration of tissue homeostasis following
influenza virus-induced tissue damage.
Whether AREG-expressing ILC2s can also contribute to pathologic airway
inflammation remains unknown. Patients undergoing acute asthma attacks have been
reported to express high levels of AREG in their sputum (Enomoto et al., 2009),
suggesting that ILC2-derived AREG could also be involved in airway remodeling in
human disease. Furthermore, given the ability of AREG to promote epithelial cell and
fibroblast proliferation and regulate mucus production (Broide, 2008; Crosby and Waters,
2010), it is possible that ILC2-derived AREG may also be involved in the pathology
associated with chronic inflammatory lung disorders such as Idiopathic Pulmonart
Fibrosis (IPF) or Chronic Obstructive Pulmonary Disease (COPD) although this has yet
to be formally explored. One recent study reported a critical role for ILC2-derived IL-13 in
driving pathologic tissue fibrosis and collagen depositions in a murine model of IPF
(Hams et al., 2014), however, the potential contribution of ILC2-intrinsic AREG to
disease progression was not examined. Future studies utilizing transgenic cytokine
reporter mice and mice with conditional deletions of multiple ILC2-derived cytokines will
be needed to fully elucidate the relative contributions of these polyfunctional ILC2
populations during settings of inflammation and tissue repair.

5.4 Innate versus adaptive mechanisms of tissue repair
At mucosal surfaces of the lung and gut, exposure to environmental insults such as
allergens or infection with pathogens can cause varying degrees of injury to the host
tissue that must be adequately repaired to avoid prolonged inflammation or loss of
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epithelial barrier function (Gorski et al., 2012; Keely et al., 2012; Morrisey and Hogan,
2010; Neurath, 2014; Rock et al., 2010). While tissue damage often begins at the very
onset of exposure, before adaptive immune responses are generated, it can later be
amplified due to T cell-driven immunopathology, suggesting there may be a temporal
regulation of tissue repair by the innate and adaptive immune systems. However, the
relative contribution of innate versus adaptive immune cells to tissue repair and
restoration of barrier integrity in different disease settings is poorly understood.
In the context of the intestine, data in Chapter 4 indicates that exogenous
rAREG or rIL-33 treatment resulted in reduced tissue damage and improved restoration
of epithelial crypt architecture independently of any potential effects on the adaptive
immune system. The pathologic versus tissue-protective role of IL-33-IL-33R signaling
during intestinal inflammation is controversial and appears to depend upon the type of
injury stimulus employed, the genetic background of the mouse strain and the duration
of inflammation (Duan et al., 2012; Grobeta et al., 2012; Imaeda et al., 2011; Lopetuso
et al., 2012; Pushparaj et al., 2013). Interestingly, a previous study identified a protective
role for IL-33 during the recovery stage following chronic DSS inflammation (Duan et al.,
2012) and observed enhanced goblet cell metaplasia during rIL-33 treatment similar to
what we observed during acute inflammation. Notably, in that study the protective effect
of IL-33 was attributed to Tregs, a well-appreciated regulator of intestinal inflammatory
disease. However, this interpretation is complicated by the fact that the authors
employed anti-CD25 mAb to eliminate Tregs, a strategy that will also target ILC2s for
depletion (Kobori et al., 2010). More recently, work from Powrie and colleagues has
demonstrated that IL-33 can directly induce Tregs which can ameliorate inflammation in
a model of T cell-driven colitis (Schiering et al., 2014).
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In contrast to those studies, the data presented in Chapter 4 of this thesis reveal
an innate immune mechanism of intestinal tissue repair, illustrated by the therapeutic
benefit of rAREG in the absence of the adaptive immune system and by the preferential
accumulation of ILC2s following IL-33 treatment without detectable effects on Treg
frequency. While the reasons for these differential cellular mechanisms are not yet clear,
it may be reflect the nature of the damage stimulus (DSS-induced barrier disruption
versus T cell transfer-driven colitis) or the duration of inflammation (acute versus
chronic). However, as Tregs have been shown to be a source of AREG at sites outside
the intestine (Burzyn et al., 2013). it remains possible that adaptive immune cell-derived
AREG may play a more important role in other inflammatory conditions besides the
acute injury model utilized in this thesis. Future studies utilizing lineage-specific deletion
in AREG would be beneficial in determining the contribution of adaptive versus innate
cell-derived AREG to IL-33-mediated tissue repair during different phases of intestinal
injury and inflammation.

5.5 Epithelial and hematopoietic targets of AREG-EGFR activity
The lung contains a complex architecture of specialized epithelial cell lineages that are
central to maintaining proper airway barrier integrity and gas exchange (Kumar et al.,
2004; Rackley and Stripp, 2012; Rock and Hogan, 2011). A similar paradigm exists in
the intestine, where distinct epithelial lineages employ anti-microbial peptides, mucus
secretions and tight junction proteins to maintain barrier integrity and prevent
translocation of trillions of commensal bacteria (Garcia-Miguel et al., 2013; Hisamatsu et
al., 2013; Neurath and Travis, 2012). Regeneration of these distinct epithelial
populations after tissue injury can occur through local proliferation of terminally
differentiated cells or can involve differentiation from progenitor stem cells (Chen et al.,
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2009; Rackley and Stripp, 2012; Rawlins et al., 2009; Rock and Hogan, 2011; Teisanu et
al., 2011).
EGFR is widely expressed in epithelial cell lineages across multiple tissues sites
although the cellular pattern of phosphorylated EGFR activity depends upon the nature
of the inflammatory stimulus (Burgel and Nadel, 2004, 2008; Nadel and Burgel, 2001).
While AREG-EGFR signaling can promote proliferation and survival of differentiated
epithelial cells in vitro (Kim and Nadel, 2009; Kim et al., 2005; Kim et al., 2002; Koff et
al., 2008; Wang et al., 2005), the in vivo cellular targets of this pathway during acute
injury repair or progression of chronic inflammation are poorly understood. Therefore, in
this thesis we sought to examine the cellular sources of EGFR activity to provide insight
into the mechanism by which the IL-33-ILC2-AREG pathway influences tissue repair.
In the lung in Chapter 3 we demonstrate that EGFR activity is selectively
upregulated in the cells lining the bronchiolar airway epithelium (consisting almost
entirely of Clara cells), with virtually no activity in the parenchyma alveolar epithelial
cells. Given the in vivo requirement for EGFR signaling to promote airway epithelial
remodeling responses, these data are consistent with a model in which ILC2-derived
AREG acts on bronchiolar airway epithelial Clara cells (or on a facultative airway
progenitor stem cell population) to promote cellular proliferation and/or differentiation to
restore the airway epithelial barrier (Fig. 34). Further studies are needed to test this
directly, however. In particular, conditional deletion of EGFR on different epithelial
lineages (CC10 for Clara cells, SFPTC for alveolar parenchyma cells, Krt5 for basal
cells) during influenza virus infection would aid in confirming the cellular target of ILCderived AREG in the respiratory tract. The apparent tropism of AREG-EGFR activity for
the Clara cells of the airway epithelium, but not the Type I and Type II alveolar cells of
the lung parenchyma, is surprising given that EGFR is expressed on all lung epithelial
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lineages (Berasain and Avila, 2014; Burgel and Nadel, 2004, 2008; Nadel, 2001; Shim et
al., 2001; Ueki et al., 2013) and influenza virus-induced injury is widespread throughout
the lung (Fukushi et al., 2011; Iwasaki and Pillai, 2014; Peiris et al., 2010). The
exclusivity of EGFR activation for bronchiolar airway epithelial cells suggests that airway
versus alveolar epithelial repair are governed by distinct cellular and molecular cues.
Indeed, a recent report demonstrates that Krt5+ basal cells of the lung parenchyma act
as facultative stem cell progenitors for regenerating alveolar, but not bronchiolar airway,
epithelial cells in response to influenza virus-induced cell damage (Kumar et al., 2011).
A similar mechanism may also apply to settings of intestinal injury and
inflammation. EGFR activity is upregulated in colonic epithelial cells during DSS-induced
injury (Yan et al., 2011) although it is unclear whether AREG-EGFR signaling acts solely
on mature, fully differentiated epithelial lineages or may promote tissue restoration by
modulating intestinal stem cell function. EGFR ligand EGF is commonly added to the
growth factor medium required for generating three-dimensional epithelial organoid
cultures from single Lgr5+ stem cells (Barker, 2014; Peterson and Artis, 2014)
suggesting that intestinal stem cells (or their immediate progeny) express EGFR and
could potentially be responsive to other ligands such as AREG. Future studies utilizing
conditional deletion of EGFR on mature epithelial cells versus Lgr5+ stem cells will aid in
determining the epithelial target of ILC2-mediated, AREG-dependent intestinal tissue
repair.
EGFR was previously thought to be primarily restricted to epithelial and stromal
cell lineages (Burgel and Nadel, 2004, 2008; Nadel, 2001) and therefore any effects of
EGFR signaling on immune cell function were presumed to be due to indirect regulation
via epithelia. Recently, however, a few studies have challenged this dogma and revealed
a direct functional role for EGFR on hematopoietic cells, where EGFR signaling can
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enhance suppressive ability of regulatory T cells (Tregs) (Zaiss et al., 2013), promote
survival of bone marrow hematopoietic stem cells (HSCs) (Doan et al., 2013) and
regulate intestinal macrophage function (Lu et al., 2014). Therefore, future studies
should address the possibility that in the context of DSS-induced colitis, AREG-EGFR
signaling does not act directly upon the epithelium but instead could activate immune
cells which in turn produce additional cytokines and growth factors to promote
restoration of the epithelial barrier.

5.6 The AREG-EGFR pathway in human health and disease
In the clinic, EGFR inhibitors are a widely used therapeutic treatment for multiple human
diseases, most commonly for cancers of the lung, intestine and pancreas (Busser et al.,
2011a; Hartmann et al., 2009; Iyer and Bharthuar, 2010). Unfortunately, fatal interstitial
lung disease of unknown etiology has been reported to occur in lung cancer patients
treated with several types of pharmacological EGFR inhibitors (Chou et al., 2010; Makris
et al., 2007; Wang et al., 2013). Given the data presented here in Chapter 3 describing
the role of endogenous EGFR signaling in regulating lung tissue repair in murine
models, it is possible that the inhibition of EGFR signaling may disrupt lung tissue
regenerative responses in these patients and potentially contribute to development of
disease. These data provoke the need for caution in utilizing these therapies and
suggest that screening patients for a history of recent viral or bacterial infections prior to
initiation of treatment may help identify patients more susceptible to developing the
interstitial lung disease. In contrast, in some circumstances such as infection with
pathogens that cause lung injury, the targeted promotion of the AREG-EGFR pathway to
promote epithelial repair may have therapeutic benefit in improving clinical outcomes.
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Inflammatory bowel disease (IBD) is a chronic, relapsing inflammation of the
intestinal mucosa that results in impaired epithelial barrier integrity and a failure to
regulate mucosal wound healing (Hisamatsu et al., 2013; Kaser et al., 2010; Neurath,
2014; Neurath and Travis, 2012; Scharl and Rogler, 2012; Strober et al., 2007). The
etiology of IBD is multi-factorial and has been linked to multiple growth factor pathways,
including EGFR-associated family members (Hisamatsu et al., 2013; Kaser et al., 2010;
Krishnan et al., 2011; Neurath, 2014; Strober et al., 2007). EGFR is normally expressed
throughout the intestine and elevated receptor activity and expression of EGFR ligands
including amphiregulin have been observed in human IBD patients (Sipos et al., 2005;
Sipos et al., 2010) and murine models of intestinal inflammation (Brandl et al., 2010; Yan
et al., 2011). Additionally, therapeutic administration of a single EGFR ligand EGF
reduced inflammation and ameliorated disease severity in a clinical trial (Sinha et al.,
2003). However, despite these advances, the cellular sources and functional
significance of specific EGFR ligands in limiting intestinal inflammation or regulating
mucosal tissue repair during disease remained poorly understood. Given our data in
Chapter 4 identifying AREG as a single ligand that is both necessary and sufficient for
limiting disease severity and promoting tissue repair, it is possible that administration of
exogenous AREG could be a potential future therapeutic treatment designed to speed
recovery of intestinal barrier integrity.

5.7 Concluding remarks
The epithelium of the respiratory and intestinal tracts serves dual roles as a physical
barrier to prevent host exposure to environmental insults, commensal microbes and
pathogens while simultaneously integrating signals from these sources to instruct the
function of sentinel immune cells. The members of the diverse family of innate lymphoid
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cells are enriched at these barrier sites and have been shown to be novel regulators of
host immunity, inflammation, and barrier maintenance. Collectively, the data presented
in this thesis reveal a conserved innate mechanism of barrier repair by which ILCs
responds to damage cues from the local microenvironment to promote restoration of
tissue homeostasis through an IL-33-AREG-EGFR axis (Fig. 34).
While advances in the ILC field have moved at an extraordinary pace the past
several years since their formal discovery, the study of ILCs still remains in its infancy
with fundamental questions about their development, activation and effector function
remaining unclear. Furthermore, advancements in the ILC field are hindered by a lack of
genetic and molecular tools to selectively target ILCs in the presence of adaptive
immune cells. Understanding the extent of the crosstalk between ILC2s and the adaptive
immune system is essential for assessing the utility of therapeutically targeting human
ILC2s in the context of generating protective immune responses, limiting tissue
inflammation and promoting barrier maintenance. Related to this, much of the recent
work on murine ILC2 development (for example GATA3 and Gfi1) and effector function
(IL-5, IL-9, IL-13) has been focused on their similarity to pathways already identified in
Th2 CD4 helper T cell biology. Extensive microarray transcriptional analyses or use of
next generation RNA-Seq technology will be an invaluable exploratory tool to uncover
the unique factors regulating the development and functional potential of murine and
human ILC2s.
Their enrichment at barrier surfaces and their rapid response to damage signals
make ILCs an attractive target for therapeutic manipulation in the clinical treatment of
multiple human infectious or inflammatory diseases. However, the rarity of ILCs makes
selective in vivo targeting challenging and therapeutic treatments aimed at modulating
upstream regulators such as IL-33 are non-specific and will influence a multitude of
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diverse immune cell subsets with contradictory pro-inflammatory versus tissue-protective
functionality. Greater understanding of the environmental cues that dictate the
heterogeneous downstream effector mechanisms employed by ILCs in inflammatory
versus host protective immune responses will be key to designing effective therapeutic
strategies to improve human health.
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Figure 34: A conserved innate immune mechanism of tissue repair at barrier
surfaces

Lung

Intestine
Epithelial cell hyperplasia
Tissue repair

Injury

Goblet cell hyperplasia
Limited inflammation
Tissue repair

Injury
()*'%

()*'%

&'()%

IL-33

!"#$%
!"#$%

!"#$%

?

!"

?
IL-33

Figure 34: A conserved innate immune mechanism of tissue repair at barrier
surfaces
Upon injury to the epithelium of the lung and intestine, IL-33 is released to activate
immune cell populations, including ILC2s. ILC2s produce the growth factor amphiregulin
(AREG) that binds to the epidermal growth factor receptor (EGFR) on the epithelium,
resulting in proliferation and/or differentiation of epithelial cells to restore barrier integrity
and tissue homeostasis. Data presented in Chapter 3 and 4 suggests that in the lung,
the primary targets of ILC2-derived AREG are EGFR+ airway Clara cells (blue cells)
while in the intestinal crypts it is not yet clear whether mature epithelial cells or stem
cells are affected.
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